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Summary 
 
Impairment of neuromuscular transmission at the neuromuscular junction is a primary 
pathomechanism of many human conditions. The congenital myasthenic syndromes (CMS) 
are caused by primary genetic defects which reduce the efficacy of neuromuscular 
transmission. CMS are increasingly diverse, both phenotypically and genetically, and the 
study of this group of disorders has improved our understanding of the role of 
neuromuscular junction proteins in health and disease. 
For most subtypes of CMS, symptomatic treatments are available. However, these are poorly 
understood and often limited by systemic side effects. In many CMS, sympathomimetics 
such as salbutamol and ephedrine lead to clinical benefit. However, the reason for this 
clinical benefit is unknown. Using animal models, this research aimed to explore the 
mechanisms underlying improved muscle strength from sympathomimetics in CMS. 
Experiments in zebrafish models revealed that salbutamol alters many aspects of 
neuromuscular junction development. Follow-up studies in the mouse model of end-plate 
acetylcholinesterase deficiency revealed that salbutamol leads to structural neuromuscular 
junction alterations which are primarily postsynaptic.  
The identification of novel CMS genes has been accelerated by the use of next generation 
sequencing. Genetic sequencing of undiagnosed patient cohorts lead to the identification of 
a novel presynaptic CMS subtype caused by mutations in SLC5A7, encoding the presynaptic 
choline transporter. Mutations in SLC5A7 were previously associated with an inherited 
motor neuropathy, and this finding expanded the overlap between disorders of the 
neuromuscular junction and of the motor nerve. In addition, through analysis of a patient 
cohort with CMS and episodic apnoea, I identified genetic, phenotypic and 
neurophysiological characteristics which provide mechanistic insights into this phenomenon.  
Understanding the mechanisms of neuromuscular junction dysfunction and of its 
therapeutic modulation are essential to facilitate earlier diagnosis and the development of 
targeted therapies for the wide range of disorders in which the neuromuscular junction is 
implicated.  
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1.1 The Neuromuscular Junction and Neuromuscular Transmission 
 
Motor nerves convey their signals to their target muscle fibres at highly specialized chemical 
synapses - neuromuscular junctions (NMJs). The last thirty years have seen great advances 
in our understanding of the cellular and molecular events taking place during development, 
maturation and maintenance of the NMJ in vitro and in vivo in a variety of species (Hall and 
Sanes, 1993; Sanes and Lichtman, 2001). Indeed, much of what we understand about 
synapse development and chemical transmission in neurobiology as a whole are due to the 
study of this relatively large and easily accessible synapse.  
 
1.1.1 Neuromuscular Transmission 
In all vertebrates, the process of neuromuscular transmission involves the release of the 
neurotransmitter acetylcholine (ACh) from the presynaptic nerve terminal onto the muscle 
fibre to trigger excitation and contraction. The NMJ is highly specialised to ensure this takes 
place quickly (less than a millisecond) and reliably (Figure 1) (Slater, 2008).  
In the motor nerve terminal, ACh is packed into membrane bound vesicles (synaptic 
vesicles) or “quanta”. When a motor nerve action potential arrives at the nerve terminal, it 
causes the opening of voltage-gated calcium channels, and an influx of Ca2+ ions. This 
increase in Ca2+ concentration causes synaptic vesicles to fuse with the presynaptic 
membrane and release ACh into the synaptic cleft, also known as “quantal release” (Del 
Castillo and Katz, 1954; Fatt and Katz, 1952). 
The released ACh then diffuses across the synaptic cleft, and binds to the ligand gated ACh 
receptors (AChRs), which are highly concentrated on the surface of the muscle membrane 
(10,000 per µm2) (Matthews-Bellinger and Salpeter, 1983). The binding of ACh induces a 
conformational change in AChRs, causing them to briefly open.  
Open AChRs are approximately equally permeable to Na+ and K+ and the resulting flow of 
ions is determined by electrochemical gradients (Takeuchi and Takeuchi, 1959). However, 
the opening of AChRs allows much more Na+ in than K+ ions out; it is the net influx of Na+ 
which constitutes the resulting inward current, known as the end-plate current (EPC) (Fatt 
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and Katz, 1951). As the bound ACh dissociates from the AChRs it is rapidly hydrolysed by 
acetylcholinesterase (AChE) in the synaptic cleft (Eccles et al., 1942; Gašperšič et al., 1999). 
The influx of Na+ ions leads to transient local depolarisation of the muscle membrane, 
known as the end-plate potential (EPP), which is typically 25-45mV (Fatt and Katz, 1951; 
Wood and Slater, 1995). This EPP leads to the opening of voltage-gated Nav1.4 channels in 
the muscle fibre (Boyd and Martin, 1956). In order to generate an action potential, the EPP 
must reach a threshold of depolarisation, at which positive charge entering the muscle 
membrane is greater than that leaving the surrounding membrane (Jack et al., n.d.). In 
mammalian muscle, an action potential typically occurs when the membrane potential 
reaches -55mV (Wood and Slater, 1995). However, at the NMJ the threshold for action 
potential is much less, being approximately 50% less than is required in a non-junctional 
region (Wood and Slater, 1997). This is due to two main structural adaptations at the 
postsynaptic membrane; the high concentration of Nav1.4 channels, and the presence of 
postsynaptic folds (see section 1.1.2.3).  
In order to ensure that this process occurs in a reliable way, transmission at the NMJ has a 
high safety factor. This can be defined as the ratio of the number of quanta of ACh released 
to the number of quanta required to generate an action potential in the muscle fibre (Wood 
and Slater, 1997). Under normal conditions, more ACh is released by a motor nerve action 
potential than is required to initiate a muscle action potential. This is estimated to be by a 
factor of four, depending on the experimental conditions in which it is tested (Boyd and 
Martin, 1956, p.; Harris and Ribchester, 1979; Wood and Slater, 1997). During high 
frequency activity, the quantal content may decline significantly in a normal NMJ (Van der 
Kloot, 1991). The safety factor means that even under these conditions, a nerve impulse will 
still lead to muscle contraction. In spite of this large reserve capacity of neuromuscular 
transmission, there are many pathological situations in which that reserve reaches its limit 
and transmission is significantly impaired, resulting in fatigable muscle weakness.   
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Figure 1: Synaptic transmission at the neuromuscular junction. 1. Motor neuron action potential initiates synaptic 
transmission in the terminal bouton. 2. Vesicles containing ACh are released by the presynaptic nerve terminal within 
100μs of nerve impulse. 3. ACh binds to the transmembrane AChRs in a hydrophobic pocket formed at the interface 
between adjacent subunits, producing a configurational change to a more open hydrophilic channel that favours passage 
of ions into the muscle fibre. 4. An influx of Na ions causes a transient depolarisation of the muscle membrane (the end-
plate potential) 5. The end-plate potential initiates the opening of the ion channels in the muscle fibre – the Nav1.4 voltage 
gated channels, and initiates an action potential in the muscle fibre. 6. The action of ACh is rapidly terminated by the action 
of the AChE anchored on the basal lamina, which splits ACh into acetate and choline. The choline is subsequently 
transported into the nerve terminal where it is recycled. 
 
 
1.1.2 The impact of NMJ structure on neuromuscular transmission 
 
The NMJ is a tripartite synapse, comprised of the motor neuron, muscle fibre and Schwann 
cell. Each of these components has a highly specialised structure which influences the 
efficacy of neuromuscular transmission.  
 
1.1.2.1 Synaptic Vesicle Exocytosis 
The efficacy of exocytosis of synaptic vesicles in response to a motor nerve impulse is an 
important determinant of neuromuscular transmission. The process of synaptic vesicle 
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exocytosis is complex and involves interaction between two sets of proteins: V-SNARES, 
which are in the vesicular membrane, and T-SNARES, which are in the nerve terminal 
membrane (Sudhof, 2004). Three essential proteins of membrane fusion are the V-SNARE 
protein synaptobrevin/VAMP (vesicular associated membrane protein), and the T-SNARE 
proteins SNAP-25 and syntaxin-1 (Südhof and Rizo, 2011). Synaptic vesicles are primed for 
release at the active zone by partial SNARE and Sec1/Munc18-like complex assembly before 
calcium triggering (Südhof and Rizo, 2011). The speed and precision of subsequent 
exocytosis are mediated by synaptotagmin and its cofactor complexin (Südhof, 2012). 
Complexin binds to the primed vesicles transforming them into an active state 
(“superpriming”) and clamps them for release. Ca2+ binding to synaptotagmin then triggers 
binding to the SNARE complex and opening of the fusion pore (Südhof, 2012; Zhou et al., 
2017). After exocytosis, vesicles are re-endocytosed, recycled, and refilled with ACh (Sudhof, 
2004). 
 
1.1.2.2 The Acetylcholine Receptor 
Each mature AChR is a complex of five subunits, 2α, β, ε and δ. ACh binds at two sites, the 
interfaces between the α and δ subunits, and between the α and ε subunits (Figure 2) (Gu 
and Hall, 1988). When both sites are bound by an ACh molecule, the AChR undergoes a 
conformational change to rapidly open the channel (Matsubara et al., 1992). There is an 
efflux of K+ and an influx of Na+ through this open channel. The channel closes again after 
approximately 1ms (Matsubara et al., 1992). During maturation of NMJs, the AChR subunits 
switch from containing a γ subunit to an ε subunit (Gu and Hall, 1988). The conductance and 
opening properties of the channel is affected by this molecular switch. In 2αβδγ AChRs, 
opening time is prolonged meaning that more Na+ enters the muscle fibre (Mishina et al., 
1986).   
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1.1.2.3 The Postsynaptic Folds 
The postsynaptic membrane is extensively invaginated with folds extending into the 
cytoplasm (Figure 3). These have an important impact on the reliability of neuromuscular 
transmission. At the crests of the folds and extending partly down the fold walls, AChRs are 
highly concentrated. The depths of the folds contain a high concentration of Nav1.4 
channels. The high concentration of AChR at the crests of the folds means ACh binds and the 
EPC enters at the fold crests. As the current travels towards the cytoplasm it must therefore 
move down a thin fold of membrane, which has high resistance, and which amplifies the 
depolarisation of Nav1.4 channels at the depths of the folds (Martin, 1994). As a result of the 
folds, the threshold at the NMJ is lowered, and fewer AChRs need to be opened in order to 
generate a muscle fibre action potential than would be the case in the absence of these 
folds (Slater, 2008).  
Figure 2: Schematic of the Acetylcholine Receptor in the postsynaptic membrane. A. The five subunits (2α, β, δ, ε) span 
the membrane and enclose the ion pore. B. View along the axis of the pore demonstrating binding sites of acetylcholine 
(ACh). 
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Figure 3: Electron micrograph of a mouse neuromuscular junction showing anatomy of the postsynaptic folds. AChRs (red) 
are concentrated at the crests of the folds and appear electron dense, while NaV1.4 channels (green) are concentrated 
in the depths of the folds. NT: nerve terminal; TSC: terminal Schwann cell; PJ: postjunctional folds. Scale bar = 500nm 
1.1.2.4 Acetylcholinesterase 
Asymmetric AChE at the NMJ acts to rapidly hydrolyse and terminate the action of ACh, 
allowing its re-uptake and recycling in the presynaptic nerve terminal (Katz and Miledi, 
1973). In developing NMJs, AChE is dispersed along the muscle fibre. As synapses mature, 
AChE becomes highly concentrated at the NMJ where it is anchored by collagen Q (ColQ) 
(Krejci et al., 2006). AChE needs to be kept at high density to prevent depolarizing blockade 
of the post-synaptic membrane channels and neuromuscular transmission failure (Martinez-
Pena y Valenzuela and Akaaboune, 2007). The mechanisms whereby AChE is localized and 
retained at the NMJ include binding to ColQ, perlecan and α-dystroglycan (Arikawa-
Hirasawa et al., 2002; Martinez-Pena y Valenzuela and Akaaboune, 2007). 
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Uptake by the nerve terminal of choline resulting from hydrolysis of acetylcholine (ACh) by 
AChE from the synaptic cleft is undertaken by the high affinity choline transporter (ChT). 
Choline acetyltransferase (ChAT) catalyzes the synthesis of ACh from acetyl-CoA and 
choline. These newly synthesised molecules of ACh are then collected into synaptic vesicles 
by the vesicular ACh transporter (VAChT).  
 
1.1.3 Signalling pathways at the Neuromuscular Junction 
 
The assembly, maintenance, and plasticity of NMJs are differentially regulated by numerous 
signalling pathways activated by the cross-talk among the three partners of the NMJ (motor 
nerve ending, muscle fibre, and terminal Schwann cell (TSC)). These pathways play 
important and intersecting roles at the NMJ during development (embryonic and early 
postnatal life), adulthood, and aging.  
 
1.1.3.1 Signalling pathways in mammalian neuromuscular junction assembly 
The formation of the NMJ requires the orchestration of several levels of organization, not 
least the precise juxtaposition and contact between presynaptic nerve terminals and the 
postsynaptic apparatus.  This orchestration occurs in a series of overlapping steps starting 
before birth and continuing for several weeks after it.  A high density (>10,000 μm−2) of 
AChRs at synapses is required to initiate a synaptic action potential in the muscle fibre 
(Slater, 2008). Conversely, in the rest of the fibre, the density of AChRs has to be kept low in 
order to allow complete maturation of the NMJ (Cohen and Fischbach, 1977; Hartzell and 
Fambrough, 1973). 
NMJs do not develop at random locations in muscles; rather, they are assembled in a 
narrow central region of the muscle fibre, so that many NMJs are located in a row, forming 
an end-plate band across the fibre (Kummer et al., 2006). Even before arrival of the motor 
nerve, in the step known as “prepatterning”, clusters of AChRs can be seen to localize along 
the central region of the muscle fibres (Kummer et al., 2006). Several muscle intrinsic 
proteins are essential for this prepatterning process, in particular the muscle specific 
receptor tyrosine kinase (MuSK), the low-density lipoprotein receptor related protein-4 
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(LRP4) and the membrane associated protein rapsyn (Figure 4). Mutation of MuSK or LRP4 
prevents prepatterning (Kim and Burden, 2008a; Weatherbee et al., 2006).  
Following innervation, some of these prepatterned AChR clusters are actively incorporated 
into developing NMJs, supporting the view that postsynaptic muscle intrinsically defines its 
central region for ingrowing axons (the myocentric model) (Flanagan-Steet et al., 2005). The 
arriving motor nerve terminals, and the ACh released by them, subsequently stabilize the 
innervated AChR clusters, and cause the dispersal of non-synaptic AChR clusters.  
The neuronal factor agrin, is a key player in this stabilization. Agrin binds the pre-formed 
MuSK-LRP4 complex to initiate a cascade of signalling pathways leading to synaptic 
differentiation and stabilization of the AChR clusters (Figure 4) (Zhang et al., 2008). 
Exogenous agrin is sufficient to induce AChR clusters and their postsynaptic specialization in 
vitro when applied to non-innervated myotubes (Bowen et al., 1996) and ectopically in adult 
muscle (Jones et al., 1997). Agrin deficient mice fail to form NMJs and die at birth (Gautam 
et al., 1996).  
MuSK (muscle-specific kinase) is a transmembrane receptor kinase which is a key 
orchestrator in NMJ development (Figure 5). MuSK is essential for the formation of aneural 
AChR clusters (Lin et al., 2001). In addition, MuSK is the central component in the agrin-
LRP4-MuSK receptor complex which initiates postsynaptic specialisation, clustering and 
anchoring AChRs in the postsynaptic membrane (Kim et al., 2008; Kim and Burden, 2008b). 
In cultured myotubes, activated MuSK is sufficient to form AChR clusters. MuSK can also 
induce the recruitment of subsynaptic nuclei and synapse-specific transcription of AChR 
genes (Moore et al., 2001). Agrin-activated MuSK sets up signalling loops that are not only 
used to control its own expression but also that of the ɛ and δ AChR subunit, AChE and 
utrophin (Jones et al., 1999; Lacazette et al., 2003). Neuregulins had been proposed to be 
the factor controlling expression of AChR subunit genes in fundamental myonuclei, 
however, postsynaptic differentiation has since been shown to occur in the absence of 
neuregulin receptors (Escher et al., 2005).   
Low-density lipoprotein receptor-related protein 4 (LRP4) is a coreceptor for agrin and 
MuSK, which is necessary for the tyrosine phosphorylation of MuSK and subsequent 
downstream signalling. In addition, prepatterning requires LRP4 to bind MuSK (Kim et al., 
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2008, p. 4; Weatherbee et al., 2006). LRP4 is expressed not only in skeletal muscle but also 
in motor nerves.  
A further key protein which is essential for MuSK activity is Dok-7 (downstream of tyrosine 
kinase-7). Dok-7 is a cytoplasmic adaptor-like protein which is expressed in skeletal muscle 
and cardiac muscle (Okada et al., 2006). Dok-7 binds the cytoplasmic region of MuSK to 
induce its tyrosine phosphorylation and activation (Herbst and Burden, 2000). The 
formation of the agrin-LRP4-MuSK complex also causes Dok-7 phosphorylation, which 
creates binding sites for Crk and CrkL which may themselves play a role in synapse 
development (Hallock et al., 2010). Overexpression of Dok-7 using AAV vectors leads to 
stable NMJ enlargement and is beneficial in mouse models of Amyotrophic Lateral Sclerosis 
and Emery-Dreifuss muscular dystrophy (Arimura et al., 2014; Miyoshi et al., 2017). 
Rapsyn (43kDa receptor associated protein of the synapse) is a cytoplasmic protein which 
binds tightly to AChRs to cluster them at high density (Tintignac et al., 2015). It also binds to 
dystroglycan, and through this action is thought to scaffold AChRs to the actin cytoskeleton 
(Bartoli et al., 2001).  
 
 
 
Figure 4: The agrin/LRP4/MuSK pathway regulates NMJ assembly. Neuronal agrin binds with the co-receptor LRP4 to 
initiate MuSK autophosphorylation and activation. Subsequently, this initiates interactions between MuSK and other key 
post-synaptic proteins including Dok-7, which are crucial for its catalytic activity and for downstream signalling. Several 
downstream signalling pathways lead to synaptic differentiation and stabilisation of the AChR clusters. 
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Figure 5: MuSK is a key orchestrator of NMJ development. MuSK is a receptor for neuronal agrin to initiate a plethora of 
downstream pathways leading to AChR clustering and stabilisation. MuSK interacts with Dok-7 and Tid-1 to initiate its own 
activation. In addition, MuSK interacts with scaffold proteins including rapsyn, ColQ and AChR. MuSK also interacts with 
proteins thought to regulate synaptic gene expression, suggesting a role in synapse-specific transcription. 
 
In addition to these key proteins, several other signalling pathways are now known to be 
involved in NMJ assembly.  
Growing evidence suggests the involvement of Wnt proteins in NMJ development (Figure 
6). Wnt proteins are evolutionarily conserved, secreted glycoproteins expressed as 19 
different isoforms in mouse and humans, which are involved in a wide range of 
developmental processes (Koles and Budnik, 2012). Wnt proteins activate a number of 
distinct signalling pathways, including the canonical Wnt pathway, the divergent canonical 
Wnt pathway, the planar cell polarity (PCP) pathway and the calcium Wnt signalling 
pathway (Cadigan and Peifer, 2009).  
The first indication that Wnt signals were involved in NMJ development was the discovery of 
the Wnt receptor cysteine rich domain (CRD) on MuSK (Masiakowski and Yancopoulos, 
1998).  Subsequently, Dishevelled (Dvl), a protein activated by several Wnt signalling 
pathways, was found to be a binding partner of MuSK (Luo et al., 2002). Wnt4, 9a and 11 
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enhance AChR clustering in muscle cells in vitro (Barik et al., 2014; Strochlic et al., 2012). 
Wnt4 and Wnt11r in zebrafish, and Wnt3 in mice contribute to AChR prepatterning (Jing et 
al., 2009; Strochlic et al., 2012, p. 4). In addition, β-catenin, which is promoted by canonical 
Wnt signalling, has been shown to bind to rapsyn (Zhang et al., 2007). In mice with muscle 
β-catenin gain- or loss-of-function, a critical level of β-catenin expression was found to be 
required for proper pre and postsynaptic specialisation (Liu et al., 2012; Wu et al., 2012). 
Finally, mice lacking the CRD domain of MuSK lack normal prepatterning of AChRs, have 
outgrowth of motor axons that bypass AChR clusters, and develop myasthenic muscle 
weakness. This demonstrates a critical functional role of Wnt-MuSK interaction. Overall, 
although the detailed mechanisms are not fully understood, Wnt morphogens are emerging 
as key players in formation of the NMJ. 
An additional auxiliary NMJ signalling pathway is via neuregulins. These are trophic 
factors expressed in muscle and nerves, and are important for cross talk between nerve, 
muscle and the TSC. Neuregulins activate the receptor tyrosine kinases ErbB2, ErbB3, and 
ErbB4, all of which are present at the NMJ (Tintignac et al., 2015). They have been shown to 
play a role in AChR expression, myogenesis and muscle repair after injury (Ford et al., 
2003; Jo et al., 1995).  
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1.1.3.2 Signalling during NMJ maturation 
NMJs undergo a long, activity-dependent maturation process, which involve structural and 
molecular changes at several levels. The number of presynaptic nerve terminals reduce as 
they compete with each other to innervate each muscle fibre. The folds in the postsynaptic 
Figure 6: The role of Wnts in AChR clustering at the vertebrate neuromuscular junction. A. Wnt3 (in mice) and 
Wnt11r (in zebrafish) contribute to the induction of AChR (acetylcholine receptor) prepatterned clustering 
independent of agrin or innervation. B. Wnts also play a role in the stabilisation of AChRs in the presence of 
neural agrin at the time of innervation. Dvl: dishevelled. Adapted from Coles and Budnik 2012.   
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membrane develop, and the extracellular matrix (ECM) matures. In addition, the primitive 
plaque-like end-plate transforms into a mature pretzel shape. Finally, the TSC caps the 
contact between the nerve and the muscle (Sanes and Lichtman, 2001). 
 
Synapse elimination 
In the early stages of NMJ development multiple motor axons may contact a single AChR 
cluster. As the final steps of NMJ formation are completed (in the first 2-3 weeks after birth 
in rodents) this multiple innervation is reduced to a single motor axon per AChR cluster 
(Brown et al., 1976). Each motor nerve terminal competes locally at the end-plate, and the 
superseding axon is the axon with the strongest input and delivering the most efficient 
synaptic communication (Darabid et al., 2014). During elimination, the immature plaque-like 
end-plate becomes remodelled into a pretzel (Slater, 1982). At the same time, fetal 2αβδγ 
AChRs are replaced by adult 2αβδε AChRs (Mishina et al., 1986). A similar molecular switch 
occurs at this time in the Nav1 channels, which change from the Nav1.5 isoform to the 
Nav1.4 isoform (Lupa et al., 1993). TSCs regulate and enhance this process. They destroy and 
phagocytose losing axons as they retract from the muscle cell surface (Bishop et al., 2004).  
In addition, by detecting the levels of transmitter released from each competing nerve 
terminal, TSCs promote the survival of the strongest input (Smith et al., 2013).  
 
Maturation of the cytoskeleton controlling AChR stability 
The synaptic basal lamina is formed from a highly differentiated network of ECM proteins 
which are synthesised and secreted by the muscle fibre. This structure plays a pivotal role in 
the maturation of the synapse. The main protein constituents of the ECM are laminin and 
collagen IV, but at the NMJ it also contains ColQ, perlecan, agrin, fibronectin, nidogen and 
others (Singhal and Martin, 2011). Laminin α and β chains play an important role in the 
development of both pre- and post-synaptic structures, with each laminin chain playing a 
specific role. In Laminin β2 knockout mice, NMJs have a reduced number of synaptic vesicles 
and loss of active zones (Noakes et al., 1995). In laminin α4 knockout mice nerve terminals 
are smaller and the active zones and postsynaptic apparatus is not properly aligned (Patton 
et al., 2001). Another important finding is that Laminin β2 mice lack postjunctional folds, as 
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do laminin α2 mice. This suggests that the distribution of each laminin chain at the NMJ may 
regulate the development of postsynaptic folds, which are important amplifiers of 
neuromuscular transmission (Rogers and Nishimune, 2017).  
Collagen IV α2, α3, and α6 chains, as well as collagen XIII are concentrated at NMJs in 
mammals. Collagens are expressed late in NMJ development (after 3 weeks postnatally in 
mice) and are particularly important for presynaptic specialisation (Fox et al., 2007). ColQ is 
the collagenic subunit of AChE which anchors asymmetric AChE in the basal lamina 
(Rotundo, 2003). Mice with a knockout of ColQ lack all AChE at the NMJ, but despite this are 
viable and survive into adulthood (Feng et al., 1999). In addition, ColQ has been shown to 
bind MuSK and plays a role in postsynaptic differentiation through this interaction (Sigoillot 
et al., 2016, 2010).  ColQ also binds to perlecan, which also plays a role in localising AChE to 
the NMJ (Singhal and Martin, 2011). It is not known precisely how ColQ, perlecan and MuSK 
interact to localise AChE to the NMJ, but it may be that they form a coordinated protein 
complex (Singhal and Martin, 2011). 
 
The Dystrophin—Glycoprotein Complex 
The dystrophin associated glycoprotein complex (DGC), which includes dystrophin, utrophin, 
sarcoglycans, sarcospan, dystrobrevin, syntrophin and three dystroglycans, forms an 
important part of the subsynaptic apparatus. Several studies have shown that the DGC is 
important for synaptic, as well as muscle, stability. Deletion of components of the DGC 
impairs the postsynaptic development of the NMJ. For example, misglycosylation of α-
dystroglycan causes fragmented and unstable NMJs to form (Hara et al., 2011). Deletion of 
α-dystrobrevin reduces AChR density and destabilises AChR clusters (Grady et al., 2003). 
These abnormalities occurred in the context of a relatively mild muscle phenotype, 
suggesting they may not be secondary to disrupted myofibre architecture. More severe NMJ 
disassembly is found in triple knockout mice lacking α-dystrobrevin, dystrophin and 
utrophin, suggesting coordinated roles for these proteins in NMJ stability (Grady et al., 
2000). However, it is not clear from this study whether these NMJ defects were more than 
would be expected given the severely dystrophic phenotype.  In addition, the localisation of 
AChRs at the crests of the folds arises through their interaction with the DGC (Apel and 
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Merlie, 1995). The stabilisation of Nav1 channels at the depths of the folds is through the 
interaction with β-spectrin and ankyrinG (Bewick et al., 1996; Wood and Slater, 1998).  
1.1.3.3 Signalling pathways in NMJ stabilisation 
The development of the NMJ can be thought of as a lifelong process. Although most mature 
NMJs persist throughout adulthood, their stability requires a dynamic equilibrium, with 
rapid remodelling in response to activity and aging.  Most of the molecules involved in NMJ 
maintenance are those that also are essential for NMJ development as has been shown by 
induced suppression of agrin, MuSK and LRP4 in postnatal mice (Tintignac et al., 2015).  
 
Metabolic stabilisation of AChRs 
The high density of AChRs in the postsynaptic membrane is determined by their rates of 
insertion into and removal from the postsynaptic membrane (Figure 7). The stability of 
AChRs can be measured by repeated labelling of AChRs with α-bungarotoxin, and 
measurement of this labelling over time in vivo (Bruneau et al., 2005). This has 
demonstrated that AChRs in mice have a half-life of 10-14 days (Bruneau et al., 2005). The 
metabolic stabilisation (prolongation of the half-life) of AChRs is through their links with the 
actin cytoskeleton via the DGC (Tintignac et al., 2015). After they are endocytosed, AChRs 
can be degraded by autophagic decay or can be recycled back to the postsynaptic 
membrane (Bruneau et al., 2005).  Several studies have demonstrated that protein kinase A 
(PKA) can promote AChR recycling back to the postsynaptic membrane (Martinez-Pena y 
Valenzuela and Akaaboune, 2007; Nelson et al., 2003; Röder et al., 2010). It is not known 
precisely which phosphorylation events control the decision making between AChR recycling 
or degradation. However it is possible that AChR itself is the target, given that it is known to 
be phosphorylated by PKA (Huganir and Miles, 1989; Miles et al., 1987; Nimnual et al., 
1998). PKA has been shown to be anchored in close vicinity to vesicles containing recycled 
AChRs, where it was anchored by rapsyn (Röder et al., 2010). Agrin also promotes the 
recycling of AChRs after their internalisation, and through this action can metabolically 
stabilise AChR clusters (Brenner and Akaaboune, 2014). 
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Subsynaptic nuclei and the regulation of NMJ gene expression 
As AChRs become innervated, genes coding for components of the NMJ become exclusively 
expressed in subsynaptic nuclei (Schaeffer et al., 2001). Several signalling pathways are 
implicated in regulating this synapse-specific gene expression. In particular, the expression 
of AChR subunit genes is maintained in subsynaptic nuclei despite repression in 
extrasynaptic nuclei through muscle activity (Sanes and Lichtman, 1999; Schaeffer et al., 
2001). The targeted expression of many synaptic genes is thought to be due to the N-box, a 
six base pair promoter element which is shared by CHRNE, CHRND, ACHE and MUSK 
(Schaeffer et al., 2001).  
 
  
Figure 7: The life cycle of AChRs at the NMJ. AChRs are assembled in the endoplasmic reticulum and glycosylated in the 
golgi apparatus before being delivered to the postsynaptic membrane and clustered by the agrin/MuSK/LRP4 complex. 
After 10-14 days, AChRs are endocytosed and either recycled through pathways involving protein kinase A and rapsyn, or 
degraded by autophagy. Adapted from Rudolf et al 2014. 
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1.2 The NMJ in Human Disease 
 
Many human diseases have, as either a primary or secondary component of their pathology, 
interruption of normal neuromuscular transmission due to defects at the NMJ. The 
advances in identifying the molecular pathways of neuromuscular transmission have been 
paralleled by the remarkable diversity of NMJ pathologies that has emerged over recent 
decades. The experimental accessibility of NMJs and availability of animal models has 
facilitated research into the mechanisms underlying selective vulnerability of distal axons 
and NMJs in these disorders.  
 
1.2.1 Autoimmune diseases of the NMJ 
 
The most common type of diseases resulting in NMJ dysfunction are acquired autoimmune 
disorders. Autoantibodies targeting AChRs, MuSK or rarely LRP4 lead to acquired 
autoimmune myasthenia gravis (MG) which presents with fluctuating skeletal muscle 
weakness, usually involving susceptible muscle groups, and has an estimated prevalence of 
77.7 per million persons.16,17 In AChR-MG, which accounts for 85% of cases, IgG1 and IgG3 
AChR antibodies predominate (Rødgaard et al., 1987). These trigger two pathogenic 
mechanisms: 1) they bind directly to AChRs causing endocytosis and degradation; 2) they 
activate the complement pathway leading to formation of the membrane attack complex 
(Verschuuren et al., 2013). This results in the removal of AChR and AChR associated 
proteins, and in the loss of postsynaptic folds, reducing the safety factor and resulting in 
myasthenic weakness (Verschuuren et al., 2013). AChR-MG can be early-onset (usually 
before 40 years) or late onset (>60 years), and typically involves ocular muscles at onset 
with subsequent generalised weakness (Gilhus and Verschuuren, 2015). Some studies have 
indicated minor pupillary abnormalities in MG patients which may be due to the presence of 
skeletal ciliary muscle (Bibby et al., 1995; Dutton et al., 1982). However, visual acuity is 
unaffected in MG (Nair et al., 2014). 
Antibodies to AChR are detected in 80-85% of cases of MG (Rodríguez Cruz et al., 2015; 
Vincent and Newsom-Davis, 1985). In 70% of the cases which are seronegative for AChR 
antibodies, antibodies to MuSK are detected (Vincent et al., 2008). Clinically MuSK-MG 
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differs from AChR-MG, with more involvement of neck, bulbar (often tongue atrophy) and 
respiratory muscles (Farrugia et al., 2006). In addition, MuSK-MG rarely occurs over the age 
of 60 years, having a peak age of onset in the 4th decade (Guptill et al., 2011). The lack of IgG 
deposits or of AChR loss at NMJs from MuSK-MG patients, lead to debate as to whether 
MuSK antibodies play a role in disease pathogenesis or are merely a disease marker (Selcen 
et al., 2004). However, several important studies demonstrated that passive transfer of 
MuSK IgG, and specifically IgG4, from MuSK MG patients to mice could induce myasthenic 
weakness and caused AChR loss (Cole et al., 2010, 2008; ter Beek et al., 2009). Subsequent 
studies demonstrated that MuSK IgG4 blocked the assembly of the agrin-LRP4-MuSK 
complex, impairing MuSK’s ability to stabilise AChR clustering (Ghazanfari et al., 2018).  
Autoantibodies to LRP4 are detected in approximately 10% of cases with double 
seronegative MG (Higuchi et al., 2011; Zhang et al., 2012). These patients share some clinical 
similarities with MuSK-MG, with prominent involvement of respiratory and bulbar muscles, 
in-keeping with the fact that LRP4 forms a complex with MuSK (Verschuuren et al., 2013). 
LRP4 antibodies inhibit the agrin-LRP4 interaction and agrin induced AChR clustering 
(Higuchi et al., 2011; Zhang et al., 2012).  
Current treatment for MG includes AChE inhibitors (e.g. pyridostigmine) for symptomatic 
control, immunosuppressants (e.g. corticosteroids, azathioprine, methotrexate, 
mycophenolate, ciclosporin and rituximab) for maintenance therapy and 
immunomodulatory therapies (intravenous immunoglobulin or plasma exchange) which are 
used for management of exacerbations or occasionally for maintenance therapy in complex 
cases (Anderson et al., 2016; Gilhus and Verschuuren, 2015; Zinman et al., 2007). MG is a B-
cell mediated disease, in that B-cells differentiate and proliferate into antibody producing 
plasma cells. MG is also T-cell dependent; CD4+ T-helper cells and T-regulatory cells 
facilitate the B-cell differentiation (Milani et al., 2006). The thymus gland is the primary site 
of production of autoantibodies in MG (Weiss et al., 2013). Thymectomy has become part of 
the standard of care for MG patients with a known thymoma. In addition, a randomised 
control trial in 2016 comparing thymectomy and prednisolone vs prednisolone alone in non-
thymomatous AChR-MG also showed that thymectomy resulted in clinical benefit, as 
measured by a reduced quantitative myasthenia gravis (QMG) score (Wolfe et al., 2016). 
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This provides evidence for thymectomy in all patients with AChR-MG regardless of whether 
thymoma is present on imaging.  
Acetylcholinesterase inhibitors (AChEIs) such as pyridostigmine, are recommended as part 
of the initial treatment for all AIMG subtypes (Sanders et al., 2016). Treatment results in 
rapid but usually incomplete symptomatic benefit. For some patients who have purely 
ocular symptoms and no generalised weakness treatment with AChEIs alone may be 
adequate. Different guidelines recommend varying escalation protocols for commencing 
AChEIs. The Association of British Neurologists guidelines are: 30mg pyridostigmine four 
times a day for 2-4 days; 60mg pyridostigmine four times a day for 5 days; then 90mg four 
times a day if required (Sussman et al., 2015).  
Corticosteroids like prednisolone are used as short-term immunosuppressants in MG. 
Patients may take up to 3 months to respond. In addition, at around 4-10 days after starting 
prednisolone, a proportion of MG patients experience exacerbation of their myasthenic 
weakness, known as the “steroid dip” (Warmolts and Engel, 1972). For this reason it is 
recommended that steroids are commenced at a low dose on alternate days (e.g. 10mg 
once daily), and gradually titrated up (e.g. increase by 10mg every 3 doses until symptoms 
improve) (Sussman et al., 2015). 
When symptom control is not achieved with corticosteroids and prednisolone, a steroid 
sparing immunosuppressant agent should be introduced. The first line agent is azathioprine, 
which is very slow to take its maximal effect (up to 2 years) (Palace et al., 1998). If 
azathioprine fails or is not tolerated, other immunosuppressive agents can be used. These 
include mycophenolate mofetil, methotrexate, ciclosporin, cyclophosphamide and rituximab 
(Sussman et al., 2015). Whilst these have been shown to be clinically effective in AIMG, they 
are also associated with serious side effects including nephrotoxicity, malignancy and bone 
marrow suppression (Sathasivam, 2011). 
The immunomodulatory therapies intravenous immunoglobulin (IVIG) and plasma exchange 
are frequently used for management of MG relapses or occasionally as maintenance 
therapy. IVIG has demonstrated clear benefit in randomised controlled trials (Zinman et al., 
2007). In general, for many aspects of the management of MG, evidence is lacking. In 
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addition, individuals with MG show a high degree of clinical variability and subsequently 
treatment is often tailored on an individual basis.    
In Lambert Eaton Myasthenic Syndrome (LEMS) antibodies to presynaptic P/Q-type voltage-
gated calcium channels (VGCCs) are detected in over 90% of patients (Eaton and Lambert, 
1957; Motomura et al., 1995). Approximately 60% of LEMS cases are associated with 
malignancy, usually small cell lung cancer. Overlapping clinical features to MG can lead to 
diagnostic delay (Pellkofer et al., 2009). In addition to fatigable proximal weakness, patients 
present with autonomic symptoms and diminished tendon reflexes (Titulaer et al., 2011). 
The diagnosis is based on the finding of a distinctive electrophysiological pattern on 
repetitive nerve stimulation; the baseline compound muscle action potential (CMAP) is 
small, but increases >100% (increment) following high frequency stimulation or exercise (Oh 
et al., 2005). Approximately 10-15% of LEMS patients are seronegative (Titulaer et al., 2011). 
Symptomatic improvement for LEMS is obtained with administration of 3,4-diaminopyridine 
(3,4-DAP). 3,4-DAP inhibits presynaptic voltage-gated potassium channels, prolonging 
presynaptic VGCCs opening time (Kirsch and Narahashi, 1978).  
1.2.2 Toxins and the NMJ 
 
In addition to autoantibody attack, there are many toxins which in particular target the NMJ 
either presynaptically (e.g. tetrodotoxin, botulinum toxin, β-bungarotoxin, α-latrotoxin) or 
postsynaptically (e.g. D-tubocurarine, α-bungarotoxin). In addition to their role in disease 
and therapeutics, the study of these toxins has provided insights into the ability of the NMJ 
to adapt and recover from changing environments in order to maintain reliable 
neurotransmission (Slater, 2008). Most environmental compounds act by inhibiting AChE, 
including organophosphates and sarin (Abou-Donia and Lapadula, 1990; De Bleecker et al., 
1994). Blocking the action of AChE leads to repeated opening of AChRs, depolarisation of 
the postsynaptic membrane, and inactivation of postsynaptic Nav1.4 channels and the loss 
of ability to generate a muscle action potential. The botulinum neurotoxins are incredibly 
potent presynaptic toxins which cleave components of the SNARE complex, preventing ACh 
release from the nerve terminal (Schantz and Johnson, 1992). Intoxication causes flaccid 
paralysis and respiratory failure which can be fatal (Schantz and Johnson, 1992). They are 
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also valuable therapeutic agents, used for the treatment of spasticity and dystonia, resulting 
in temporary paralysis of selected muscles (Johnson, 1999). 
 
1.2.3 The NMJ in disorders of the motor nerve 
 
1.2.3.1 The NMJ in spinal muscular atrophy 
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease with an 
incidence of 1 in 10,000 live births, caused by mutations in the survival motor neuron gene 
(SMN1) (Prior et al., 2010; Verhaart et al., 2017). The centromeric homolog SMN2 can 
generate a small amount of functional SMN protein, accounting for the four main clinical 
subtypes (SMA type I-IV) which vary in severity (Bürglen et al., 1996; Finkel et al., 2015). The 
SMN protein is ubiquitously expressed, but SMN mutations lead to selective loss of lower 
motor neurons. The SMN protein plays an essential role in regulating RNA metabolism, actin 
cytoskeleton dynamics, mRNA transport, ubiquitin homeostasis and synaptic vesicle release 
(Donlin-Asp et al., 2016; Groen and Gillingwater, 2015; Hensel and Claus, 2018; Kong et al., 
2009; Li et al., 2014). However, it is still not precisely known how a reduction in SMN leads 
to death of motor neurons. 
Several lines of investigation have sought to determine whether retrograde signals from the 
NMJ may contribute to the loss of motor neurons in SMA. Numerous studies have shown 
early morphological NMJ abnormalities in the SMNΔ7 SMA mouse, which precede the loss 
of motor neurons. These include smaller nerve terminals, reduced synaptic vesicle density, 
delayed switch of the AChR subunit from γ to ε, reduced postsynaptic area and simplified 
end-plates (reduced number of perforations per end-plate) and neurofilament accumulation 
(Boido et al., 2018; Kariya et al., 2008; Kong et al., 2009; Ling et al., 2012; Ruiz et al., 2010; 
Valsecchi et al., 2015). These findings were confirmed in post-mortem studies from SMA 
type 1 patients, which demonstrated small, non-perforated end-plates with prolonged 
expression of the γ-AChR subunit (Harding et al., 2015; Martínez-Hernández et al., 2013). In 
addition, in an in vitro model co-culturing motor neurons derived from induced pluripotent 
stem cells from SMA patients with murine C2C12 myoblasts, impaired AChR clustering and 
neurofilament accumulation was observed (Yoshida et al., 2015). These structural 
alterations are compounded by changes in NMJ function, including reduced quantal content 
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and intermittent failure of transmission in the SMNΔ7 SMA mouse (Kariya et al., 2008; Kong 
et al., 2009).  
However, whether these abnormalities play a significant role in motor dysfunction in SMA is 
a topic of debate. More recent studies have shown impairment of spinal networks, including 
proprioceptive input, occurs well in advance of NMJ deficits in SMA mouse models (Mentis 
et al., 2011). Further studies in SMA mouse models and particularly in humans are required 
in order to elucidate the contribution of the NMJ to motor neuron loss in SMA. One study 
has shown that treatment of SMA mice with a soluble fragment of agrin (NT-1654) lead to 
improved motor function, reduction in NMJ morphological defects and increased muscle 
fibre area (Boido et al., 2018). These results indicate that the NMJ could represent a 
therapeutic target, at least for development of therapies to complement gene therapies and 
antisense oligonucleotide approaches. 
  
1.2.3.2 The NMJ in amyotrophic lateral sclerosis 
Motor neuron disease (MND)/Amyotrophic lateral sclerosis (ALS) is a fatal neuromuscular 
disease with degeneration of motor neurons leading to muscle weakness and wasting, 
paralysis, and respiratory failure (Paez-Colasante et al., 2015). The only approved ALS 
therapy, riluzole, does not modify the disease trajectory and prolongs life by a few months 
only (Lacomblez et al., 1996). Multiple pathological processes are implicated in ALS, 
including oxidative stress, abnormal energy metabolism, accumulation of protein 
aggregates, glutamate excitotoxicity, and glial dysfunction (Paez-Colasante et al., 2015). It 
remains in question whether motor neuron degeneration in ALS occurs through primary 
pathological insult in the motor cortex, and extends towards corticospinal neurons (dying 
forward), or whether degeneration begins at motor nerve terminals at the NMJ and 
progresses towards the anterior horn cell (dying back) (Cappello and Francolini, 2017). 
However, it has been shown that NMJ disassembly is a critical point in ALS pathogenesis. 
The SOD1G93A mouse is a transgenic model which overexpresses human SOD1 (Gurney et al., 
1994). This results in adult onset motor neuron degeneration with the first signs of muscle 
weakness becoming apparent at 4 months, and death occurring by 5-6 months of age 
(Gurney et al., 1994).  NMJ structural alterations have been shown to be present in SOD1G93A 
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mice before the onset of weakness or of motor neuron cell body loss (Fischer et al., 2004). 
In the SOD1G93A mouse, early in the disease process, the postsynaptic membrane becomes 
fragmented, AChR density is reduced, some end-plates become denervated and some NMJs 
exhibit sprouting and collateral innervation (Valdez et al., 2012). In addition, ultrastructural 
analysis of NMJs of SOD1 mice showed mitochondrial alterations and reduced synaptic 
vesicle density in nerve terminals (Cappello et al., 2012). Presymptomatic NMJ disassembly 
has also been shown in canine ALS (Rich et al., 2002). The clinical relevance of the possible 
early and central role of the NMJ is the potential for treatment. A single dose of AAV DOK7 
gene therapy was shown to improve lifespan and motor activity and reduce muscle atrophy 
in the SOD1 mouse (Miyoshi et al., 2017). 
Unfortunately, studies of the NMJ in the early stages of ALS in patients are very limited, due 
to the difficulty in obtaining muscle samples containing NMJs. Therefore, little is known 
about whether these structural defects also occur in humans, and what their functional 
implications might be on neuromuscular transmission. A few studies in patients have 
demonstrated that the postsynaptic architecture is not significantly altered in ALS, but nerve 
terminals are smaller (Tsujihata et al., 1984; Yoshihara et al., 1998). However, in a more 
recent study, which benefits from confocal fluorescence microscopy, significant 
postsynaptic morphological alterations were observed in all patients regardless of disease 
stage (Bruneteau et al., 2015).  Only a single study has analysed NMJ function in ALS 
patients using intracellular electrophysiology (Maselli et al., 1993). This showed that mean 
quantal content of endplate potentials, the mean quanta available for immediate release, 
and the mean quantal stores were all decreased in ALS patients. However, it is not known 
whether these effects imply a primary NMJ defect or whether the reduced quantal content 
reflects NMJ denervation and axonal degeneration. Further functional studies will be 
important therefore, in understanding the clinical relevance of NMJ dismantling in ALS. 
 
1.2.3.3 The NMJ in inherited motor neuropathies 
Genetic neuropathies are a heterogenous group of inherited disorders affecting peripheral 
motor and/or sensory nerves. The most common form is Charcot–Marie–Tooth (CMT) 
disease, or hereditary motor sensory neuropathy (HMSN) in which both motor and sensory 
nerves are involved and which can be demyelinating (CMT1) or axonal (CMT2). With a 
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prevalence of 1 in 2500, CMT is one of the most common inherited neuromuscular diseases 
(Rossor et al., 2016). More than 80 genes are now known to be associated with CMT 
(Stojkovic, 2016). Although our understanding of the various biological processes that CMT 
genes are involved in has improved, there is still no effective treatment available for the 
majority of CMT (Corrado et al., 2016). 
Several recent discoveries have implicated the NMJ in the pathogenesis of CMT. One 
recently discovered disease gene is SYT2, which encodes Synaptotagmin 2, a synaptic vesicle 
protein which functions as the main calcium sensor for neuromuscular transmission (Shields 
et al., 2017). Mutations in SYT2 were identified in two large kinships with an autosomal 
dominant motor neuropathy syndrome and evidence of a presynaptic neuromuscular 
transmission defect on neurophysiological tests (see also section 1.3.2.1) (David N. 
Herrmann et al., 2014; Whittaker et al., 2015a). In addition, mutations in the presynaptic 
choline transporter CHT1, encoded by SLC5A7, have also been shown to cause an autosomal 
dominant motor neuronopathy (distal hereditary motor neuropathy type 7)(Barwick et al., 
2012). These findings suggest that presynaptic NMJ dysfunction may be a more general 
mechanism for peripheral axonopathies. 
NMJ defects have also been found in animal models of motor neuropathies. The Garsc201r 
mouse, a model of Charcot–Marie–Tooth Type 2D (CMT2D), which is caused by dominant 
mutations in Glycyl tRNA synthetase (GARS), exhibits smaller and fragmented end-plates 
which is independent of innervation status of the NMJs, and occurs prior to the loss of 
motor neuron connectivity (Sleigh et al., 2014; Spaulding et al., 2016). The Cramping1 
(Cra1/+) mouse has hypomorphic mutations in DYNC1H1, which encodes the heavy chain of 
cytoplasmic dynein-1, a motor complex required for retrograde axonal transport. Mutations 
in DYNC1H1 are implicated in a wide range of human neurological diseases, including 
CMT2O, and spinal muscular atrophy with lower extremity predominance (SMALED) (Niu et 
al., 2015, p. 1; Weedon et al., 2011). Cra1/+ mice exhibit simplified end-plates with reduced 
pre and postsynaptic colocalisation early in the disease process prior to the loss of motor 
neurons (Courchesne et al., 2011). In the mouse model of CMT4C (Sh3tc2ΔEx1/ΔEx1 
knockout), which is caused by recessive mutations in SH3TC2, NMJ morphological defects 
have been demonstrated, including increased fragmentation of end-plates and reduced area 
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of contact between pre- and post-synaptic components. In addition, the Sh3tc2ΔEx1/ΔEx1 
knockout mice displayed prolonged expression of AChR γ subunit (Cipriani et al., 2018). 
Using neurophysiological studies (repetitive nerve stimulation and single fibre 
electromyography), NMJ defects have been identified in a subgroup of CMT patients  
(Bansagi et al., 2017). Further studies will be aimed at characterising the role of the NMJ in 
CMT disease pathogenesis, and in assessing the therapeutic benefit of both novel and 
readily available therapies which enhance neuromuscular transmission.  
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1.3 Congenital Myasthenic Syndromes 
 
The most recently identified conditions which arise from impairment of neuromuscular 
transmission are the congenital myasthenic syndromes (CMS). Although CMS are the rarest 
of the myasthenic disorders affecting man (estimated prevalence 1 per 100,000), they have 
nevertheless shown the greatest clinical and pathological diversity, and the study of CMS 
has expanded our knowledge both of how NMJ dysfunction can present clinically and of the 
role of previously uncharacterised proteins at the NMJ. CMS arise from mutations affecting 
crucial presynaptic, synaptic or postsynaptic proteins, resulting in impairment of the safety 
margin by one or more mechanisms (Engel et al., 2015a). The first identified mutations were 
in the subunits of the AChRs, and these remain the most common subtype of CMS 
worldwide today. However, in recent years and with the advent of next generation 
sequencing, the discovery of CMS related genes has accelerated and to date 31 genes have 
been implicated (Figure 8) (McMacken et al., 2017).    
 
1.3.1 Clinical diversity in Congenital Myasthenic Syndrome 
 
A generic diagnosis of a CMS is suggested on the basis of early onset (at birth to early 
childhood) of fatigable weakness in particular affecting the ocular and other cranial muscles. 
However, several pitfalls and challenges in diagnosis exist.  CMS may first become evident 
during adolescent or adult life (Engel et al., 1982). In addition, unlike the fatigability in 
autoimmune MG, fatigability in CMS tends to fluctuate over a longer period, being week-to-
week or month-to-month, rather than minute-to-minute, and thus may not be 
demonstrable on clinical exercise tests. Muscle weakness in some subsets of CMS may be 
predominantly proximal and axial with minimal involvement of cranial muscles, mimicking a 
limb-girdle muscular dystrophy (known as LG-CMS) (Evangelista et al., 2015). Early onset 
and a positive family history are also indicative, but their absence should not rule out the 
consideration of CMS as several subtypes may first become evident during adolescent or 
adult life (Engel et al., 1982). CMS may be particularly difficult to diagnose in neonates in 
whom non-specific features such as poor suck or cry, generalised hypotonia or 
arthrogryposis may be the only clinical features. A candidate gene may be indicated by 
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certain clinical, histopathological and neurophysiological findings (Table 1), although a 
subset of clinical CMS patients remain genetically undefined (estimated 10% in UK 
population) (McMacken et al., 2017). 
Neurophysiological confirmation of a defect in neuromuscular transmission is an important 
step towards securing a diagnosis of CMS. The main tests used are repetitive nerve 
stimulation (RNS) and single-fibre electromyography (SFEMG). RNS involves stimulation of 
the motor nerve via surface electrodes and measurement of the resulting summated 
response, the CMAP (Whittaker, 2011). In patients with impaired neuromuscular 
transmission, the CMAP amplitude can vary with repetitive stimulation, with a reproducible 
percentage change (decrement) of 10% or more between the 1st and 4th CMAP amplitude 
being indicative of a NMJ disorder. In other presynaptic CMS subtypes in which the defect is 
not in impairment of ACh release, but in its synthesis in the presynaptic nerve terminal (e.g. 
due to mutations in CHAT, SLC5A7 and SLC18A3), often no decrement is detected at low 
frequency (3Hz) stimulation, and it isn’t until the pool of synaptic vesicles has been 
exhausted that any decrement is observed. Thus in such cases, prolonged high frequency 
RNS (e.g. 10Hz for 5 minutes) is necessary to ensure the diagnosis is not overlooked (Byring 
et al., 2002; McMacken et al., 2018; Mora et al., 1987). A “double CMAP” response should 
lead to consideration of slow channel CMS and ColQ-CMS, and is caused by generation of a 
second action potential within a muscle fibre following only a single motor nerve 
stimulation (van Dijk et al., 1996). 
SFEMG is a more sensitive test and can detect milder defects of NMT, as it measures the 
variability (or “jitter”) in the time taken to excite the muscle fibre. When normal in a weak 
muscle, SFEMG can exclude the diagnosis of an NMJ defect with some certainty. However, 
SFEMG is not a specific test for NMJ dysfunction as increased jitter can be found in the early 
stages of reinnervation and in myopathies (e.g. mitochondrial myopathy), and will increase 
slightly with age (Bromberg and Scott, 1994; Cruz-Martínez et al., 2004; Whittaker, 2011). 
Any neurophysiological evidence of an NMJ defect therefore must be interpreted in the 
context of clinical symptoms and signs.  
All patients with suspected CMS and negative family history should have confirmation of a 
lack of antibodies to AChR or MuSK. Serum creatine kinase (CK) is typically normal in CMS, 
apart from CMS due to mutations in GMPPB in which the serum CK can be elevated 10 times 
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higher than normal (Rodríguez Cruz et al., 2016). Muscle MRI and muscle biopsy may be 
useful particularly in confirming a lack of major muscle pathology despite significant clinical 
weakness (Finlayson et al., 2016). An exception is MRI in CMS due to glycosylation defects 
(see below) in which non-specific fatty change can be observed. Most CMS subtypes display 
minimal myopathic features on muscle biopsy. These may be more marked in Dok7 CMS, 
ColQ CMS and slow channel syndrome (Engel et al., 1982; Hutchinson et al., 1993; Selcen et 
al., 2008). In CMS due to glycosylation defects, specifically DPAGT1 and GFPT1, tubular 
aggregates may be seen on NADH staining (Belaya et al., 2012; Guergueltcheva et al., 2012).  
 
Figure 8: Genetic subtypes of congenital myasthenic syndrome. Genes can be grouped according to their role in the development 
and function of the NMJ, although for a subset of these genes their specific role in the development of CMS is unknown. ACh: 
acetylcholine; AChE: acetylcholinesterase; AChR: acetylcholine receptor; ChT: high affinity choline transporter, DGC: dystrophin 
associated glycoprotein complex, Nav1.4: voltage gated sodium channel. Adapted from McMacken et al 2017. 
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Gene Protein and function Key Clinical features Treatment 
 
Genes influencing ACh synthesis and release 
 
CHAT Choline acetyltransferase (ChAT); resynthesis of ACh from choline 
and acetyl-CoA in the presynaptic nerve terminal.(Oda, 1999) 
Early onset CMS-EA. Mild clinical course between symptoms with varying degrees of progressive proximal weakness 
both between and within families. 
Pyridostigmine 
SLC5A7 Presynaptic high affinity choline transporter 1 (CHT1); ACh re-
uptake into synaptic vesicles 
Severe CMS of early onset. Presentations include a severe prenatal form resulting in arthrogryposis, hypotonia and 
early lethality, to neonatal onset CMS-EA 
Pyridostigmine 
SLC18A3 
 
Vesicular acetylcholine transporter (VAChT); concentration of ACh in 
presynaptic vesicles. 
Patients present with respiratory crises, ptosis, ophthalmoplegia and fatigability. Deterioration of symptoms in cold 
temperature described in one case.  
Pyridostigmine 
MYO9A Myosin9A; unconventional myosin with presumed pre-synaptic 
origin. 
Described in three cases of neonatal onset hypotonia with bulbar and ocular involvement, as well as respiratory 
crises with EA.(O’Connor et al., 2016) 
Pyridostigmine  
Adjunctive therapy with 3,4-DAP 
SYT2 Synaptotagmin 2; main calcium sensor for neurotransmission. Motor axonopathy syndrome, with some fatigability on examination and neurophysiological features of a 
presynaptic myasthenic syndrome, similar to LEMS (David N. Herrmann et al., 2014) 
3,4-DAP 
SNAP25B SNAP25 (synaptosomal-associated protein of 25 kD); forms part of 
SNARE complex, required for regulation of synaptic vesicle 
fusion(Chen et al., 2002) 
Severe CMS of neonatal onset, with associated cortical excitability, intellectual disability and cerebellar ataxia.(Shen 
et al., 2014, p. 2)   
3,4-DAP 
MUNC13-1 
 
Munc13-1; associates with the SNARE complex to regulate docking 
and priming of synaptic vesicles.(Augustin et al., 1999; Betz et al., 
1998; Siksou et al., 2009) 
Described in one case, causing a severe syndrome of neonatal onset with hypotonia, respiratory distress, ptosis and 
ophthalmoplegia, as well as facial dysmorphism, microcephaly and abnormal cortical electrical activity.(Engel et al., 
2016)  
Pyridostigmine and 3,4-DAP 
(limited benefit) 
VAMP1  Synaptobrevin 1; component of the SNARE complex required for 
synaptic vesicle fusion(Adams et al., 2015) 
A homozygous frameshift mutation in VAMP1 is described in a case of severe neonatal CMS with marked 
hypotonia, with respiratory and oculomotor involvement.(Shen et al., 2017) 
Pyridostigmine (modest 
improvement) 
 
Genes influencing the interchange between nerve and muscle in the synaptic cleft 
 
COLQ ColQ; collagenic-like strand responsible for anchoring AChE to the 
synaptic basal lamina  
Broad phenotype ranging from adult onset LG-CMS, to the early onset severe and progressive forms.(Mihaylova et 
al., 2008; Shapira et al., 2002) Slowing of pupillary light reflex in 25% of cases. 
Salbutamol or ephedrine 
Worsening with pyridostigmine 
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LAMB2 
 
Laminin β2; component of the synaptic basal lamina of the 
NMJ.(Noakes et al., 1995) 
Mutations in LAMB2 are well described in Pierson syndrome, which causes congenital nephrosis and ocular 
abnormalities.(Zenker et al., 2004) LAMB2 mutations have also been found in one patient who, in addition to the 
renal and ocular manifestations, presented with a CMS with ptosis, respiratory insufficiency and proximal limb 
weakness.  
Ephedrine 
Worsening with pyridostigmine 
AGRN Agrin; nerve-derived component of the basal lamina which induces 
AChRs to cluster on the post-synpatic membrane.(McMahan, 1990) 
AGRN mutations are a relatively rare cause of CMS, and may cause ptosis, fatigable proximal limb weakness and 
respiratory insufficiency.(Huzé et al., 2009; Maselli et al., 2012) AGRN mutations are also described in cases of CMS 
with distal weakness and features in-keeping with a distal myopathy on MRI.(Nicole et al., 2014) 
Salbutamol or ephedrine 
COL13A1 α-chain of the muscle derived collagen 13; embedded in the ECM 
and plays a role in NMJ maturation.(Latvanlehto et al., 2010) 
COL13A1 mutations cause CMS bearing some resemblance to the more common CMS due to Rapsyn deficiency, 
with neonatal onset, dysmorphic features, ptosis and respiratory involvement.(Logan et al., 2015) 
Ephedrine 
Adjunctive therapy with 3,4 DAP 
LAMA5 Laminin α5; binds to the luminal side of synaptic vesicles(Rogers and 
Nishimune, 2017) 
Severe early onset with CNS involvement.(Maselli et al., 2017) Pyridostigmine 
Adjunctive therapy with 3,4-DAP 
 
Genes affecting the AChR and its transmission of action potentials 
 
AChR 
deficiency 
(CHRNE) 
ε-subunit of the pentameric AChR The most common form of CMS. Clinically variable but typically ophthalmoplegia, ptosis, dysphagia and fatigable 
proximal muscle weakness with onset in early infancy. 
Pyridostigmine 
Adjunctive therapy with 
salbutamol or ephedrine 
AChR 
deficiency 
(CHRNA1/
B1/D) 
α, β and δ subunits of the AChR Not as common AChR deficiency due to CHRNE, but often more severe(Engel et al., 2015b; Gomez et al., 2002; Shen 
et al., 2016), with arthrogryposis, dysmorphism, scoliosis and respiratory involvement. 
Pyridostigmine 
Adjunctive therapy with 
salbutamol or ephedrine 
RAPSN Rapsyn; scaffolding protein, interacts with AChRs to induce 
clustering.(Gautam et al., 1995)  
Typically early-onset with life-threatening apneic crises from birth, hypotonia, arthrogryposis multiplex congenital 
and feeding difficulties.(Burke et al., 2003) Later onset milder form also occurs.  
Pyridostigmine 
Fast 
channel 
syndrome  
Altered kinetic properties of the AChR, so as to cause an 
inappropriately fast closure of the channel following binding of 
ACh.(Ohno et al., 1996) 
Severe myasthenic weakness with respiratory crises, with onset in early infancy or childhood(Webster et al., 2014)   Pyridostigmine 
Adjunctive therapy with 3,4-DAP 
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Slow 
channel 
syndrome  
Prolonged opening of the AChR following ACh binding Usually onset in late childhood, often selective involvement of finger flexors and neck extensors and no extraocular 
involvement.  
Fluoxetine or quinidine 
Adjunctive therapy with 
salbutamol or ephedrine 
SCN4A Voltage gated sodium channel (Nav1.4); allow influx of sodium ions 
into postsynaptic membrane and generation of a muscle action 
potential 
More commonly associated with non-dystrophic myotonia. However, mutations have also been described in three 
unrelated cases of CMS.(Arnold et al., 2015; Habbout et al., 2016; Tsujino et al., 2003) Relatively severe limb 
weakness, ophthalmoplegia and ptosis are described in all cases.  
Pyridostigmine 
 
Genes affecting the core proteins required for post-synaptic development 
 
DOK7 Dok-7; cytoplasmic adaptor protein which activates MuSK and is 
essential for normal maturation of the post-synaptic 
membrane.(Yamanashi et al., 2008) 
LG-CMS with waddling gait, tongue wasting +/- ptosis. Typically onset in late childhood but variable. Varying 
degrees of respiratory involvement. Respond well to sympathomimetics  
Salbutamol or ephedrine 
Worsening with pyridostigmine 
MUSK Muscle specific receptor tyrosine kinase (MuSK); interacts with a 
large number of effectors and pathways converging toward the 
regulation of AChR clustering and postsynaptic specialisation. 
Ranging from severe phenotype, respiratory insufficiency at birth and proximal muscle weakness to later onset LG-
CMS.(Mihaylova et al., 2009; Owen et al., 2018)  
Salbutamol or ephedrine 
Adjunctive treatment with 3,4-
DAP  
LRP4 LRP4; transmembrane post-synaptic protein which triggers NMJ 
development when bound to by agrin.(Kim et al., 2008) 
Mutations in LRP4 have been identified in Cenani-Lens syndactyly syndrome, bone overgrowth and low bone 
mineral density,(Leupin et al., 2011; Li et al., 2010, p. 4; Styrkarsdottir et al., 2009) but are a very rare cause of CMS. 
Few cases described exhibit a variable phenotype, from a severe neonatal presentation with hypotonia, ptosis and 
ophthalmoplegia, to a progressive LG-CMS.(Ohkawara et al., 2014, p. 4; Selcen et al., 2015, p. 4) 
Worsening with pyridostigmine 
PLEC1 
 
Plectin; intermediate filament-associated protein concentrated at 
sites of mechanical stress, including Z-discs in muscle.(Maselli et al., 
2011) 
Pathogenic mutations in PLEC1 are associated with neonatal epidermolysis bullosa simplex, and, in some cases, 
with a muscular dystrophy and a defect of neuromuscular transmission.(Forrest et al., 2010) 
Ephedrine 
Pyridostigmine no/limited benefit 
 
Genes affecting ubiquitous proteins with unknown NMJ function  
 
GFPT1 Required for synthesis of the rate limiting enzyme for N- and O-
linked glycosylation 
LG-CMS with minimal extraocular involvement. Tubular aggregates on muscle biopsy. Onset in late childhood or 
adulthood 
Pyridostigmine 
Adjunctive therapy with 3,4-DAP 
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DPAGT1 Encodes the enzyme which catalyses the first step of N-linked 
glycosylation 
LG-CMS with minimal extraocular involvement. Tubular aggregates on muscle biopsy. Onset in late childhood or 
adulthood 
Pyridostigmine 
Adjunctive therapy with 3,4-DAP 
ALG2 and 
ALG14 
Encodes enzymes which catalyse early steps in N-linked 
glycosylation 
LG-CMS with ptosis but minimal ophthalmoplegia of onset in childhood. Joint laxity and pes planus also described. Pyridostigmine 
GMPPB Required for O-glycosylation of α-dystroglycan LG-CMS of late childhood or adult onset. Uniquely elevated CK (10 times higher than normal). Mutations also 
associated with congenital muscular dystrophy with generalised epilepsy.(Raphael et al., 2014) 
Pyridostigmine 
Adjunctive therapy with 
salbutamol or ephedrine 
SLC25A1 Encodes the mitochondrial citrate transporter, responsible for the 
movement of citrate across the mitochondrial inner membrane. 
Varying presentations from a severe mitochondrial disease with cardiac, eye and brain involvement, to less severe 
CMS.(Chaouch et al., 2014; Edvardson et al., 2013) The reason for mutations in a ubiquitous mitochondrial citrate 
carrier manifesting primarily as a NMJ defect remains to be determined. 
3,4-DAP 
PREPL Encodes the enzyme Prolyl endopeptidase-like, which is expressed 
in brain, kidney and muscle.(Régal et al., 2014)  
PREPL deficiency in combination with other deletions causes the hypotonia cystinuria syndrome, characterised by 
neonatal hypotonia, cystinuria, growth hormone deficiency and feeding problems.(Parvari et al., 2001) PREPL 
deficiency is also described in one case of a neonatal CMS without cystinuria.(Régal et al., 2014) 
Pyridostigmine (transient 
response) 
Table 1:  Congenital Myasthenic Syndrome subtypes and treatment response. Definitions: ACh – acetylcholine; AChE – acetylcholinesterase; AChEI – acetylcholinesterase inhibitor; AChR – 
acetycholine receptor; CMS – congenital myasthenic syndrome; CMS-EA – congenital myasthenic syndrome with episodic apnea; LG-CMS – limb-girdle congenital myasthenic syndrome; NMJ 
– neuromuscular junction. Adapted from McMacken et al 2017.
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1.3.2 Genetic heterogeneity in CMS 
 
Genetic diagnosis is of paramount important in CMS because it allows the administration of 
tailored treatment, as well as providing prognostic information and facilitating genetic 
counselling. Single gene testing may be carried out on a gene-after-gene basis if certain 
clinical or laboratory findings indicate a specific subtype, although multi-gene panel testing 
is becoming frequently used as a first-line investigation. When single gene or panel testing 
fail to identify the genetic defect, whole genome or whole exome sequencing may be 
considered. Apart from the slow channel syndrome and SYT2 CMS which are inherited in an 
autosomal dominant manner, all CMS are autosomal recessive.  
Genes of particular interest and recent developments of some CMS genetic subtypes are 
discussed below. 
1.3.2.1 Novel presynaptic genes 
Until very recently, almost all CMS subtypes were due to defects in the postsynaptic 
apparatus or the synaptic cleft. The last three years have seen a rapid increase in the 
number of presynaptic CMS genes. These encode proteins involved in processes related to 
ACh re-uptake and recycling, and ACh vesicular release; (CHAT, SLC5A7 and SLC18A3) and 
(SYT2, VAMP1, SNAP25, and MUNC13-1) respectively (Figure 9). Two additional genes are 
also thought to have a presynaptic role; SLC25A1 encoding the mitochondrial citrate carrier 
and MYO9A (Chaouch et al., 2014, p. 25; O’Connor et al., 2016). Presynaptic CMS subtypes 
are often more severe, and may be associated with intellectual disability and behavioural 
problems, reflecting their role at cholinergic neurons in the CNS. 
ACh re-uptake and recycling 
The first pre-synaptic gene identified as causative for CMS was CHAT, which encodes the 
enzyme choline acetyltransferase (ChAT). ChAT is essential for the resynthesis of 
acetylcholine (ACh) from choline and acetyl-CoA in the presynaptic nerve terminal (Oda, 
1999). In ChAT-CMS, recessive loss-of-function mutations impair the catalytic efficiency of 
the enzyme and decrease the release of ACh during physiologic activity (Arredondo et al., 
2015). The clinical course between crises may be mild with minimal symptoms (Ohno et al., 
2001), however long-term follow-up in these patients has shown that progressive limb 
weakness despite appropriate therapy may be a feature (Schara et al., 2010). SLC5A7 
 36 
 
encodes the presynaptic high affinity choline transporter 1 (ChT), which was previously 
identified as the causative gene in distal hereditary motor neuronopathy type 7 (Barwick et 
al., 2012). Mutations in SLC5A7 have also been identified in CMS, with 11 published cases to 
date (Bauché et al., 2016b). The presentations range from a severe form resulting in 
arthrogryposis, hypotonia and early lethality, to neonatal onset CMS with EA. SLC18A3 
encodes the vesicular associated choline transporter (VAChT) which packages newly 
synthesised ACh into synaptic vesicles. Recessive mutations are associated with a severe 
CMS with arthrogryposis and respiratory failure (Aran et al., 2017; O’Grady et al., 2016). A 
degree of positive response to AChEIs is seen in most cases with mutations in CHAT, SLC5A7 
or SLC18A3. 
Genes involved in ACh synthesis and release are particularly associated with episodic 
apnoea (CMS-EA), recurrent periods of respiratory arrest emerging in the neonatal period or 
during the first months of life, and often resolving with age (Schara et al., 2010). Sudden 
recurrent apnoeic episodes are one of the most poorly understood features of CMS, and 
result in significant morbidity and mortality. The mechanism underlying these recurrent 
attacks is not known. The fact that this phenomenon occurs predominantly in presynaptic 
genes and in patients with a complex phenotype with CNS involvement suggests it may be a 
centrally mediated mechanism (Bauché et al., 2016a; McMacken et al., 2018).  
CMS-LEMS 
In CMS subtypes in which the primary defect results in impairment of ACh release, 
electrophysiological signatures which were previously felt to be diagnostic for Lambert 
Eaton Myasthenic Syndrome (LEMS) have been demonstrated. In these subtypes the 
baseline CMAP amplitude is low, and exhibits decrement on low-frequency RNS. However, 
RNS carried out at high frequency (e.g. 50Hz for 10 seconds) results in an opposing effect 
and an increment in CMAP amplitude is observed (Engel et al., 2016; Shen et al., 2017; 
Whittaker et al., 2015b). High frequency stimulation increases presynaptic calcium influx, 
saturating the calcium dependent release machinery and subsequently transiently 
increasing ACh release (Whittaker et al., 2015b). To date, the genes that have been 
associated with CMS–LEMS are AGRN, SYT2, MUNC13-1, VAMP1, and LAMA5, and this 
finding has shed new light on the role of these proteins in calcium-triggered ACh vesicle 
release at the NMJ (Lorenzoni et al., 2018).  
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SYT2 encodes Synaptotagmin 2, a presynaptic vesicle protein which functions as the main 
calcium sensor for neurotransmission. Mutations in SYT2 were identified in families with a 
non-progressive motor axonopathy, with some patients showing subtle fatigability on 
examination (David N. Herrmann et al., 2014). This is the second identified CMS subtype 
which is inherited in an autosomal dominant fashion, and its discovery has expanded the 
role of the NMJ in hereditary motor axonopathies. 
LAMA5 encodes laminin α5, an ECM protein which binds to synaptic vesicles after they have 
fused with the presynaptic membrane (Son et al., 2000). Despite the fact that it is 
ubiquitously expressed, mutations in LAMA5 have been associated with  a syndrome limited 
to a severe presynaptic CMS with underdeveloped nerve terminals (Maselli et al., 2017).  
 
Figure 9: The presynaptic proteins at the NMJ implicated in congenital 
myasthenic syndromes. Synaptotagmin 2, synaptobrevin, SNAP25 and 
Munc13-1 are involved in synaptic vesicle release. Laminin alpha 5 binds to 
synaptic vesicles after fusion with the presynaptic membrane. ChAT, ChT and 
VAChT are instead involved in the re-uptake and recycling of choline from the 
synaptic cleft. Myosin 9A contributes to vesicle trafficking and agrin secretion. 
ChAT, choline acetyltransferase; ChT, high-affinity presynaptic choline 
transporter; SNAP25, synaptosomal-associated protein 25; VAChT, vesicular 
acetylcholine transporter.  
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1.3.2.2 Genes of the extracellular matrix 
CMS caused by mutations in the COLQ gene have a broad phenotype ranging from adult 
onset limb girdle myasthenia which may be difficult to distinguish from a limb girdle 
muscular dystrophy, to the early onset severe and progressive forms (Mihaylova et al., 
2008; Shapira et al., 2002). Uniquely to this CMS subtype, patients may exhibit slowing of 
the pupillary light reflex, which may serve as a diagnostic clue, but is only present in around 
25% of cases (Mihaylova et al., 2008). In addition, a recent study has shown attenuated 
heart rate variability in ColQ patients, suggesting some degree of autonomic dysfunction 
(Günbey et al., 2019).  
COL13A1 encodes Collagen XIII, which is ubiquitously expressed but concentrated at the 
NMJ, and stabilises AChR clusters (Latvanlehto et al., 2010). Patients with recessive 
mutations in COL13A1 present with severe CMS, respiratory crises, non-fatigable ptosis and 
axial weakness (Beeson et al., 2018; Dusl et al., 2019; Logan et al., 2015, p. 1).  This is a 
recently identified CMS subtype, but the emerging phenotype appears to be homogenous, 
which may facilitate earlier diagnosis in these patients (Dusl et al., 2019).  
 
1.3.2.3 Postsynaptic CMS 
Dok7-CMS is the second most common subtype of CMS in the UK. Patients with mutations 
in DOK7 frequently present in late childhood, but presentations in adulthood or in infancy 
are well recognised. The spectrum of Dok7 CMS ranges from severe neonatal hypotonia 
with stridor, to adult onset LG-CMS with a classical waddling gait. In addition, wasting of 
tongue muscles may serve as a diagnostic clue (Cossins et al., 2012; Selcen et al., 2008; 
Yamanashi et al., 2008). The exon 7 frameshift duplication c.1124_1127dupTGCC is 
commonly found in at least one allele in these patients (Cossins et al., 2012). Analysis of 
motor point biopsies from Dok-7 patients demonstrate that their motor nerve terminals and 
motor endplates are significantly smaller than controls (Slater et al., 2006). 
Closely related to Dok7 CMS is CMS due to mutations in Dok7’s signalling partner MUSK. 
Mutations in MUSK were previously thought to be a very rare cause of CMS, and associated 
with a severe early onset disease (Mihaylova et al., 2009; Wilbe et al., 2015). However, 
through the use of next generation sequencing, a less severe adult-onset phenotype is now 
recognised, which overlaps with the LG-CMS phenotype of Dok7 CMS (Owen et al., 2018). 
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1.3.2.4 CMS caused by disorders of glycosylation 
Glycosylation of nascent peptides is an essential post-translational modification throughout 
many biological processes (Krištić and Lauc, 2017). It follows therefore, that the congenital 
disorders of glycosylation are multisystem disorders which present in infancy. However, in 
contrast to this phenotype, 5 CMS causing genes have been identified which result in 
impairment of glycosylation; GFPT1, DPAGT1, ALG2, ALG14 and GMPPB (Ohno, 2013). The 
role of glycosylation in CMS was first outlined following the discovery of mutations in GFPT1 
and DPAGT1 in patients with LG-CMS, with limited involvement of facial or extraocular 
muscles. GFPT1 is involved in the synthesis of the rate limiting enzyme required for N- and 
O-linked glycosylation, whilst DPAGT1 encodes the enzyme which catalyses the first step of 
N-linked glycosylation (Belaya et al., 2012; Senderek et al., 2011). Patients exhibit several 
features overlapping with a myopathy, including myopathic features on EMG (in addition to 
decrement on RNS), fatty infiltration on MRI, and mildly elevated CK in some (Belaya et al., 
2012; Finlayson et al., 2016; Guergueltcheva et al., 2012). Two further identified genes ALG2 
and ALG14 are involved specifically in N-linked protein glycosylation. Affected patients 
exhibit limb-girdle weakness, mild ptosis, and minimal ophthalmoplegia, with onset in late 
childhood. The 5th identified glycosylation gene in CMS patients, GMPPB, had been 
previously shown to cause congenital muscular dystrophy due to hypoglycosylation of α-
dystroglycan (Carss et al., 2013). Mutations in GMPPB were also identified as the cause of 
CMS with fatigable limb-girdle weakness presenting in late adolescence and adulthood, with 
the distinguishing feature of raised CK levels (Rodríguez Cruz et al., 2016). Like other CMS 
subtypes caused by glycosylation defects, these patients exhibited some myopathic features 
on both EMG and muscle biopsy (Rodríguez Cruz et al., 2016).   
Many NMJ proteins are glycosylated, but the reason that defects in such key biological 
processes would lead to clinical syndromes restricted to NMJ dysfunction is unclear. The 
recent development of a mouse model of GFPT1 CMS may aid in the understanding of to the 
pathomechanism of these disorders. This muscle specific knockout replicates many features 
of the human disease, suggesting the defect in these patients is primarily postsynaptic, and 
also identified dysregulated proteins in the agrin/MuSK pathway as a consequence of GFPT1 
deficiency (Issop et al., 2018). Intracellular electrophysiological studies of NMJs in these 
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patients may also help to localise the site of the defect, although these have not been 
carried out to date. 
 
1.3.3 Treatment of CMS 
 
A precise molecular classification of CMS subtype is of great importance for the diagnosis 
and genetic counselling of patients, but also to allow administration of effective treatment 
as different drugs may be beneficial or deleterious depending on the CMS subtype (Engel et 
al., 2015a). Unlike many inherited neuromuscular disorders, most CMS subtypes are 
amenable to treatment with one or more symptomatic treatments (Table 1). However, for 
most of these treatments the mechanism of action is poorly understood or completely 
unknown. In addition, due to the genetic heterogeneity and rarity of CMS, high-level 
evidence on the efficacy and safety of these treatments is not available (Thompson et al., 
2019). 
1.3.3.1 Acetylcholinesterase inhibitors 
Most CMS subtypes respond to AChE inhibitors (e.g. pyridostigmine) which augment the 
synaptic response to ACh (Schara and Lochmüller, 2008). The onset of action is rapid, and 
responsive patients will typically report functional benefit within days of starting the drug. 
Limb and bulbar weakness typically improve, but ptosis and ophthalmoplegia are often 
resistant to treatment. AChE inhibitors have a short duration of action and are given 
regularly throughout the day (e.g. four or five times per 24 hours); patients will often report 
mild worsening of symptoms when their next dose is due. The main side-effects are 
muscarinic (in particular diarrhoea, abdominal cramping and increased urination) and 
muscle fasciculations. In addition, inappropriately high doses may precipitate cholinergic 
crises. 
1.3.3.2 3,4 Diaminopyridine 
AChE inhibitors are often combined with 3,4 diaminopyridine (3,4-DAP) which blocks 
potassium channels in nerve terminals thereby prolonging action potential and increasing 
ACh release (Kirsch and Narahashi, 1978). 3,4-DAP has particular benefit in presynaptic 
subtypes. 3,4-DAP is well tolerated, with the most common side effect being mild 
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paraesthesia. However, 3,4-DAP can be associated with epileptic seizures, an adverse effect 
which is dose-dependent (Lindquist and Stangel, 2011). 
1.3.3.3 Open Channel Blockers 
Fluoxetine and quinidine are long-acting open channel blockers of the AChR. They are 
beneficial only in the treatment of slow channel syndrome (Fukudome et al., 1998; Harper 
et al., 2003). The open channel blockers act quickly to improve neuromuscular transmission, 
but there is also an increasing beneficial effect over time (e.g. 4 weeks), suggesting they may 
improve also improve the end-plate myopathy of slow channel syndrome (Harper and Engel, 
1998). Fluoxetine is generally used first line due to a better safety profile (Engel, 2007). 
Quinidine can lead to a prolonged QT interval, and ECG monitoring is required.  
 
1.3.3.4 Sympathomimetics 
Ephedrine is a sympathomimetic amine with α- and β-adrenergic effects, which was first 
used in the treatment of autoimmune MG following the publication in the 1930s of case 
reports by Harriet Edgeworth, a physician who had noticed a dramatic improvements in her 
own myasthenic weakness when she began taking ephedrine (Edgeworth, 1933, 1930). The 
use of ephedrine in MG was subsequently superseded by the introduction of 
immunomodulating therapies and AChE inhibitors, and it wasn’t until the discovery of CMS 
that the use of ephedrine in NMJ disorders was reintroduced. In countries where ephedrine 
is not easily available or in cases where ephedrine is not tolerated, salbutamol, a selective β2 
adrenoceptor (AR) agonist, has been successfully used to treat subsets of CMS.  
Ephedrine or salbutamol are used in CMS subtypes where AChE inhibitors are ineffective or 
even detrimental, particularly end-plate AChE deficiency (COLQ) and Dok-7 CMS (Schara and 
Lochmüller, 2008; Slater et al., 2006). These have been successfully used to treat patients 
with CMS due to mutations in AGRN, MUSK, LRP4 and glycosylation defects (Gallenmüller et 
al., 2014; Nicole et al., 2014; Salih et al., 2015; Selcen et al., 2008). In addition, salbutamol or 
ephedrine are increasingly used as an adjunctive therapy along with pyridostigmine in AChR 
deficiency (Cruz et al., 2015).  
Whilst no randomised control trials have been carried out, owing to the rarity of these 
conditions, several case series and open label trials have confirmed the clinical benefit of 
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salbutamol and ephedrine (Table 2) (Thompson et al., 2019). Salbutamol and ephedrine 
appear to be equally efficacious, although again this has not been confirmed in clinical trials. 
Unlike the rapid clinical benefit seen with AChE inhibitors, the effect of salbutamol and 
ephedrine is a more gradual one (McMacken et al., 2017). Initial symptomatic benefit is 
observed within weeks, although peak effect may not be reached until 6 months of 
treatment (Engel, 2007). The typical adult starting dose of salbutamol is 4mg three times a 
day, and of ephedrine is 15mg three times a day. Doses should be titrated up according to 
clinical effect.  
The main side-effects are muscle cramps, insomnia and cardiac effects (tachycardia, 
palpitations and hypertension). However, studies are lacking in the long-term effects of 
salbutamol and ephedrine in CMS, particularly in terms of cardiotoxicity (Thompson et al., 
2019).  In some cases, the clinical benefit from salbutamol may attenuate after years of 
treatment (unpublished observations). This may be due to desensitisation of β2-ARs after 
chronic agonist administration, as occurs when β2-AR agonists are used in the treatment of 
chronic heart failure and asthma. The development of more targeted therapies for CMS, 
which benefit muscle strength whilst minimising systemic side-effects is therefore essential 
to improve quality of care. In addition, an understanding of the effect of sympathomimetics 
at the NMJ is important in order to target treatment to the most appropriate patient 
groups. Furthermore, given the implication of the NMJ in CMT, ALS and SMA, 
pharmacological improvement of the NMJ will have wider applications beyond CMS. 
 
1.3.3.5 Experimental CMS treatments 
An engineered c-terminal fragment of agrin which is soluble (NT-1654) has been shown to 
be beneficial in mouse models of SMA and sarcopenia, and in NMJ recovery following nerve-
crush (Boido et al., 2018; Hettwer et al., 2014). In addition, Dok7 gene therapy has been 
shown to be beneficial in a mouse model of Dok7 CMS (Arimura et al., 2014). Further 
experimental therapies are using repurposed drugs, including the antiepileptic zonisamide 
which increases nerve sprouting in mouse models (Ohno, 2017).  
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Publication Dx Subj Drug Length Design Efficacy  
(Liewluck et 
al., 2011) 
COLQ 
and 
DOK7 
CMS 
18 
(3,15) 
Salbut 1-24m Uncontrl Significantly improved 
walking distance and no. 
of steps climbed (both 
groups) 
(Burke et al., 
2013) 
DOK7 
CMS 
9 Salbut  30m Uncontrl Improvements in timed 
tests, minimal observed 
functional benefits in ADL 
(Gallenmüller 
et al., 2014) 
MUSK 
CMS 
2 Salbut NA Case report Walking and stair climbing 
(Lorenzoni et 
al., 2013) 
DOK7 
CMS 
5 Salbut 12m Uncontrl QMG score, 6mwt, ADL 
score  
(Mihaylova et 
al., 2008) 
COLQ 
CMS 
5 Ephed NA Case report Improved FVC and motor 
symptoms 
(Bestue-
Cardiel et al., 
2005) 
COLQ 
CMS 
2 Ephed 24m Case report Improved motor 
symptoms 
(Schara et al., 
2009) 
DOK7 
CMS 
8 Ephed 12-
24m 
Uncontrl Improved weakness (MRC 
scale) 
(Owen et 
al., 2018) 
MUSK 
CMS 
4 Salbut NA Case series Functional benefits in 
ADL 
(Rodríguez 
Cruz et al., 
2016) 
GMPPB 
CMS 
3 Salbut NA Case series Improved motor 
symptoms 
(Finlayson 
et al., 2013) 
DPAGT1 
CMS 
1 Salbut NA Case series Improved MRC scale 
and motor symptoms 
(Cruz et al., 
2015) 
CHNRE 
CMS 
6 Salbut/ 
Ephed 
8m Uncontrl QMG score, 10mwt 
Table 2: Clinical Experience of β-Adrenergic Agonists in Congenital Myasthenic Syndrome. Definitions – 6mwt: 6 
minute walk test, 10mwt: 10 minute walk test, ADL: activities of daily living, Dx: Diagnosis, Ephed: ephedrine, 
FVC: forced vital capacity, MRC: manual muscle testing using Medical Research Council scale, QMG: 
Quantitative myasthenia gravis score, Salbut: salbutamol, Subj: total subjects enrolled, uncontrl: uncontrolled; 
no placebo group.  
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1.4 Adrenergic Signalling and its role at the NMJ 
 
1.4.1 Adrenoceptors and the Sympathetic Nervous System 
The sympathetic nervous system (SNS) is one of the two main divisions of the autonomic 
nervous system, with the other being the parasympathetic nervous system, which serve to 
regulate involuntary reactions to stressors throughout the body tissues (Clar and Sharma, 
2019). The two major chemical transmitters in the SNS are adrenaline and noradrenaline. 
These bind to adrenergic receptors to illicit a variety of responses, depending on the receptor 
subtype bound (Lynch and Ryall, 2008).  Noradrenaline is the predominant neurotransmitter 
at sympathetic nerves. Noradrenaline is stored in synaptic vesicles in sympathetic nerve 
terminals and is released in response to sympathetic nerve impulses, and subsequently 
diffuses across the synapse to the effector organ.  Adrenaline is a circulating neurohumoral 
factor which is synthesized and released from by the adrenal medulla. It is carried to local 
effector organs by the circulation (Stamper et al., 2009).  
 
All adrenergic receptors are guanine nucleotide-binding G protein-coupled receptors (GPCRs) 
(Haga et al., 1994). G proteins are made up of the Gα subunit and the Gβ and Gγ subunits, which 
form a stable dimeric complex (the Gβγ complex) (Clapham and Neer, 1997). All GPCRs have a 
conserved structure of seven transmembrane α-helices forming three extracellular loops, 
including an NH2 terminus, and three intracellular loops, including a COOH terminus (Johnson, 
2006). The third intracellular loop of the adrenergic receptor is the site of interaction with the 
guanine nucleotide-binding regulatory protein (G protein); activation of the adrenergic 
receptor causes a conformational change in the intracellular binding loop and subsequent 
dissociation of the Gα subunit (which is bound to GTP) from the Gβγ dimer (Filipek et al., 2004).  
There are at least nine different subtypes of adrenergic receptor, which are expressed 
throughout various body tissues (Table 3). Adrenoceptors can be activated by catecholamines 
either via neural synapses or via the circulation and are responsible for mediating a diverse 
array of physiological effects. Two major families of α-adrenoceptors have been identified: 
α1- and α2-, which are further subdivided into six subtypes α1A-, α1B- α1D-, α2A-, α2B-, and α2C-
adrenoceptors. These play a role in regulating blood pressure, vasoconstriction (including 
regulation of blood flow through skeletal muscle) and cardiovascular performance. Numerous 
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secondary signalling pathways are activated by α-adrenoceptors, including phospholipases, 
Ca2+ channels, K+ channels, Na+/H+ exchange pumps and the mitogen-activated protein kinase 
(MAPK) pathway (Saunders and Limbird, 1999).  
The β-ARs are comprised of three main subtypes, β1-, β2-, and β3-adrenoceptors. These are 
classically identified in cardiac, airway smooth muscle and adipose tissue, respectively 
(Johnson, 1998). The receptors consist of seven membrane-spanning domains, three intra- 
and three extracellular loops, one extracellular N-terminal domain, and one intracellular C-
terminal tail (Johnson, 2006). 
The most well-documented β-AR signalling pathway involves the cyclic AMP (cAMP)-protein 
kinase A (PKA) signalling pathway (Taskén and Aandahl, 2004a). In addition, PKA-independent 
cAMP signalling pathways are increasingly recognised, including the exchange protein directly 
activated by cAMP (Epac). 
cAMP is involved in a huge number of biological processes and is able to control multiple 
processes within the same cell simultaneously. This is achieved through numerous 
mechanisms to ensure that the second messenger actions of cAMP are spatially and 
temporally regulated. These include: 
1. Adenylyl Cyclase (AC): There are nine isoforms of AC, which are differentially 
expressed throughout body tissues. These isoforms differ in the way in which they 
respond to regulatory proteins, meaning that in a tissue or a cell type at a specific 
time, extracellular signals received through the adrenoceptors can be differentially 
integrated. 
2. Phosphodiesterases (PDE): PDE are responsible for the degradation of cAMP, and 
therefore regulate the concentration of intracellular cAMP along with AC (Omori and 
Kotera, 2007). There are more than 50 different PDE proteins, encoded by 21 genes 
(Omori and Kotera, 2007). They differ in their tissue-expression, enzymatic activity, 
regulatory proteins and gene regulation. 
3. PKA: PKA is composed of two regulatory and two catalytic subunits. When cAMP binds 
to two sites on each regulatory subunit a conformational change results in the release 
of the active catalytic subunit (Taskén and Aandahl, 2004b). These then phosphorylate 
various serine and threonine residues on proteins which initiate multiple signalling 
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pathways. In addition, the catalytic subunits can diffuse into the nucleus, where 
through the phosphorylation of the cAMP response element binding protein (CREB), 
they can regulate the expression of target genes (Mayr and Montminy, 2001).  
4. Exchange proteins directly activated by cAMP (Epac): Epac are involved in a large 
number of cellular functions including cell division, adhesion differentiation and 
growth (Breckler et al., 2011). In addition, Epac proteins are expressed in distinct 
subcellular compartments such as the nucleus, the cytosol, nuclear and plasma 
membranes, allowing the compartmentalization of their signalling pathways 
(Breckler et al., 2011, p.; Gloerich and Bos, 2010). 
5. A Kinase Anchoring Proteins (AKAP): Another group of proteins contributing to the 
compartmentalization and localization of cAMP-mediated signals are AKAP (Zaccolo 
and Pozzan, 2002). These are scaffolding proteins which bind to several cAMP 
messengers including PKA and Epac (McConnachie et al., 2006). AKAPs can also bind 
PDEs, creating temporal control over intracellular cAMP concentration 
(McConnachie et al., 2006).  
An overview of β-AR signalling pathways is illustrated in Figure 10. 
 
Adreno-
ceptor 
Effector 
molecules 
Expression Main effect in 
muscle 
Agonists Antagonists 
α1A, B, D   PLC, PLA, PLD2, 
Ca2+ channels 
Coronary blood 
vessels, 
smooth muscle 
Vasoconstriction Phenylephrine Prazosin, 
phentolamine 
α2A, B, C Inhibit cAMP, 
AC and PKA 
Cerebral blood 
vessels, 
platelets 
Vasoconstriction Clonidine Mirtazepine 
β1 Activate AC, 
increase cAMP 
and PKA 
Heart and 
kidneys >> 
skeletal muscle 
Unknown Dobutamine, 
xamoterol 
Metoprolol, 
bisoprolol 
β2 Increase cAMP, 
activate PKA, 
activate L-type 
Ca2+ channels 
Heart, skeletal 
muscle  
Hypertrophy Salbutamol, 
formeterol, 
salmeterol, 
clenbuterol 
Propranolol, 
ICI118,551 
β3 Increase cAMP, 
activate PKA, 
activate L-type 
Ca2+ channels 
Heart, adipose 
tissue 
Unknown Mirabegron Carvedilol 
Table 3: Adrenoceptor subtypes, their expression and their effect in skeletal muscle. 
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Figure 10: Schematic of β-adrenoceptor signalling pathways. β-Adrenoceptors belong to the G protein-coupled receptor 
family. Following β-adrenoceptor stimulation, the receptor couples to the Gαs subunit and activates adenylate cyclase, 
generating cAMP. A major effect of cAMP is the activation of cAMP-dependent protein kinase A (PKA), which then enters 
the cell nucleus and phosphorylates the ubiquitous transcription factor CREB. CREB increases the expression of cAMP-
inducible genes containing the cAMP response element (CRE) sequence in mitochondria, myocytes, neurons, astrocytes, 
microglia and immunocytes. Other PKA catalytic subunits diffuse into the cytoplasm and nucleus and phosphorylate target 
proteins. In addition, increase in intracellular cAMP activates pathways via exchange protein activated directly by cAMP 
(Epac, also referred to as cAMP regulated guanine nucleotide exchange factors). Pathways activated by Epac are PKA 
independent. In addition, several pathways independent of Gαs have recently been discovered. ECM: extracellular matrix; 
PKA-cat: PKA catalytic subunits; PKA-reg: PKA regulatory subunits. 
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1.4.2 Adrenergic signalling in skeletal muscle 
 
The importance of adrenergic signalling in skeletal muscle is now increasingly recognised, in 
particular for its role in skeletal muscle growth and repair (Lynch et al., 2007). The 
predominant adrenoceptor in skeletal muscle is the β2AR, although β1ARs comprise almost 
10% (Williams et al., 1984). 
Many β2AR signalling pathways have been investigated in skeletal muscle. The AC-cAMP-
PKA pathway is the most well characterized and is generally thought to be responsible for 
many of the changes in skeletal muscle growth which are mediated by the β2AR (Lynch and 
Ryall, 2008). 
The predominant isoforms of AC in skeletal muscle are AC2 and AC9, with small amounts of 
AC6 and AC7 (Suzuki et al., 1998). However, the specific roles of each isoform in skeletal 
muscle is not yet known (Lynch and Ryall, 2008). AC2 and AC9 have been found to be 
expressed at high levels in the neonatal mouse, suggesting a role in skeletal muscle 
development (Suzuki et al., 1998).  β2AR signalling has also been found to activate the Epac 
signalling pathway in skeletal muscle, and this accounts for some part of the β2AR agonist 
induced hypertrophy of skeletal muscle (Shi et al., 2007). An abundance of Epac activity in 
fast-twitch muscle may also account for some of the fibre type-specific hypertrophy seen 
with β2AR agonists (Shi et al., 2007). Skeletal muscle also contains multiple isoforms of 
AKAP. Muscle AKAP (mAKAP) has been identified at the sarcoplasmic reticulum (SR) 
indicating that it may play a role in the targeted phosphorylation of proteins and other 
receptors (e.g. the ryanodine receptor) in and around the SR (McCartney et al., 1995; Ruehr 
et al., 2003). 
 
1.4.3 β-adrenoceptor agonists 
 
1.4.3.1 Overview 
One of the most important characteristics of adrenoceptors is that catecholamines can elicit 
a variety of responses depending on the adrenoceptor subtype bound. This means that 
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adrenoceptors can be targeted specifically by synthetic adrenoceptor agonists and 
antagonists (Table 3).  
βAR agonists have been used to treat bronchoconstriction in asthma and chronic 
obstructive pulmonary disease for more than a century. These can be divided into two 
broad categories, short-acting β-agonists (SABA) and long-acting β-agonists (LABA). Given 
that it is β2AR which is predominantly expressed in skeletal muscle, the rest of this summary 
focusses on β2AR agonists.  
The accepted model of agonists binding to the of the β2AR is one in which the agonist is 
bound within the hydrophobic core of the protein and anchored there by specific molecular 
interactions between amino acid residues in the receptor and functional groups on the 
ligand (Johnson, 2006). The way in which a β2AR agonist interacts with the β2AR is 
determined by its molecular structure. Salbutamol, which is a SABA, is hydrophilic and 
therefore can access the active hydrophobic β2AR binding site directly (Johnson, 2008). This 
means it will have a rapid onset of action (within 5 minutes) (van Noord et al., 1998). This 
structure also accounts for the short duration of action of salbutamol (4-6 hours) as the time 
that it binds to the active site of the receptor is limited (Johnson, 2008). LABAs, such as 
formoterol, are lipophilic, and therefore have to be taken up into the cell membrane before 
interacting with the receptor (Johnson, 2008). This means that the onset of action is slightly 
delayed, and the duration of activity is longer (Ringdal et al., 1998).    
The potency of a drug (i.e. the amount required to produce a given effect) depends on 
affinity and efficacy. The affinity of a ligand is a measure of the strength of the molecular 
force binding it to the receptor. Salbutamol has a relatively low affinity for the β2AR, 
compared to salmeterol, formoterol or isoprenaline (Johnson, 2006). Efficacy is the 
relationship between receptor occupancy and the ability to initiate a response. Most β2AR 
agonists have intermediate efficacy and will behave as full agonists if receptor numbers 
permit. If receptor density or receptor coupling is inadequate, some β2AR agonists can 
behave as partial agonists. Isoprenaline and formoterol are full agonists, whereas 
salbutamol and terbutaline are partial agonists (Johnson, 2008). 
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1.4.3.2 Side effects of β-adrenoceptor agonists 
Many of the side effects of β2AR agonists are pharmacologically predictable as a result of 
the adrenaline-like stimulation of the β2AR. Tachycardia is common, particularly on first 
exposure to βAR agonists, and occurs due to a combination of peripheral vasodilation and 
subsequent reduced venous return and direct stimulation of the cardiac muscle (Lipworth et 
al., 1988; Sears, 2002). Cardiac arrhythmias are a much less common side effect, and tend to 
only occur in susceptible patients (Finn et al., 1997). Other studies have linked β-agonists 
with cardiac ischemia, heart failure, and cardiomyopathy, but these relationships are not 
confirmed (Sears, 2002). The LABAs salmeterol and formeterol have been shown to have 
greater effects on heart rate and on QTc interval than salbutamol (Bennett and Tattersfield, 
1997; Malolepszy et al., 2001). In addition, studies in COPD patients with known cardiac 
arrhythmias suggest LABAs may be more cardiotoxic than SABAs (Cazzola et al., 1998). They 
may also decrease serum potassium more than SABAs which could lead to cardiac 
arrhythmia (Cazzola et al., 1998).  
Tremor is a dose-related side effect of β2AR agonists, which like tachycardia reduces with 
continued use. It is also more frequent with oral therapy than with inhaled therapy (Legge 
et al., 1971; Lipworth et al., 1988). The exact mechanism for tremor induction by β2AR 
agonists is unknown. Early studies showed that β2AR agonists reduced the force of tetanic 
contraction in slow muscles, and suggested that this was the primary mechanism leading to 
tremor (Waldeck, 1976). More recent studies have correlated tremor with reduced serum 
potassium (Lakie et al., 2004; Tesfamariam et al., 1998). 
β2AR agonists cause dose-dependent hypokalaemia by causing an intracellular shift of 
potassium (Bremner et al., 1993). In addition, through increasing glycogenolysis, β2AR 
agonists can increase plasma glucose levels (Lipworth et al., 1988). As with tremor and 
tachycardia, these metabolic effects attenuate with repeated use (Lipworth et al., 1990). 
In addition to these pharmacologically predictable side-effects, several studies have 
confirmed that frequent use of β2AR agonists can cause airway hyperresponsiveness. This 
can occur after only short-term agonist exposure, and is thought to be due to tachyphylaxis 
of β-receptors on mast cells and a subsequent inflammatory response (Evans et al., 1997). 
This leads to a paradoxical increased asthmatic response, particularly induced by allergens 
and exercise (Kraan et al., 1985). This is particularly associated with fenoterol, salbutamol, 
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and terbutaline (Scalabrin et al., 1996; Wilding et al., 1996). Airway hyperresponsiveness is 
thought to account for unexpectedly high rates of morbidity and mortality in association 
with β2AR agonist use during acute exacerbations of asthma (Sears, 2002).   
 
1.4.3.3 β2-adrenoceptor desensitisation  
When β2AR are stimulated by an agonist for some time, the response from the association 
of the receptor with the ligand is attenuated, a process known as desensitisation. 
Desensitisation can occur after short or prolonged agonist exposure and differs markedly 
between tissues. In short-term agonist exposure, the main mechanism underlying 
desensitisation is receptor phosphorylation. This is a transient process and can be quickly 
reversed on removal of the agonist. In prolonged agonist exposure, receptors are 
internalised resulting in a reduction in β2AR density at the cell membrane. This can occur 
after hours of agonist exposure, and is also reversible within hours. Beyond this time period, 
β2AR are downregulated due to ubiquitination of the receptors (Shenoy et al., 2001). 
Reversal of this requires an increase in βAR at the transcriptional level, and is therefore less 
easily reversible. Desensitisation of β2AR is felt to account for the attenuation of clinical 
response seen after chronic agonist administration in heart failure and asthma (Billington et 
al., 2017; Bristow et al., 1982).  
 
1.4.4 β2-adrenoceptors and their agonists in Skeletal Muscle 
 
There have been numerous studies on animals and several studies on humans regarding the 
effects of chronic β2AR agonist administration on skeletal muscle. These were initially 
exploited by the livestock industry, but their potential for clinical use in muscle growth and 
repair was quickly recognised. 
The most well recognised effect of β2AR agonists on skeletal muscle is the repartitioning 
effect, i.e. an increase in skeletal muscle mass with a decrease in body fat (Yang and 
McElligott, 1989). In animal models these effects occur after 10-20 days of administration. 
The increase in muscle mass is cause by hypertrophy of individual muscle fibres and is due 
to a combination of an increase in muscle protein synthesis and reduction in protein 
degradation (Yang and McElligott, 1989).  The hypertrophic effects occur in both fast and 
 52 
 
slow twitch fibres, but there has been a lot of debate as to whether the magnitude of the 
effect is comparable in both fibre types (Lynch and Ryall, 2008). In addition to their anabolic 
effect, numerous studies have reported that β2AR agonists can induce changes in fibre type, 
with a slow-to-fast fibre type switch (Agbenyega and Wareham, 1990; Hayes and Williams, 
1994; Maltin et al., 1986; Zeman et al., 1987). Chronic clenbuterol administration in the 
mouse has been shown to alter myosin heavy chain (MHC) composition, however the 
mechanisms controlling this switch are not known (Lynch et al., 1996). 
Because of these effects, the therapeutic potential of β2AR agonists on skeletal muscle has 
been explored in several animal and human studies. Several studies in aged rats have shown 
that chronic administration of β2AR agonists can increase muscle mass and force production 
(Ryall et al., 2007, 2006, 2004). In addition, several studies have shown that mouse models 
of muscular dystrophy, including the mdx mouse and the laminin deficient mouse, have 
improved muscle mass after β2AR agonists administration (Agbenyega et al., 1995; 
Agbenyega and Wareham, 1990; Dupont-Versteegden, 1996; Dupont-Versteegden et al., 
1995; Harcourt et al., 2007). Subsequent clinical trials focussed on the functional effects of 
salbutamol administration in muscular dystrophy. However, these trials have been limited in 
that equivalent doses to pre-clinical studies could not be achieved in humans due to 
cardiovascular side effects. In trials of fascioscapulohumeral muscular dystrophy, effects on 
muscle strength were very limited and treatment was limited by cardiotoxicity (Kissel et al., 
2001, 1998). In a trial in Duchenne and Becker muscular dystrophy, a lower dose of 
salbutamol was well tolerated and increased  lean body mass but had only modest effects 
on muscle strength (Skura et al., 2008). In addition, whilst β2AR-agonist administration 
showed promising improvements in mouse models of ALS, again no improvement in muscle 
function was shown in clinical trials at tolerable doses in humans (Sorarù et al., 2006; Teng 
et al., 2006). Overall, whilst animal studies show clinical potential for β2AR agonist 
administration for muscle wasting disorders, a greater understanding of βAR signalling in 
skeletal muscle is required if this pathway is to be manipulated for clinical use. Of particular 
necessity is the development of therapies that alter pathways benefitting skeletal muscle 
without simultaneously activating pathways that affect the cardiovascular system 
deleteriously. 
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1.4.5 β-adrenergic signalling at the NMJ 
 
The innervation of skeletal muscle by sympathetic neurons was first established in the early 
1900s, and subsequent studies sought to establish what role this innervation might play 
(Boeke J, 1909). In particular, several early studies provided evidence that 
symapthomimetics could alter neuromuscular transmission in preparations of isolated 
skeletal muscles in physiological salt solutions. These studies seemed to demonstrate wide-
ranging and occasionally opposing effects of sympathomimetics depending on the context in 
which they were tested (Bowman and Raper, 1966). Adrenaline was shown to have a 
facilitatory action on neurotransmission in amphibian, mammalian and avian muscles 
following intra-arterial injection, where it lead to a rapid increase in CMAPs, and the 
amplitude of EPPs in the presence of the AChR antagonist tubocurarine (Bowman and 
Raper, 1967).  This effect was re-produced to a lesser extent by noradrenaline, suggesting 
an α-adrenoceptor mediated effect. These effects were found to occur to an equal extent in 
both fast and slow twitch muscles, and were independent of vascular changes as evidenced 
by concomitant blood flow recordings (Bowman and Raper, 1966). In addition, adrenaline 
and noradrenaline can potentiate neuromuscular transmission, and activation of α1 and β 
adrenoceptors has been shown to enhance nerve evoked ACh release (Burn, 1945; Vizi, 
1991; Wessler and Anschütz, 1988). However, in conditions where neuromuscular 
transmission has already been blocked (by prior administration of tubocurarine) 
sympathomimetics demonstrate an opposing effect, leading to prolonged depth of paralysis 
(Bowman and Raper, 1966; Dybing, 1954). Many of these effects only occurred when 
sympathomimetics were used at higher concentrations than achieved in humans (Milone 
and Engel, 1996; Sieb and Engel, 1993).  
Much of this early work was done in the belief that NMJs received a direct sympathetic 
innervation, and there exist several descriptions of an accessory innervation of skeletal 
muscle with endings of non-myelinated sympathetic fibres terminating within motor 
endplates (Hinsey, 1934). However, several subsequent studies demonstrated that these 
unmyelinated fibres were instead branches of motor nerves (Bowman and Nott, 1969; 
Bowman and Raper, 1967; Tiegs, 1953). Although the possibility was never entirely 
excluded, the accepted consensus became that the sympathetic effect on skeletal muscle 
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and possibly the NMJ was indirect on a humoral basis from the vascular sympathetic nerves, 
instead of involving sympathetic endings which act directly on the skeletal muscle fibre 
(Bowman and Raper, 1967).  
Our ability to identify sympathetic nerves has greatly advanced since these early studies, 
which relied mainly on the diameter of the nerve and/or myelination to discriminate nerves 
of sympathetic origin. Sympathetic nerves can now be easily and specifically labelled with 
antibodies to tyrosine hydroxylase, neuropeptide Y or dopamine-β-hydroxylase (Kim et al., 
2001; Yamamoto et al., 2000). Using this labelling, one recent study has shown evidence of 
sympathetic innervation of the NMJ in mice and enlargement of NMJ and upregulation of 
NMJ specific proteins in a mouse model of slow-channel CMS following β2AR agonist 
(clenbuterol) administration (Khan et al., 2016). A subsequent study demonstrated that this 
innervation increases during postnatal development and is present in many muscle groups 
(Straka et al., 2018). This suggests a role for the sympathetic nerves at the motor end-plate 
in synaptic homeostasis. 
The anatomical distribution of this possible sympathetic activity at the NMJ has clear 
relevance to the improvement in NMJ disorders seen with administration of exogenous 
sympathomimetics. The mechanisms by which sympathomimetics might mediate synapse 
integrity however, remain unknown.  
Given the temporality of the observed effect of β2AR-agonists in patients (a delayed and 
progressive improvement in weakness over months) it could be hypothesised that β2AR 
agonists cause morphological restoration of the NMJ in certain subtypes of CMS. The 
pathology of Dok7 and ColQ CMS subtypes may be unified by the role of both proteins in 
post-synaptic differentiation and AChR clustering. Given that it is these subtypes in which 
the effect of β2AR agonists is most established and dramatic, in particular β2AR agonists may 
play a role in postsynaptic differentiation and maintenance. Indeed, several lines of 
evidence point towards cAMP/PKA dependent pathways involved in metabolic stabilization 
of AChRs (Khan et al., 2016; Poyner, 1992; Rudolf et al., 2013b). In addition, PKA is known to 
regulate the activity dependent morphological change that occurs to AChRs during early 
synapse development in vivo and in vitro (Nelson et al., 2003) (Li et al., 2001). Salbutamol 
has also been shown to enhance AChR clustering in C2C12 myotubes (Clausen et al., 2018).  
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1.5 Animal models of CMS 
 
Animal models have been instrumental in understanding the role of many proteins in NMJ 
structure and function, and in investigating therapies which enhance neuromuscular 
transmission. Species used include rat and mouse, C. elegans, drosophila, frog, zebrafish, 
chick and canine models. The most frequently used, and arguably the most informative, has 
been the mouse model.  
1.5.1 Mouse models of congenital myasthenic syndromes 
 
The mouse NMJ is relatively large and easily accessible, and accurately reflects the human 
NMJ in many situations. While numerous differences between mouse and human NMJs 
exist, including morphological differences and temporal differences in development, many 
molecular pathways which impact on NMJ structure and function show considerable overlap 
(Tintignac et al., 2015). As previously discussed, knockouts of several NMJ proteins (agrin, 
rapsyn, MuSK, Dok7, laminins) lead to neonatal lethality. However, many CMS-related 
mouse models have been generated which exhibit myasthenic weakness and replicate the 
human disease to varying degrees (Table 4). 
Experiments in this thesis utilised CollagenQ deficient mutant (ColQ-/-) mice. Original 
founders of the ColQ-/- mouse line were provided by the Krejci laboratory, Inserm, Paris. This 
mouse line was obtained through homologous recombination. Male and female 
heterozygotes were mated to produce wild type and nullizygote littermates for the 
experiments in this thesis. ColQ-/- mice lack all asymmetric AChE at the NMJ. This is 
analogous with the ColQ CMS mutations in humans, which typically result in a complete 
absence of AChE at the NMJ (Ohno et al., 2000). The mice exhibit low body weight, 
approximately 50% of WT littermates, and limb muscle weakness (Feng et al., 1999). NMJs 
in ColQ-/- exhibit varying degrees of structural defects, with some synapses appearing 
smaller, immature or fragemented (Feng et al., 1999). However, these mice do survive into 
adulthood. This suggests that NMJs in these mice, as in ColQ CMS patients, have adaptive 
mechanisms to compensate for the lack of AChE. 
Several objective assessments of muscle strength and fatigue can be used in characterising 
the phenotype and effect of treatment in these models. These include the inverted screen 
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test, grip strength test (forelimb or forelimb and hindlimb), and the treadmill fatigue test 
(Bonetto et al., 2015; Castro and Kuang, 2017). In neonatal mice, tests are more limited but 
the hindlimb suspension test and righting reflex can provide objective measures (Feather-
Schussler and Ferguson, 2016). These tests are of principal importance, given the potential 
for poor correlation between abnormalities in NMJ morphology  and NMJ function (Willadt 
et al., 2016). 
Several important morphological differences between mouse and human NMJs have been 
characterised, and consideration of these is essential in interpreting pre-clinical studies 
using mouse models (Jones et al., 2017; Slater et al., 1992). Relative to the size of the 
muscle fibre, human NMJs are significantly smaller than mouse NMJs. In particular, the area 
of the motor nerve terminal and the area of AChR rich membrane are reduced (Slater et al., 
1992). In addition, mouse NMJs are much less fragmented than humans (Jones et al., 2017). 
The extent of postjunctional folding in humans is much greater than in mice, meaning that 
despite reduced quantal content compared to mouse NMJs, neuromuscular transmission is 
significantly enhances by postsynaptic amplification (Slater et al., 1992). 
In terms of the timeline development of the NMJ, very few studies exist in humans. In 
humans, synapse elimination occurs between 16 and 25 weeks in utero, compared to 2-3 
weeks postnatally in mice (Brown et al., 1976; Hesselmans et al., 1993). In addition, NMJs 
change very little after the first year of life and remain very stable across the human lifespan 
(Hesselmans et al., 1993; Jones et al., 2017). This is in contrast to the apparent NMJ 
remodelling which takes place in mice (Jones et al., 2017; Valdez et al., 2012; Willadt et al., 
2016). 
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CMS subtype Gene Protein Allele type Phenotype NMJ abnormalities Therapies tested 
AChR 
deficiency(Missias et 
al., 1997) 
CHRNE AChR ε subunit Knockout Weakness apparent from 4w, lethality 10-12w. Reduced AChR density, reduced AChR area  
Slow channel 
syndrome 
CHRNE, 
CHRND AChR ε subunit 
Overexpression of mutant 
AChR εL269F or δS268F 
(Gomez et al., 1997) 
Rapid respiratory rate, fatigable weakness 
from 6w, normal lifespan 
Progressive myopathy and synaptic 
degeneration, focal Ca2+ deposition and 
accumulation of vacuoles 
Fluoxetine(Zhu et 
al., 2015) 
Expression of εL221F 
mutation on CHRNE 
knockout (Chevessier et 
al., 2012) 
Fatigable weakness from 6w, normal lifespan Fragmented elongated endplates, damaged PJ folds 
Ephedrine(Webster 
et al., 2013) 
MuSK MUSK MuSK 
V789M mutation 
hemizygous with MuSK 
knockout(Chevessier et al., 
2008) 
Reduced body weight, thoracolumbar 
kyphosis, weakness from P18, lethality 8-
16w 
Axonal overgrowth, loss of end-plate band, 
smaller and fragmented end-plates  
Deletion of MuSK frizzled-
like domain 
(MuSKΔCRD)(Messéant et 
al., 2015) 
Fatigable weakness after 3w AChR deficiency, motor axon outgrowth 
Lithium 
chloride(Messéant 
et al., 2015) 
Dok7 DOK7 Dok7 
Homozygous for common 
c.1124_1127dupTGCC 
mutation (Arimura et al., 
2014)  
Severe weakness, low body weight, lethality 
within 2w Small, immature NMJs 
DOK7 AAV gene 
therapy (Arimura 
et al., 2014) 
End-plate 
acetylcholinesterase 
deficiency 
COLQ ColQ Knockout(Feng et al., 1999) 
Weakness from  P5, low body weight, 30% 
lethality at 12w, improvement with age 
Variable NMJ morphology, muscle atrophy, 
reduced MuSK expression(Feng et al., 1999; 
Sigoillot et al., 2016, 2010) 
 
Agrin AGRN Agrin 
Homozygous for 
p.Phe1061Ser mutation 
(nmf380)(Bogdanik and 
Burgess, 2011) 
Myasthenic weakness from P13, atrophy, 
low body weight, lethality 12-16w 
Progressive degeneration of NMJs, motor nerve 
sprouting and AChE loss  
GFPT1 GFPT1 
Glutamine-
fructose-6-
phosphate 
transaminase 1 
Muscle specific 
knockout(Issop et al., 
2018) 
Mild myasthenic weakness, normal lifespan Reduced AChR area, reduced postjunctional folds, tubular aggregates in muscle  
VAMP1 VAMP1 Synaptobrevin 
Spontaneously generated, 
homozygous null 
mutation(Nystuen et al., 
2007) 
Severe weakness and atrophy, lethality 
before 3w Small NMJs, reduced EPP amplitudes  
Table 4: Summary of  mouse models of congenital myasthenic syndrome
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1.5.2 Zebrafish models of NMJ dysfunction 
 
There are many factors which make zebrafish, Danio rerio, a useful model organism, 
including their ability to breed large numbers of offspring rapidly, their rapid ex utero 
development, their optical transparency and the ease of several methods of genetic 
manipulation which can be used (Gibbs et al., 2013). In addition, zebrafish offer several 
specific qualities making them an attractive model for the study of human neuromuscular 
diseases. Their motility and movement patterns can be easily and quantitatively measured 
in a reproducible way from just 24 hours post fertilisation (hpf). In addition, skeletal muscle 
is the largest organ of the developing zebrafish, and shares many structural and molecular 
features with mammalian muscles (Dou et al., 2008; Hirata et al., 2007; Parsons et al., 2002).  
1.5.2.1 Muscle development in the zebrafish 
Each muscle fibre type in zebrafish has distinct morphological and developmental properties 
(Figure 11) (Ochi and Westerfield, 2007). The first muscle fibres to differentiate are the slow 
twitch fibres. These migrate from a medial position near the notochord to the periphery of 
the somites by 16hpf. Following this, fast-twitch fibres differentiate and form the bulk of the 
somite (Bassett and Currie, 2003). By 24hpf, somitic muscle in the trunk of the zebrafish 
forms a series of pairs of chevron-shaped somites, divided by sheets of ECM, the vertical 
myosepta. Individual muscle fibres span the entire length of the somite, parallel to these 
vertical myosepta. The dorsal (upper) and lower (ventral) halves of each somite is further 
divided by another sheet of ECM, the horizontal myoseptum. The myoseptae (vertical and 
horizontal) are the main sites of NMJ formation (Blagden et al., 1997; Ochi and Westerfield, 
2007).  
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1.5.2.2 NMJ development in zebrafish 
Zebrafish NMJs share many similarities with mammalian NMJs. Zebrafish NMJs are 
cholinergic and have pentameric AChRs. In addition, many of the key NMJ proteins in 
zebrafish have mammalian counterparts with identical or similar functions (Bayés et al., 
2017). 
In terms of NMJ development, this occurs in a similar stepwise manner in zebrafish as it 
does in mammals. Prior to arrival of the motor axons, a prepatterned band of AChRs form in 
the central region of adaxial muscle fibres, some of which will be incorporated into NMJs 
when the axonal growth cone makes contact between the nerve and muscle (Flanagan-
Steet et al., 2005; Panzer et al., 2006). The first NMJs are formed between 16 and 24 hpf, 
and in parallel to the muscle somite development, the NMJs form in a rostral to caudal 
sequence (Myers et al., 1986; Westerfield et al., 1986). AChR clusters not incorporated into 
NMJs will disappear. By 120 hpf, most synapses are localized at the end of muscle fibres at 
Figure 11: Schematic of cross-section of zebrafish muscle layers by 24hpf. Adaxial muscle cells migrate laterally 
to form a superficial monolayer of slow twitch muscle, whilst lateral presomitic cells remain deep and form a 
layer of fast twitch muscle 
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the vertical myosepta and are scattered over the entire length of muscle fibres (Westerfield 
et al., 1986). 
1.5.2.3 Zebrafish models of congenital myasthenic syndromes 
Studies on motor pathway choice in zebrafish have demonstrated that each segmentally 
arranged myotomal muscle of the zebrafish trunk is initially innervated by just three primary 
motor neurons, termed CaP, MiP and RoP, and each of these three primary motor neurons 
has a distinct spinal cord position and a stereotyped trajectory (Myers et al., 1986). Initially, 
all three motor growth cones extend along the medial surface of the somites toward a 
somitic “choice point” on the horizontal myoseptum (Myers et al., 1986; Schneider and 
Granato, 2003). Here, all growth cones pause and make contacts with muscle cells, and then 
select a cell-type specific path to ventral, dorsal or medial myotomal regions.  
The speed at which the neuromuscular system develops, has allowed the consequences of 
mutations in key synaptic proteins that are lethal in mammals to be examined in zebrafish 
before death occurs, including functional knock-outs of AChRs, AChE, MuSK, rapsyn, GFPT1 
and Dok7 (Müller et al., 2010a; Ono et al., 2001, 2002; Senderek et al., 2011; Westerfield et 
al., 1986; Zhang et al., 2004a). The ability to perform mutagenesis screens in zebrafish has 
revealed the molecular mechanisms underlying many aspects of NMJ development. The 
spontaneous zebrafish mutant phenotype twitch once is caused by rapsyn defects (Granato 
et al., 1996). This model lacks AChR clusters. In addition, rapsyn fails to localised to the 
postsynaptic membrane in these zebrafish (Ono et al., 2002). Other mutants include nic1, 
which lacks the α subunit of AChRs, sofa potato, which is due to a point mutation in the δ 
AChR subunit and lacks AChRs,  twister, which has a gain-of-function mutation in the α AChR 
subunit and displays pre- and postsynaptic defects and the AChE 
mutants ache and zieharmonika which also show reduced AChR clustering (Behra et al., 
2002; Downes and Granato, 2004; Ono et al., 2001; Westerfield et al., 1990). In addition, 
several point mutations of NMJ genes have been developed using random mutagenesis by 
use of N-ethyl-N-nitrosourea (ENU) (Daikoku et al., 2015). In many of these models, new 
functional roles for the synaptic proteins have been characterised.  
zMuSK(unplugged) has two splice variants; SV1 which has a role in AChR prepatterning and 
axon guidance, and SV2 (full-length) which is dispensable for both of these processes (Jing et 
al., 2009; Zhang et al., 2004b). zMuSK transcripts are first detectable at 10 hpf and 
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expression is restricted to in adaxial muscle cells until late somitogenesis (>24hpf) when it is 
downregulated to coincide with the arrival of motor growth cones and lateral migration of 
adaxial cells (Zhang et al., 2004b). Unplugged null mutant zebrafish display axon guidance 
defects, with the motor axon stalling and/or producing abnormal branches at the choice 
point (Zhang et al., 2004b). The role of wnts in MuSK signalling was first identified in 
zebrafish, where it was shown that wnt11r binds to zMuSK, and that wnt11r, wnt4a and 
MuSK are mutually required for AChR prepattern (Gordon et al., 2012; Jing et al., 2009).  
There are two Dok7 isoforms expressed in zebrafish. These are expressed from 10hpf when 
somatic segmentation begins, and peak at 19-24hpf, coinciding with NMJ formation. 
Functional knockdown using an antisense morpholino oligonucleotide was shown to lead to 
dramatic reduction in AChR prepattern, and reduced size of areas of synaptic contacts on 
the horizontal myoseptum (Müller et al., 2010b). In addition, these zebrafish morphants 
were shown to have structural abnormalities in slow muscle fibres, in-keeping with the 
myopathic features often found in Dok7 CMS patients (Müller et al., 2010b).  
Zebrafish mutants lacking the MuSK and agrin binding domains of LRP4 have also been used 
to explore the specific roles of LRP4 in synapse formation (Remédio et al., 2016). Without 
LRP4, zebrafish fail to form en passant NMJs. However, although LRP4 is essential for AChR 
prepatterning in mice, it is not required for this process in zebrafish (Remédio et al., 2016). 
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Figure 12: Schematic of the path taken by motor neurons in zebrafish somites during NMJ development. Primary CaP 
(orange), MiP (purple), and RoP (green) motor neurons project axons from the spinal cord. Each primary motoneuron 
projects its axon to a different area of muscle. Arrow marks the choice point on the horizontal myoseptum. SC: spinal cord. 
NC: notochord. Adapted from Panzer et al 2005. 
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Chapter 2. Thesis Objectives and Hypotheses 
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2.1 Thesis Objectives and Scope 
 
The main aims of this thesis were 
1. To improve our understanding of the role of β2AR agonists in NMJ development by 
utilising zebrafish models of CMS 
2. To explore the effect of β2AR agonists in a CMS mouse model 
3. To identify and delineate poorly understood aspects of the clinical features of CMS 
4. To genetically characterise undiagnosed CMS patient cohorts 
 
2.2 The beta-adrenergic agonist salbutamol modulates neuromuscular junction development in 
zebrafish models of human myasthenic syndromes 
 
The mechanisms underlying the clinical benefit from β2AR agonists in the treatment of CMS 
are not known. In this study, I utilised two zebrafish models to examine the effect of the 
selective β2AR agonists on NMJ development. Many factors made these zebrafish models 
the ideal model to study the effect of salbutamol. The rapid development of the NMJ and 
large numbers of morphants tested meant that changes in NMJ morphology could be 
robustly quantified. This allowed me to confirm precisely how salbutamol altered NMJ 
morphology at each stage of NMJ development. In particular, the observed increased in 
AChR prepattern would not have been possible to observe in mammalian models. In 
addition, the use of zebrafish meant I could achieve functional knockdown of Dok7 and 
MuSK, something which would have been embryonically lethal in mouse models. I used 
morpholino oligonucleotides which inhibited pre-mRNA splicing of Dok7 and MuSK 
respectively, confirming reduction in mRNA levels by PCR. The effects of salbutamol on 
these models were compared to zebrafish injected with a control morpholino directed 
against human β-globulin mRNA. This study showed that salbutamol altered many steps of 
NMJ development in zebrafish with functional knockdown of Dok7 and MuSK, and could 
rescue motility defects in these models. In addition, using a selective β2AR antagonist 
(ICI118,551) it was possible to block the effect of salbutamol, confirming that the 
mechanism of NMJ alteration was via the β2AR, and not via an off-target effect. One final 
and exciting outcome of this study was that administration of forskolin replicated the 
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beneficial effects of salbutamol in these models. Forskolin is an AC activator, thus it directly 
increases cAMP without activating the β2AR. This finding suggested that these patients may 
be amenable to alternative therapies which do not activate β2ARs, which is of importance 
given the challenges of side-effects, cardiotoxicity and β2AR desensitisation that arise with 
chronic β2AR agonist use. 
 
2.3 Salbutamol modifies the neuromuscular junction in a mouse model of ColQ myasthenic 
syndrome 
 
Experiments in zebrafish pointed towards β2AR agonists having a direct effect on the NMJ 
during development. However, this model was distant from the human condition in many 
ways. Apart from being a lower phylogenetic species, the use of the morpholino models 
meant that the effect of salbutamol could only be analysed at the embryonic stage of the 
zebrafish. In addition, it meant that salbutamol could only be administered for up to 5 days. 
In humans, the effect of salbutamol on muscle weakness is gradual, peaking after 6 months 
of treatment. In addition, in most CMS patients, it is not until clinical weakness develops and 
a diagnosis is made that treatment is started, which would usually be after NMJs are fully 
matured. I therefore sought to investigate the effect of salbutamol on the NMJ in a mouse 
model. I utilised the ColQ-/- mouse model, a model of AChE deficiency. AChE deficiency, 
along with Dok7, is a CMS subtype in which the beneficial effect of salbutamol is well 
established, and in which AChE inhibitors are often detrimental. This mouse model exhibits 
myasthenic weakness and NMJ abnormalities, but survives into adulthood. This allowed for 
a relatively long-term treatment regimen in these animals, with knockouts receiving 7 weeks 
of daily salbutamol via subcutaneous injections. 
Expanding on the findings in the zebrafish models, 7 weeks of salbutamol lead to alterations 
in many parameters of NMJ structure in the ColQ-/- mouse. Predominantly, these changes 
were in the postsynaptic membrane. At an ultrastructural level, NMJs from mice treated 
with salbutamol had an increase in postjunctional folding, an effect which is likely to be 
functionally significant for neuromuscular transmission. Furthermore, mice treated with 
salbutamol had an increase in the expression of membrane bound MuSK, raising the 
possibility that salbutamol acts via a MuSK mediated pathway in this model. 
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2.4 Congenital myasthenic syndrome with episodic apnoea: clinical, neurophysiological and 
genetic features in the long-term follow-up of 19 patients 
 
Congenital myasthenic syndrome with episodic apnoea (CMS-EA) is one of the least 
understood aspects of CMS. It was initially felt to be synonymous with mutations in CHAT, 
but several case reports and case series suggested it may occur in other genetic subtypes. 
CMS-EA is a cause of significant morbidity and mortality in children with CMS. In this study I 
sought to improve understanding of exacerbating factors, diagnostic clues, response to 
treatment and prognosis in patients with CMS-EA, in the hope of providing mechanistic 
insights into these events and of providing much needed clinical data on long-term 
outcomes. This was facilitated by the resource of tertiary referrals for clinical management 
and exome analysis for patients with CMS from around the world. From this cohort, 19 
cases with CMS-EA were identified. The genotypes of these cases included mutations in 
CHAT but also SLC5A7, COLQ, CHRNE, RAPSN and MYO9A. This study revealed several 
unexpected findings. In particular, many of these CMS cases had CNS involvement, 
something that was not felt to be part of the CMS phenotype. Since the discovery of several 
recent presynaptic genes however, it is clear that many new CMS subtypes have a more 
complex presentation than a neuromuscular disorder alone. Several other findings pointed 
towards EA being a centrally mediated mechanism, although this remains to be confirmed. 
A relatively large proportion of CMS patients with this phenotype were undiagnosed when I 
identified them in 2017, suggesting the presence of additional presynaptic genes. In fact, 
since publication an additional three genes have been described which cause presynaptic 
defects and respiratory failure (MUNC13-1, VAMP1, LAMA5).  
 
2.5 Impaired Presynaptic High-Affinity Choline Transporter Causes a Congenital Myasthenic 
Syndrome with Episodic Apnoea. 
 
In two cases of CMS-EA undergoing exome analysis with collaborators at Inserm, Paris, 
mutations in the presynaptic high affinity choline transporter (encoded by SLC5A7) were 
identified. Mutations in SLC5A7 had not been associated with CMS before, although 
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dominant mutations are associated with distal hereditary motor neuronopathy (dHMN7). 
After reviewing clinical histories and examinations from the cohorts of genetically 
undiagnosed CMS referred to our centre, I identified 56 cases with phenotypic overlap with 
CMS due to CHAT mutations. After sequencing exons 1-10 of SLC5A7 in these cases, two 
further cases carrying loss of function variants were identified. In the first case, two 
heteroallelic missense mutations were identified, c.524A>G (p.Tyr175Cys) and c.1030G>C 
(p.Val344Leu). The second case harboured two missense variants c.331T>C (p.Tyr111His) 
and c.1252T>G (p.Phe418Val). Segregation of the variants revealed that all had been 
inherited from heterozygous, healthy carriers apart from c.331T>C which had arisen de 
novo.  
39 additional cases were sequenced by collaborators. In total, 4 cases with SLC5A7 CMS 
were identified from a cohort of 95 genetically undiagnosed CMS-EA cases. Since 
publication, further cases of SLC5A7 CMS have been described (Pardal-Fernández et al., 
2018; Wang et al., 2017). Importantly, almost all cases show response to pyridostigmine, 
making the identification of this syndrome of great importance. The variants were 
confirmed to affect the activity of ChT in transfected HEK293T cells. In addition, the 
reduction of ChT activity was more severe in the variants associated with CMS-EA than in 
the previously reported variants associated with dHMN.  This suggests that there may be a 
genotype-phenotype correlation in terms of the severity of the phenotype and the 
reduction in choline transport caused by the mutations.  
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3. The beta-adrenergic agonist salbutamol modulates neuromuscular junction 
development in zebrafish models of human myasthenic syndromes 
 
 
McMacken G, Cox D, Roos A, Müller J, Whittaker R, Lochmüller H. The beta-adrenergic 
agonist salbutamol modulates neuromuscular junction formation in zebrafish models of 
human myasthenic syndromes. Hum Mol Genet. 2018 May 1;27(9):1556-1564. 
 
Contribution: I designed and carried out the experiments. I carried out the morpholino 
injections, analysis of zebrafish motility, immunostaining and microscopy of whole mount 
zebrafish and image analysis using ImageJ. I analysed the results and wrote the main draft of 
the manuscript.  
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4. Salbutamol modifies the neuromuscular junction in a mouse model of ColQ 
myasthenic syndrome 
 
McMacken G, Spendiff S, Whittaker RG, O’Connor E, Howarth RM, Boczonadi V, Horvath R, 
Slater CR, Lochmüller H. Salbutamol modifies the neuromuscular junction in a mouse model 
of ColQ myasthenic syndrome. In Press. Hum Mol Genet 2019 
 
Contribution: I designed the salbutamol treatment protocol in the mouse models. I carried 
out analysis of muscle strength and body weight in the ColQ mice. I carried out 
immunostaining of whole mount muscle for NMJs and subsequent image analysis using 
ImageJ. I carried out sectioning and staining of gastrocnemius and soleus muscles and 
subsequent analysis of fibre type and area, and staining for additional NMJ proteins. I 
analysed the electron microscopy NMJ images using ImageJ. I drafted the manuscript.  
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5. Congenital myasthenic syndrome with episodic apnoea: clinical, 
neurophysiological and genetic features in the long-term follow-up of 19 
patients 
 
 
McMacken G, Whittaker RG, Evangelista T, Abicht A, Dusl M, Lochmüller H. Congenital 
myasthenic syndrome with episodic apnoea: clinical, neurophysiological and genetic 
features in the long-term follow-up of 19 patients. J Neurol. 2018 Jan;265(1):194-203 
Contribution: I designed the study, collected the data and analysed the results. I drafted the 
manuscript.   
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6. Impaired Presynaptic High-Affinity Choline Transporter Causes a Congenital 
Myasthenic Syndrome with Episodic Apnoea. 
 
 
Bauché S, O'Regan S, Azuma Y, Laffargue F, McMacken G, Sternberg D, Brochier G, Buon C, 
Bouzidi N, Topf A, Lacène E, Remerand G, Beaufrere AM, Pebrel-Richard C, Thevenon J, El 
Chehadeh-Djebbar S, Faivre L, Duffourd Y, Ricci F, Mongini T, Fiorillo C, Astrea G, Burloiu CM, 
Butoianu N, Sandu C, Servais L, Bonne G, Nelson I, Desguerre I, Nougues MC, Bœuf B, 
Romero N, Laporte J, Boland A, Lechner D, Deleuze JF, Fontaine B, Strochlic L, Lochmuller H, 
Eymard B, Mayer M, Nicole S. Impaired Presynaptic High-Affinity Choline Transporter Causes 
a Congenital Myasthenic Syndrome with Episodic Apnea. Am J Hum Genet. 2016 Sep 
1;99(3):753-61.  
 
Contribution: I identified 56 cases with a phenotype in-keeping with CMS-EA from a large 
cohort of possible CMS cases. I performed sequencing of exons 1-9 of SLC5A7 in these 
patients. I identified pathogenic SLC5A7 mutations. I clinically characterised these cases and 
contributed to the final draft of the manuscript.  
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Discussion and Future Work 
 
The current treatment strategies for CMS are limited in that they are poorly understood, of 
varying efficacy and often limited by systemic side-effects. The optimum treatment regimen 
remains to be established and is difficult to study systematically given the individual rarity of 
these disorders. In many patients, optimum doses of sympathomimetics cannot be achieved 
due to side-effects and cardiotoxicity and despite promising pre-clinical studies in other 
neuromuscular disorders, widespread activation of β2ARs limits clinical use. In order to 
develop more targeted therapies, an improved understanding of the mode of action of 
these drugs at the NMJ is essential.   
Due to the known effects of β2AR agonists on skeletal muscle (increased protein synthesis, 
reduced degradation, change in fibre type proportion), it has been hypothesised that the 
clinical benefit in CMS is primarily due to an anabolic effect in skeletal muscle. Indeed, the 
CMS subtypes which typically respond to these drugs are those which are also associated 
with myopathic changes on muscle biopsy (e.g. Dok7 and ColQ CMS). However, the findings 
in this thesis refute this by demonstrating that salbutamol directly affects NMJ structure in 
zebrafish and mouse models of CMS. Some findings pointed towards salbutamol altering 
MuSK dependent pathways, including the increase in prepatterning in zebrafish (a process 
which is orchestrated by MuSK) and an increase in the expression of membrane bound 
MuSK in the ColQ-/- mouse. Further studies will be required in order to determine whether 
MuSK activity is altered by salbutamol, and to explore which pathways upstream of MuSK 
are altered by β2AR signalling.  
What are the possible pathways by which β2AR agonist induction of cAMP/PKA signalling 
could stabilize motor end-plates? The DGC stabilizes the myofibre membrane by linking the 
actin-based cytoskeleton to the basal lamina. The DGC also has well-evidenced roles in AChR 
clustering and AChE anchoring at the synaptic basal lamina (Bayne et al., 1984; Campanelli 
et al., 1994; Peng et al., 1999; Pilgram et al., 2010). Several components of the DGC 
physically associate with, or are phosphorylated by, PKA thus the activity of the DGC 
components could be modulated by the cAMP/PKA signalling pathway (Ceccarini et al., 
2007; Fratini et al., 2012).  
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A further cell signalling pathway which is known to interact with the cAMP/PKA pathway is 
the Wnt signalling pathway. PKA inhibits the ubiquitination co-activator of Wnt, β-catenin, 
allowing its accumulation and the subsequent activation of the Wnt pathway (Hino et al., 
2005). Another potential target is the ECM MuSK ligand biglycan, which has been shown to 
play key roles in synapse maintenance (Amenta et al., 2012). Biglycan regulates agrin 
induced MuSK phosphorylation and is particularly important in mature synapses, rather 
than during NMJ development (Amenta et al., 2012). Biglycan gene expression has been 
shown to be regulated by the cAMP/PKA pathway in other tissues (Ungefroren et al., 1998, 
1997). In addition, a study using sympathetic ablation in mouse skeletal muscle 
demonstrated that the SNS may modulate levels of AChRs by regulating AChR turnover via 
the Gαi2 -Hdac4-Myogenin-MuRF1pathway (A. C. Z. Rodrigues et al., 2019; Rudolf et al., 
2013a). Thus multiple pathways could be activated by β-agonist cAMP/PKA signalling to 
induce AChR stabilization and modulation of key components of the post-synaptic 
apparatus.  
Most evidence has pointed towards postsynaptic modulation by sympathomimetics. 
However, one recent study has focussed on the effect of β-agonists on presynaptic vesicle 
release (A. Z. C. Rodrigues et al., 2019). This showed that acute or chronic administration of 
salbutamol lead to an increase in synaptic vesicle release, and these effects could be 
blocked by reducing intracellular Ca2+. This suggests that βAR agonists may have pre and 
postsynaptic effects (A. Z. C. Rodrigues et al., 2019).  
My experiments in zebrafish showed that increasing intracellular cAMP downstream of the 
β2AR could replicate the effects of salbutamol; in fact, the rescue effect of forskolin 
surpassed that observed with salbutamol. The diterpene derivative forskolin is an AC 
activator. Forskolin has been used in several clinical settings including asthma, congestive 
cardiomyopathy and obesity, and is safe and readily available. It is not currently in use in the 
treatment of CMS or any neuromuscular disorder, however. ACs are an important 
pharmacological target for many reasons. The nine AC isoforms have tissue-specific 
distribution, with isoforms 2, 6, 7 and 9 being expressed in skeletal muscle. In addition, as 
AC activation is receptor independent, it does not pose the same problems with loss of drug 
efficacy during long-term treatment. In follow up experiments, I am exploring how novel 
compounds which activate the muscle specific isoforms of AC can alter AChR clustering in 
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vitro. The development of a muscle specific AC activator could be an interesting therapeutic 
pathway in the management of CMS patients.  
Despite huge advances in the last decade, many aspects of CMS are not understood. 
Episodic apnoea (EA) was one identified clinical feature on which data was lacking, and 
which is associated with significant mortality and morbidity. The study of a large cohort of 
CMS patients referred to our centre, revealed new insights into this condition, including 
prognostic factors, diagnostic pitfalls and genotype associations. This study highlights the 
value of data-sharing for rare diseases such as CMS. Without multi-centre collaboration, 
generation of clinical data on CMS-EA would be very limited.  
The mechanisms underlying CMS-EA are yet to be defined, but understanding them will be 
essential in order to improve outcomes for this cohort. The cohort I identified had features 
which pointed towards a centrally mediated mechanism for recurrent apnoeic events. 
Respiratory rhythm is produced by two respiratory rhythm generators in the medulla 
oblongata, the parafacial respiratory group and the pre-Bötzinger complex (Koshiya et al., 
2014; Smith et al., 1991). This respiratory rhythm is modulated by sites in the lower 
brainstem, including the Bötzinger complex, and in the pons, including the Kölliker–Fuse 
nucleus and the parabrachial complex (Alheid et al., 2004; Smith et al., 2007). Respiratory 
motor activities are then formed through premotor and motor-efferent networks including 
interneurons in the brainstem and spinal cord, which drive the muscles in the respiratory 
pump and the muscles regulating airway resistance (De Troyer et al., 2005). Cholinergic 
innervation and nAChRs are intrinsically involved in respiratory control in both the 
brainstem and spinal cord. Pontine cholinergic neurons can accelerate respiratory rate 
during REM sleep, and can activate breathing during wakefulness (Kubin and Fenik, 2004). 
AChRs can also modulate motor output of respiratory motor neurons (Bellingham and Funk, 
2000). In addition, activation of AChRs in the pre-Bötzinger complex can modulate 
respiratory rhythm (Murakoshi et al., 1985; Shao and Feldman, 2001; Stewart and Anderson, 
1968). Given the contribution of cholinergic signalling to respiratory control, it is possible 
that CMS mutations resulting in impaired ACh synthesis and release may disrupt the central 
neural control of respiration.  
However, the discovery that SLC5A7 mutations cause CMS-EA also raises an alternative 
explanation. The dHMN phenotype associated with SLC5A7 mutations is associated with 
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vocal cord paralysis, raising the possibility that EA is caused by pharyngeal collapse. Another 
gene which is known to be associated with CMS-EA is SCN4A which encodes Nav1.4 on the 
postsynaptic membrane. SCN4A mutations are more commonly associated with the skeletal 
muscle sodium channelopathies (hyperkalemic periodic paralysis, hypokalemic periodic 
paralysis, paramyotonia congenita and potassium-aggravated myotonia) which are caused 
by gain of function mutations (Lee et al., 2009). In infancy, these conditions are associated 
with brief, recurrent episodes of life-threatening respiratory muscle myotonia and 
laryngospasm causing apnoea, hypoxia, and cyanosis (Gay et al., 2008; Matthews et al., 
2011; Yoshinaga et al., 2012). In addition, 4 cases with SCN4A mutations were recently 
identified from DNA of a cohort of 278 cases of sudden infant death syndrome (Männikkö et 
al., 2018). 
In addition, examination of the cohort of CMS-EA cases revealed a relatively large 
proportion of these cases are genetically undiagnosed compared to CMS in general. Since 
the publication of this cohort, new presynaptic genes associated with CMS-EA have been 
identified. These patients have now all undergone whole exome sequencing, and analysis is 
ongoing for mutations in the newly described CMS genes and for novel presynaptic genes.  
The identification of the novel presynaptic CMS gene SLC5A7 is another treatable cause of 
CMS-EA associated with defects in ACh re-uptake and recycling. Dominantly and recessively 
acting SLC5A7 mutations can lead to distinct clinical outcomes: a distal hereditary motor 
neuropathy with vocal cord paralysis (dHMN-VII) or a severe CMS-EA phenotype, 
respectively. Transmembrane SLC5A7 mutations (causing CMS) lead to severely impaired 
CHT transporter function, which is reduced to a greater extent than the reduction caused by 
the cytoplasmic C-terminus mutations (associated with dHMN-VII). Nonetheless, the dHMN-
VII associated mutations do exert a dominant-negative effect, as the reduction in choline 
transport is lower than would be expected in from haploinsufficiency alone (Barwick et al., 
2012). This variable impact on choline transport activity goes some way to explain these two 
distinct phenotypes. In addition, cell surface expression studies indicate that 
transmembrane mutations may not be effectively transported to the NMJ, preventing any 
possible dominant negative effect (Wang et al., 2017). This provides a potential explanation 
for the lack of dHMN phenotype in heterozygous carrier parents of the SLC5A7 CMS cases.   
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This finding is one of a series of recent discoveries highlighting the overlap between CMS 
and motor neuropathies. In an ongoing clinical study, I am further characterising this 
overlap using serial neurophysiological studies of the NMJ (RNS and SFEMG) in a cohort of 
patients with inherited motor neuropathies. In addition, this study will address the potential 
of therapeutic modulation of the NMJ with salbutamol in these conditions.  
The introduction of next-generation sequencing strategies has accelerated the pace of rare 
disease gene discovery. A definitive molecular diagnosis can negate the need for further 
diagnostic investigations, facilitate appropriate access to treatment, provide prognostic 
information, facilitate genetic counselling and allow reproductive choices for families. In 
addition, understanding the genetic basis of these undiagnosed CMS subtypes will provide 
further information on the biological pathways at the human NMJ, and the development of 
targeted therapies. However, although substantial progress has been made, the underlying 
genetic basis for approximately 10% of cases remain undiscovered. These remaining 
unsolved cases are likely to be more complex for several reasons: the disease may have a 
lack of homogeneity of clinical phenotype, the disease may be ultra-rare, affected 
individuals may harbour variants which are not readily detected by whole exome/genome 
sequencing, and there may be a lack of clear investigative findings. The discovery of disease-
gene associations requires confirmation of pathogenic variants in multiple unrelated 
individuals with an overlapping phenotype (Thompson et al., 2014). Therefore, data-sharing 
using standardised frameworks and with careful phenotypical characterisation will be crucial 
if the discovery of CMS causative genes is to continue at the current pace.  
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Conclusions 
 
In recent decades there have been enormous advances in our understanding of the 
physiology and pathology of neuromuscular transmission, and the group of diseases 
associated with NMJ dysfunction is ever more clinically diverse. Emerging in parallel is the 
increasing implication of the NMJ in diseases beyond congenital and autoimmune 
myasthenia as a secondary pathological target. 
In many of these conditions, the underlying pathomechanisms remain unclear. Treatments 
for the range of diseases affecting the NMJ are still limited. Furthermore, important 
unanswered questions remain about some of the most commonly used drugs. The essential 
task of developing improved treatments depends on enhancing our understanding of these 
underlying pathological mechanisms.   
A primary aim of this thesis was to address the effect of βAR agonists in CMS. These 
experiments have demonstrated that salbutamol directly effects NMJ structure during 
development and maintenance, providing a possible explanation for the clinical benefit 
observed in patients. In addition, the data generated on the long-term outcomes of patients 
with CMS-EA will provide valuable information in a clinical setting, and insights into the 
mechanism underlying this unexplained clinical feature.  Finally, through careful 
phenotyping of undiagnosed CMS patients, this work has contributed to the discovery of a 
novel presynaptic CMS gene.  
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Abstract
Inherited defects of the neuromuscular junction (NMJ) comprise an increasingly diverse range of disorders, termed
congenital myasthenic syndromes (CMS). Therapies acting on the sympathetic nervous system, including the selective b2
adrenergic agonist salbutamol and the a and b adrenergic agonist ephedrine, have become standard treatment for several
types of CMS. However, the mechanism of the therapeutic effect of sympathomimetics in these disorders is not understood.
Here, we examined the effect of salbutamol on NMJ development using zebrafish with deficiency of the key postsynaptic
proteins Dok-7 and MuSK. Treatment with salbutamol reduced motility defects in zebrafish embryos and larvae. In addition,
salbutamol lead to morphological improvement of postsynaptic acetycholine receptor (AChR) clustering and size of synaptic
contacts in Dok-7-deficient zebrafish. In MuSK-deficient zebrafish, salbutamol treatment reduced motor axon pathfinding de-
fects and partially restored the formation of aneural prepatterned AChRs. In addition, the effects of salbutamol treatment
were prevented by pre-treatment with a selective b2 antagonist. Treatment with the cyclic adenosine monophosphate
(cAMP) activator forskolin, replicated the effects of salbutamol treatment. These results suggest that sympathomimetics exert
a direct effect on neuromuscular synaptogenesis and do so via b2 adrenoceptors and via a cAMP-dependent pathway.
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Introduction
The development of the neuromuscular junction (NMJ) requires
several levels of organization, and occurs in a series of overlap-
ping steps which require interplay between presynaptic nerves
and postsynaptic muscle components. NMJs assemble in a nar-
row central region of the myofibre, where the density of acetyl-
choline receptors (AChRs) must be high in order to initiate a
synaptic potential (1). Prior to innervation, in the step termed
prepatterning, clusters of AChRs localize in a central band on
muscle fibres (2). Several intrinsic muscle proteins are required
for this process including the muscle-specific receptor tyrosine
kinase (MuSK) and the low-density lipoprotein receptor-related
protein-4 (LRP4) (3,4). Following innervation, some of these pre-
patterned AChR clusters are actively incorporated into develop-
ing NMJs, supporting the view that the postsynaptic apparatus
defines its central region for ingrowing motor axons (5). The ar-
riving motor nerve, and the agrin released by it, subsequently
stabilize the AChR clusters and cause the dispersal of non-
synaptic AChR clusters (6). Agrin binds the preformed MuSK/
LRP4 complex to initiate MuSK autophosphorylation and activa-
tion, thereby initiating a cascade of signalling pathways leading
to AChR clustering and postsynaptic differentiation (7,8). MuSK
also recruits the adaptor protein Downstream of Kinase-7
(Dok-7), which stimulates further MuSK phosphorylation (9,10).
Thus, the LRP4/MuSK/Dok-7 agrin receptor complex is indis-
pensable for tyrosine phosphorylation and clustering of AChRs.
Components of the LRP4/MuSK/Dok-7 complex are the tar-
gets of mutations responsible for subsets of congenital myas-
thenic syndromes (CMS), which are characterized by fatigable
muscle weakness (11). CMS are one of the few neuromuscular
diseases for which symptomatic treatments are readily avail-
able. For many subtypes, clinical benefit is gained from admin-
istration of acetylcholinesterase (AChE) inhibitors, which
augment the synaptic response to acetylcholine. For other CMS
subtypes, including those with mutations that cause deficits in
Dok-7, MuSK, and in end-plate AChE deficiency, the sympatho-
mimetics ephedrine and salbutamol are first-line treatment.
These drugs lead to increasing and sustained improvements in
muscle strength, with the effect peaking after 3–6 months of
commencing treatment (12–14). However, the mechanism by
which these drugs may alter neuromuscular transmission in
these patients is not known.
In order to address this, we examined the effects of the b2
agonist salbutamol on NMJ development in zebrafish. There are
several factors which make zebrafish a useful model system to
study synaptogenesis. NMJ development occurs in a similar se-
ries of steps in zebrafish as in mammals, with a diffuse elon-
gated band of prepatterned AChRs forming in the central region
of adaxial muscle fibres prior to the arrival of the motor growth
cone (5). The first NMJs are formed between 16 and 24 h post fer-
tilization (hpf) and by 120 hpf synapses are localized at the end
of muscle fibres (the vertical myosepta) and scattered over the
entire length of muscle fibres (15,16). The speed at which the
neuromuscular system develops has allowed the consequences
of deficiency of key synaptic proteins which would be lethal in
mammals to be examined in zebrafish before death occurs, in-
cluding functional knockouts of AChRs, AChE, MuSK, Rapsyn
and Dok-7 (17–21).
Here, we use antisense morpholino oligonucleotides (MO)
which knockdown expression of two key postsynaptic proteins,
Dok-7, which leads to impaired motility and smaller NMJs, and
unplugged, the zebrafish orthologue of MuSK, which demon-
strates aberrant motor axon pathfinding and impaired AChR
prepatterning (19,21,22). We show that salbutamol leads to im-
provement in AChR clustering, motor axon guidance and the
development of prepatterned AChR clusters, as well as having
functional benefit on motility and swim behaviour in zebrafish
embryos. In addition, we show that the primary effect of salbu-
tamol on NMJ development is mediated via b2 receptors and via
the cyclic adenosine monophosphate (cAMP)/protein kinase A
(PKA) pathway. Our results suggest that b2 agonists directly in-
fluence synaptic organization and that their therapeutic benefit
in myasthenic disorders may be through morphological restora-
tion of the NMJ.
Results
Salbutamol treatment of Dok-7 morphant zebrafish
improves motility and synaptogenesis
In zebrafish, knockdown of NMJ proteins usually affects motility
and swimming behaviour. The first locomotor behaviour stage
observed is spontaneous alternating tail movements inside the
chorion from 17 hpf. Dok-7 MO-injected embryos perform these
at a reduced frequency to wild-type (WT) embryos, when mea-
sured at 24 hpf (21). Following 24 h of salbutamol treatment,
Dok-7 embryos performed these tail twists at an increased fre-
quency compared with untreated Dok-7 embryos (Fig. 1A,
P< 0.01). After hatching from the chorion, zebrafish embryos re-
spond to touch stimulus rapidly by swimming away from the
stimulus. Approximately 50% of Dok-7 embryos demonstrate an
abnormal response to touch stimuli, and may make abnormal
twitching movements or fail to move away from the stimulus
(21). Following salbutamol treatment, an increased percentage
of Dok-7 embryos demonstrated normal swimming behaviour
following touch stimuli (Fig. 1B, P< 0.01).
The morphology of the NMJ was examined in the Dok-7 zebra-
fish by immunostaining of AChRs and presynaptic nerve termi-
nals (Fig. 2A). Although Dok-7 zebrafish lack prepatterned AChR
clusters, they do subsequently develop AChR clusters opposed to
the growth cone along the horizontal midline of each myotome
(the horizontal myoseptum). In Dok-7 embryos, this area of pre-
and postsynaptic co-localization is smaller than in WT embryos.
We calculated the area of co-localization following salbutamol
treatment as a percentage of the area of the myotome it occupied.
Following salbutamol treatment, the area of co-localization on
the horizontal myoseptum increased significantly (Fig. 2B, 6.2% in
treated Dok-7 embryos, compared with 5.5% in untreated Dok-7
embryos, P< 0.01). In addition, the number of AChR clusters
larger than 20 lm2 on myotomal muscle fibres increased follow-
ing salbutamol treatment (Fig. 2C, mean number of AChR clusters
per myotome 2.9 in treated Dok-7 embryos, compared with 1.49
in untreated Dok-7 embryos, P< 0.0001).
Salbutamol treatment alleviates axon pathfinding
defects in zMuSK zebrafish
The results of salbutamol treatment in the Dok-7 zebrafish
prompted us to explore the effect of salbutamol on NMJ devel-
opment when another key postsynaptic protein was knocked
down. We studied the effect of salbutamol in unplugged mor-
phants, the zebrafish homologue of MuSK. Unplugged has
two splice variants; splice variant 1 (SV1) which has a role in
AChR prepatterning and axon guidance, and splice variant 2
(full-length, FL) which is dispensable for both of these processes
(19,22). We used a MO targeting only the unplugged SV1
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isoform (19). Unplugged SV1 transcripts are first detectable at 10
hpf and expression is restricted to adaxial muscle cells until
late somitogenesis (>24 hpf) when it is downregulated to coin-
cide with the arrival of motor growth cones and lateral migra-
tion of adaxial cells, thus embryos were examined in the first 24
hpf (19). We refer to zebrafish embryos with MO knockdown of
unplugged SV1 as zMuSK.
In zebrafish, each myotomal muscle is initially innervated
by just three primary motor neurons, termed CaP, MiP and RoP
(16). Initially, all three motor growth cones extend along the me-
dial surface toward a ‘choice point’ on the horizontal myosep-
tum (16,23). Here, growth cones pause and make contacts with
muscle cells, and then select a specific path to ventral, dorsal or
medial myotomal regions.
In contrast to WT embryos, zMuSK embryos display charac-
teristic stalling and branching at the choice point, even though
their dorsal adaxial cells are properly specified and migrate cor-
rectly (19). Following treatment with salbutamol, zMuSK MO-in-
jected embryos displayed a restoration of axonal pathfinding
defects at 24 hpf (Fig. 3A and B); in untreated embryos, 51%
(n¼ 123/240) of imaged somites displayed axons which failed to
cross the midline at 24 hpf, compared with 14% (n¼ 34/240) in
embryos treated with salbutamol (P< 0.0001). In addition, zMuSK
knockdown causes complete absence or greatly reduced numbers
of AChRs at 24 hpf. In zMuSK MO embryos treated with salbuta-
mol, however, AChR clusters could be seen as a band on the hori-
zontal myotome at 24 hpf (Fig. 3C and D), which was similar
although not as organized as the band seen in WT embryos.
In order to ascertain whether salbutamol treatment had an ef-
fect on the formation of prepatterned AChR clusters, we examined
the caudal segments of embryos at 17 hpf for the presence of
AChR clusters prior to the arrival of the motor growth cone. In sal-
butamol-treated embryos, a partial rescue of the formation of pre-
patterned AChR cluster formation was observed (Fig. 3E and F).
The effects of salbutamol on NMJ development are via
the b2 receptor
In order to ascertain whether the effects seen following salbuta-
mol treatment were due to its action as a b2 agonist, or via an
off-target effect, we pre-treated zebrafish embryos with the se-
lective b2 antagonist ICI118, 551. Following 3 h of pre-treatment
with this b2 blocker, the addition of salbutamol failed to have
the same effect on motor axon growth cones (Fig. 4), indicating
that the effects observed are mediated via b2 receptors.
The effects of salbutamol on NMJ development are via
the cAMP signalling pathway
Agonist activation of b2 adrenoceptors stimulates a cascade of
intracellular signalling pathways, with the most prolific being
the cAMP/PKA pathway. Following b2-adrenoceptor stimula-
tion, the receptor couples to the Gas subunit and activates ade-
nylate cyclase, generating cAMP. However, several additional
pathways which are Gas-independent can also be activated by
b2-adrenoceptors binding (24). In order to ascertain whether the
downstream signalling pathway involved in rescue of the NMJ
morphology in zebrafish was via cAMP or via a Gas-independent
pathway, we treated zebrafish embryos with the adenylyl
cyclase activator forskolin. Following incubation for 24 h with
5lM forskolin, the effects of salbutamol axon pathfinding
(Fig. 5A and B) and AChR clustering (Fig. 5C) in zMuSK embryos
were replicated. In addition, forskolin treatment lead to an in-
crease in the number of prepatterned AChR clusters (mean 3.5
prepatterned clusters per myotome in forskolin-treated em-
bryos, compared with 0.5 in untreated embryos, P< 0.0001).
Discussion
The process of neuromuscular transmission is complex and in-
volves several levels of specialization. There are numerous cel-
lular and molecular pathways which may be potential
pathological or therapeutic targets. Given that b2 adrenoceptors
activate many signalling pathways linked to a variety of
changes in different tissues and cell types, the mechanisms of
improved neurotransmission by b-agonists may be numerous,
and may include postsynaptic expansion of end plates, growth
of presynaptic nerve terminals or restoration of normal levels of
neurotransmitter release. Zebrafish models allow the analysis
of the effect of b-agonists during each step of NMJ development,
Figure 1. Dok7 morphant zebrafish demonstrate improved motility in the presence of salbutamol. (A) When monitored at 24 hpf, Dok7 MO-injected embryos are able to
perform tail twisting movements in their chorion but do so at lower frequency than WT embryos. Following salbutamol treatment, Dok7 embryos performed tail twists
at an increased frequency (mean 6.1 per 60 s) compared with untreated embryos (mean 4.6 per 60 s). A total of 30 embryos were observed for each category. ** indicates
P<0.01, Student’s t-test, n ¼30 treated and 30 untreated embyros observed. (B) Dok7 embryos demonstrate equal percentages of normal and abnormal touch-evoke re-
sponse (TER) to stimuli at 48 hpf. Embryos treated with salbutamol demonstrate an increased percentage of normal swim behaviour. ** indicates P< 0.01, chi-square
test, n¼3 tests on 30 embryos were performed for each category. All error bars depict S.E.M.
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which in turn may give some indication as to which molecular
mechanisms may be involved, based on the previously charac-
terized role of key NMJ proteins at each of these steps. We ob-
served that salbutamol treatment led to morphological
improvement of the NMJ at several developmental steps: an
increase in the area of co-localization of presynaptic nerve ter-
minals and AChR clusters on the horizontal myoseptum in Dok-
7 MO-injected embryos, improvement in AChR clustering at in
Dok-7 MO-injected embryos, rescue of the axonal pathfinding
defects in zMuSK MO-injected embryos and improvement in
Figure 2. Salbutamol treatment of Dok-7 MO-injected zebrafish improves NMJ morphology. Lateral views of 48 hpf embryos with neuromuscular synapses labelled
with antibodies against SV2 (green, presynaptic vesicles) and aBTX (red, postsynaptic AChRs). Scale bar¼50 mm. (A) In Dok7 MO-injected embryos, the focal innervation
point along the horizontal myoseptum is reduced in size compared with wild type, but is increased following treatment with 20 mM salbutamol (arrows). In addition,
the morphology of myoseptal (boxes) and myotomal (asterisks) AChR clusters is partially rescued with salbutamol treatment. A representative 20 lm2 AChR cluster is
labelled with a bracket. (B) Following salbutamol treatment, the area of synaptic contact on the horizontal myoseptum is significantly increased (** indicates P<0.01,
Student’s t-test, n ¼160 treated and 160 untreated myotomal segments examined). (C) Salbutamol treatment caused a significant increase in the number of AChR clus-
ters>20 lm2 per myotome in Dok7 zebrafish embryos (**** indicates P<0.0001, Student’s t-test, n ¼100 treated and 100 untreated myotomal segments examined).
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the formation of prepatterned AChR clusters. We did not ob-
serve an improvement in the number of prepatterned AChR in
Dok-7-deficient zebrafish (data not shown). This is unexpected,
given the known function of the MuSK/Dok-7 complex at the
NMJ, and it is possible that changes in expression of prepat-
terned AChR in the Dok-7 MO-injected embryos may have been
too small to be detected as changes on immunostaining. In ad-
dition, we observed that the adenylyl cyclase activator forskolin,
lead to dramatic improvements in axonal pathfinding and
AChR clustering, and improved AChR prepatterning in zMuSK
zebrafish.
Each of these steps are governed primarily by muscle-de-
rived signals in zebrafish (19,25). This is in-keeping with the fact
that it is mainly postsynaptic CMS subtypes in which the effect
of b-agonist therapy is beneficial. Salbutamol treatment leads to
an increasing and sustained response in Dok-7 CMS (13).
Although the pathomechanisms of Dok-7 CMS are not yet fully
understood, it is widely accepted that mutations in DOK7 impair
Dok-7’s ability to activate MuSK. This assumption is supported
by the fact that many mutations in Dok-7 CMS target the COOH
terminal, phosphotyrosine binding (PTB) or pleckstrin homology
(PH) domains, which are critical sites for activation of MuSK in
Figure 3. Salbutamol treatment of zMuSK MO-injected embryos improves motor axon pathfinding defects and AChR clustering. Lateral views of embryos with neuro-
muscular synapses labelled with antibodies against SV2 (green, presynaptic vesicles) and aBTX (red, postsynaptic AChRs). Scale bars¼10 mm. (A) zMuSK MO-injected
embryos at 24 hpf demonstrate characteristic stalling of the outgrowing motor axon at the choice point on the horizontal midline (arrow). Following salbutamol treat-
ment more axons cross the horizontal midline and extend to the periphery of the myotome (double arrow). (B) Quantification of the improvement of motor axon
growth following salbutamol treatment. (**** indicates P<0.0001, chi-square test, n¼240 treated and 240 untreated myotomal segments examined). (C) zMuSK embryos
at 24 hpf display almost complete absence of AChR clustering. In salbutamol-treated zMuSK embryos, AChR clustering is restored. (D) Quantification of the improve-
ment in AChR clustering following salbutamol treatment of zMuSK embryos. AChR clustering is significantly increased with the mean number of AChR clusters>20
lm2 per myotome 1.16 in salbutamol treated embryos compared with 0.64 in untreated embryos (**** indicates P<0.0001, Student’s t-test, n¼ 100 treated and 100
untreated myotomal segments examined). (E) zMuSK MO-injected embryos at 17 hpf. Untreated embryos lack elongated, diffuse prepatterned clusters on the myoto-
mal surface prior to the arrival of the motor growth cone (boxed areas), but following salbutamol treatment some zMuSK embryos display prepatterned clusters.
(F) Quantification of the effect of salbutamol on prepatterned AChR clustering in zMuSK embryos. Following salbutamol treatment, the number of prepatterned AChR
clusters>3 lm2 in zMuSK embryos increased, with a mean of 0.5 prepatterned clusters per myotome in untreated embryos, compared with 1.3 in salbutamol-treated
embryos (* indicates P<0.05, Student’s t-test, n¼30 untreated and 30 untreated myotomal segments examined).
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vitro and in vivo (26,27). The other CMS subtype in which treat-
ment with b agonists leads to consistent improvement is CMS
due to end-plate AChE deficiency, which is caused by mutations
in COLQ (28,29). In addition to its role in anchoring AChE in the
basal lamina, the C-terminus domain of ColQ binds MuSK, and
ColQ has been shown to have an important regulatory role in
postsynaptic differentiation through this interaction (30). The
pathology of Dok-7 and ColQ CMS subtypes may be unified by
the role of both proteins in postsynaptic specialization and
AChR clustering. b agonist therapy may therefore also play a
role in postsynaptic differentiation in mammals. Indeed, sev-
eral lines of evidence point toward cAMP/PKA-dependent path-
ways involved in metabolic stabilization of AChRs (31–33).
The effect of salbutamol on both axonal pathfinding and
number of prepatterned AChR clusters in zebrafish indicates a
possible role for b2 agonists in upregulation or activation of a
MuSK-dependent pathway in early synapse development,
which has been previously shown to be indispensable for nor-
mal regulation of both of these processes in zebrafish (19).
There are several potential pathways by which b2-adrenergic
agonist-mediated activation of the cAMP/PKA pathway could be
activating MuSK, including the b-catenin/Wnt signalling path-
way. The zebrafish homologue of MuSK has been previously
shown to interact with Wnt11r to restrict AChR prepattern in a
central muscle zone (22), in a similar manner to the interaction
with Wnt signalling and mammalian MuSK (34). However, given
that salbutamol and forskolin treatment led to only partial res-
cue of the motility and NMJ defects in our zebrafish models, it is
conceivable that additional pathways not upregulated by cAMP
signalling are also involved.
The effects of forskolin on the NMJ not only indicate the cAMP
mimetic action of salbutamol at the NMJ, but also were even more
marked than those observed following salbutamol exposure. This
more obvious effect may reflect increased absorption, bioavailabil-
ity or efficacy of forskolin compared with salbutamol in zebrafish.
Forskolin has been used in several clinical settings including
asthma, congestive cardiomyopathy and obesity (35–37). However,
its efficacy in neuromuscular disease is unknown. One possible
role for forskolin could be in the treatment of CMS patients who
have become tolerant to the effect of beta-adrenergic receptor
stimulation following many years of treatment, given that its
mechanism of action is receptor independent. Further preclinical
studies will be required to confirm these findings.
We accept there are limitations to our disease models. Whilst
treatment of zebrafish embryos provides a model for NMJ forma-
tion and exploring the role of b2 agonists in this process, effects
can only be studied over a short treatment period. The therapeu-
tic effect of b agonists seen in CMS patients is a delayed one, with
an increasingly positive response after many months of treat-
ment (13). The relatively short exposure duration of the zebrafish
Figure 4. Pre-treatment with a selective b2 antagonist blocks the rescue of NMJ development by salbutamol. Lateral views of 24 hpf embryos with neuromuscular syn-
apses labelled with antibodies against SV2 (green, presynaptic vesicles) and aBTX (red, postsynaptic AChRs). Scale bar¼50 mm. zMuSK embryos were treated with 5 mM
of the selective b2 antagonist ICI118, 551 or control (water) added to E3 medium for 3 h prior to the addition of 20 mM salbutamol. (A) In zebrafish embryos pre-treated
with ICI118, 551 no rescue of the axonal pathfinding defects was seen following 21 h of salbutamol treatment, with stalling and branching of motor growth cones (as-
terisks). (B) Quantification of the effect of pre-treatment of ICI118, 551 on motor axon growth. Following pre-treatment with 5 mM ICI118, 551, salbutamol treatment did
not have an effect on axon pathfinding (n.s. P>0.05, ****P<0.0001, chi-square test, n¼240 treated and 240 untreated myotomal segments examined).
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to salbutamol and forskolin may further explain why only a par-
tial rescue of the phenotype was observed in both models. In ad-
dition, patients with CMS due to DOK7 mutations frequently
present after infancy or in early adulthood (38), and postnatal
knockdown of Dok-7 gene expression has been shown to cause
CMS in mice (39), indicating a further role for Dok-7-mediated ac-
tivation of MuSK in postnatal NMJ maintenance. Therefore, it is
possible that the improvement seen in b-agonist-treated CMS pa-
tients is due to an additional role they play in NMJ homeostasis.
This hypothesis is supported by the recent finding of sympathetic
innervation in close contact with the NMJ contributing toward
NMJ maintenance (32). Further work will be in identifying the
mechanism of altered postsynaptic specialization by either en-
dogenous or exogenous b2-adrenoceptor ligands and cAMP acti-
vation. Nevertheless, the effects demonstrated during NMJ
development in these zebrafish models, indicate that sympatho-
mimetics may alter the regulation of key NMJ signalling mole-
cules, and suggest that b2 agonists illicit their therapeutic effect
in myasthenic disorders through a direct effect at the NMJ.
Materials and Methods
Zebrafish husbandry
The Golden strain (slc24a5b1/þ) of zebrafish was used (Zebrafish
International Resource Centre, Oregon). Zebrafish embryos were
raised in E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2,
0.33 mM MgSO4, 0.01% methylene blue) at 28.5C and staged in
hours post fertilization (hpf) according to standard protocols.
Phenotype and motility observation
Tail twists in chorion at 24 hpf were measured by observing
each embryo for 60 s and counting total number of complete
twists. A total 30 embryos were measured for each category.
Touch-evoked swimming response (TER) was observed by
touching the head or tail of the zebrafish with a fine pipette tip.
TER was defined as abnormal if embryos exhibited either cir-
cling movements, twitching with no movement away from the
stimulus, or had no movement at all as a response. At least 20
embryos were observed for each category and the experiment
was repeated five times.
Antisense morpholino oligonucleotide knockdown
Antisense MO were injected into the yolk of one-to-two cell
stage embryos. Dok-7 embryos were injected with 15 ng of Dok-
7 MO. MuSK embryos were injected with 5 ng of zMuSK MO. In
addition, control MOs were injected at the same concentration
for each injection experiment. MOs were purchased from Gene
Tools LLC (Pilomath, OR). A splice-blocking MO was used to tar-
get Dok-7 transcripts at exon 2: 50-ATTTATAGGATTTACCTG
CTACCGG. This splice-blocking MO causes skipping of the exon
and premature translation termination through targeting of the
splice donor site of exon 2 (21). For MuSK experiments, a MO tar-
geting the unplugged splice transcript variant 1 (unplugged/
SV1) was used (19,22): 50-GTAGAGGATTACCGTATTGCCGTT.
This causes skipping of exon 2, frameshift and a premature stop
codon after 24 cryptic residues. The Gene Tools standard control
MO (50-CCTCTTACCTCAGTTACAATTTATA-30) targeting a hu-
man beta-haemoglobin gene was used as a negative control.
MOs were suspended in 1 Danieau buffer (58 mM NaCl, 0.7 mM
KCl, 0.4 mM MgSO4, 0.6 mM Ca(NO3)2, 5 mM HEPES; pH 7.6) with
phenol red as an injection indicator. At least two independent
MO injection experiments were performed for each MO and
200–800 injected embryos were evaluated for each treatment
regimen.
Treatment of zebrafish with salbutamol, ICI118, 551 and
forskolin
Zebrafish embryos were raised post injection in E3 medium con-
taining the compounds or control vehicle. We conducted
Figure 5. The effects of b2 receptor agonist activation on NMJ morphology are replicated by cAMP activation. Lateral views of 24 hpf embryos with neuromuscular syn-
apses labelled with antibodies against SV2 (green, presynaptic vesicles) and aBTX (red, postsynaptic AChRs). Scale bar¼50 mm. (A) zMuSK embryos at 24 hpf demon-
strate improvement in AChR clustering and axon pathfinding defects following forskolin treatment. (B) Quantification of motor axon guidance defects. About 88%
(n¼28/240) of imaged somites of zMuSK embryos treated with forskolin displayed no axon guidance defects, compared with 41% (n¼ 142/240) of those in untreated
zMuSK embryos. **** indicates P<0.0001, chi-square test. (C) The number of AChR clusters larger than 20 lm2 on myotomal muscle fibres increased with forskolin treat-
ment, with mean number of clusters 0.39 per myotome in untreated embryos, and 1.48 in treated zMuSK embryos. **** indicates P<0.0001, Student’s t-test, n¼100
treated and 100 untreated myotomes examined.
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preliminary dose response testing for salbutamol (1, 10, 20 and
50 mM), forskolin (0.1, 1, 3, 5 and 10 mM) and ICI118, 551 (1, 3, 5, 20
and 50 mM). Concentrations of 20 mM salbutamol, 5 mM forskolin
and 5 mM ICI118, 551 resulted in strong effects and limited toxic-
ity, and these concentrations were selected for all further exper-
iments. For salbutamol treatment, embryos were exposed to 20
mM concentration of salbutamol (Sigma) or 20 mM of methanol for
up to 72 hpf. For pre-treatment with the selective b2 receptor
blocker ICI118, 551, zebrafish embryos were incubated with E3
medium containing either 5 mM of ICI118, 551 hydrochloride
(abcam) or 5 mM of distilled water. After 3 h, 20 mM of salbutamol
was added to the same E3 medium. For forskolin treatment,
zebrafish embryos were raised in E3 medium containing 5 mM of
forskolin (abcam) or 5 mM ethanol for up to 72 hpf.
Zebrafish whole-mount immunofluorescence staining
Embryos were fixed in 4% paraformaldehyde (PFA) in
phosphate-buffered saline (PBS) overnight and then permeabi-
lized in cold acetone at 20C. Depending on their age, 3–5
days post fertilization old larvae were permeabilized with col-
lagenase A (Roche Diagnostics, 1 mg/ml) for 60 min. Embryos
were blocked in 5% horse serum in PBS 0.1% Tween-20 (PBS-T).
Embryos were incubated in 5% horse serum in PBS-T contain-
ing primary antibody overnight at 4C (presynaptic nerve ter-
minals: SV2, 1: 200 from Developmental Studies Hybridoma
Bank, Iowa), washed several times with PBS-T and incubated
with secondary antibody (goat anti-mouse Alexa Fluor 488,
donkey anti-mouse Alexa Fluor 594, goat ant-rabbit Alexa
Fluor 680, all Invitrogen). AChRs were visualized by using
Alexa Fluor 594-conjugated a-bungarotoxin (1 lg/ml,
Invitrogen). Immunofluorescence staining was imaged using a
Nikon confocal microscope (Nikon A1R Invert). For quantifica-
tion of NMJ morphological changes, 30 embryos were imaged
for each category. Because of the rostral-to-caudal gradient of
embryonic development in zebrafish, we used the same myo-
tomal segments for comparison, by examining the five myo-
tomes centred around the caudal-most part of the yolk
extension. WT, untreated morphant and treated morphant tis-
sues were processed for immunofluorescence in parallel and
images were acquired with the same confocal microscopy set-
tings (laser power, gain, magnification and Z-stack interval).
Image analysis was performed using ImageJ software.
Immunostained structures were counted as NMJs when SV2
was opposed to a-bungarotoxin with at least 50% co-localiza-
tion. The outer perimeter of each area of co-localization on the
horizontal myoseptum was drawn by hand and the enclosed
area was measured. The area of each myotome was also mea-
sured, and the area of co-localization was measured as a frac-
tion of the myotome it occupied. For AChR quantification,
AChR clusters were thresholded and their area and intensity
measured, and the number AChR clusters greater than 20 lm2
in size per myotome were compared. For prepatterned AChR
quantification, the five caudal-most myotomal segments were
compared in 17 hpf embryos, and the number of AChRs greater
than 3 lm2 per myotome were quantified. Axon pathfinding
defects were quantified by counting the percentage of myo-
tomes with axons which failed to cross the horizontal midline
at 24 hpf. When comparing values from treated zebrafish with
values from untreated zebrafish an unpaired Student’s t-test
or chi-square test was used. Thresholds of P< 0.05 were con-
sidered significant. We confirmed normal distributions of data
before performing parametric tests.
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Abstract
The β-adrenergic agonists salbutamol and ephedrine have proven to be effective as therapies for human disorders of the
neuromuscular junction, in particular many subsets of congenital myasthenic syndromes. However, the mechanisms
underlying this clinical benefit are unknown and improved understanding of the effect of adrenergic signalling on the
neuromuscular junction is essential to facilitate the development of more targeted therapies. Here, we investigated the
effect of salbutamol treatment on the neuromuscular junction in the ColQ deficient mouse, a model of end-plate
acetylcholinesterase deficiency. ColQ−/− mice received 7 weeks of daily salbutamol injection, and the effect on muscle
strength and neuromuscular junction morphology was analysed. We show that salbutamol leads to a gradual improvement
in muscle strength in ColQ−/− mice. In addition, the neuromuscular junctions of salbutamol treated mice showed
significant improvements in several postsynaptic morphological defects, including increased synaptic area, acetylcholine
receptor area and density, and extent of postjunctional folds. These changes occurred without alterations in skeletal muscle
fibre size or type. These findings suggest that β-adrenergic agonists lead to functional benefit in the ColQ−/− mouse and to
long-term structural changes at the neuromuscular junction. These effects are primarily at the postsynaptic membrane and
may lead to enhanced neuromuscular transmission.
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Introduction
Motor neurons contact their target muscle fibres at highly
specialised chemical synapses, neuromuscular junctions (NMJ).
The NMJ is the pathogenic target in a wide range of human
diseases, including those resulting fromgenetic defects affecting
a diverse range of proteins which are critical for synaptic
function, the Congenital Myasthenic Syndromes (CMS) (1,2).
CMS arise from mutations affecting presynaptic, synaptic or
postsynaptic proteins at the NMJ, resulting in impairment of
neuromuscular transmission by one or more mechanisms. A
precise molecular classification of CMS subtype is of great
importance for the diagnosis and genetic counselling of patients,
but also to allow administration of effective treatment as
different drugs may be beneficial or deleterious depending on
the CMS subtype (3). Formany subtypes, clinical benefit is gained
from acetylcholinesterase (AChE) inhibitors, which augment the
synaptic response to acetylcholine (ACh) (4). However, AChE
inhibitors are ineffective or even detrimental in Dok7 CMS, slow-
channel CMS, end-plate AChE deficiency and MuSK CMS.
Ephedrine, a sympathomimetic with α- and β-adrenergic
effects, and salbutamol, a selective β2−agonist, have been
successfully used to treat many patients with CMS subtypes
which are not effectively treated by anticholinesterases. These
include those withmutations that cause deficits in Dok-7, Agrin,
MuSK, ALG2, AChR (ε -subunit) and in end-plate AChE deficiency
(5–10). In contrast with the effects of anticholinesterases, the
full effects of these adrenergic treatments are not immediate,
reaching a peak only after several months (5,11). Among the
varied pharmacologic effects of β-agonists, there is considerable
evidence for their numerous effects in regulating skeletal
muscle structure and function, and in exerting an anabolic
effect on skeletal muscle protein metabolism (12–16). These
actions are predominantly mediated through the β2 receptors
(ADBR2), and involve cAMP signalling (17). While these effects
were initially exploited by the livestock industry, their use
quickly expanded to include body builders and athletes. In
more recent years, experimental interest has further expanded
to trial the treatment of a wide range of muscle-wasting
and neuromuscular diseases. In animal and human studies,
β2-adrenergic agonists have been reported to have a positive
but limited effect in dystrophic and injured muscle, as well as
in congenital myopathies and fascioscapulohumeral muscular
dystrophy (18–21). In addition, further studies have suggested
β2-agonistsmay have amodest effect in spinalmuscular atrophy,
and in denervated muscle following spinal cord injury (22,23).
It is in treatment of CMS however, that sympathomimetics
have demonstrated conclusive clinical benefit, and they now
comprise standard treatment for some subtypes of CMS
in the form of oral ephedrine or salbutamol (24). Several
observational studies demonstrate improvements in motor
symptoms and timed tests when CMS patients are administered
ephedrine or salbutamol and mobility may often improve to the
extent of regaining ambulation in wheelchair bound patients
(7,9–11,25–27). However, it is not known why treatments acting
via pathwaysmediated by the sympathetic nervous systemhave
therapeutic benefit in disorders of the NMJ. Despite its potential
implications in the understanding of both the pathogenesis
and treatment of many neuromuscular diseases, the effect of
β-agonists on the maturation and maintenance of NMJs has
never been clearly defined.
In order to address this, we have studied the effect of salbu-
tamol treatment on a model of end plate AChE deficiency, the
ColQ knockout (ColQ−/−) mouse. In these mice, endplate AChE
deficiency is caused bymutations not in ACHE itself but in COLQ,
which encodes the collagenic tail subunit bound to the catalytic
subunit in the asymmetric AChE found at the skeletal NMJ
(28,29). The N-terminal domain of ColQ anchors asymmetric
AChE to the synaptic basal lamina (30). In humans,mutations in
COLQ typically result in fatigable muscle weakness presenting
in the neonatal period or early infancy, often accompanied by
episodes of respiratory failure (31). The NMJs of these patients
have abnormalities in both the function (prolonged response to
ACh due to the absence of AChE activity) and structure (dis-
rupted postsynaptic apparatus, probably resulting from exces-
sive Ca2+entry into the muscle through the AChRs) (32,33).
Generally, these patients show either no long-term benefit or
worsening of symptoms with AChE inhibitors. However, treat-
ment with salbutamol and ephedrine has been shown to lead
to improved mobility and respiratory function in these patients
(25). ColQ−/− mice also lack all asymmetric AChE and exhibit
both muscle weakness and abnormalities of the NMJ (34,35),
thus closely resembling the human disease. In addition to its
role in anchoring AChE, ColQ binds to the key postsynaptic
organiser protein MuSK, and ColQ has also been shown to have
an important regulatory role in postsynaptic development and
maturation through this interaction (36–38). Given the clinical
improvement from salbutamol treatment in CMS patients is
gradual, requiring a period of weeks to months for full benefit,
we have tested the effects of long-term administration of salbu-
tamol, i.e. administered over a period of 7 weeks, in the ColQ−/−
mouse.
Here, we show that salbutamol treatment leads to a grad-
ual improvement in muscle strength in the ColQ−/− mouse.
In addition, we show that morphological defects of the NMJ
in the ColQ−/− mouse can be partially rescued by salbutamol
treatment, in ways which are likely to lead to enhanced neuro-
muscular transmission. These results provide new evidence for
the long-term effects of adrenergic signalling on the structural
properties of the NMJ.
Results
Salbutamol treatment improves muscle strength in
ColQ−/− mice
From 3 weeks of age, ColQ−/− mice received daily subcuta-
neous injections of salbutamol or vehicle control (water) for
7 weeks. Previous work has shown that ColQ−/− mice exhibit
muscle weakness which is apparent from P5 (34). We used fore-
limb grip strength to assess muscle strength at 3 time points
(Fig. 1A) in wild type (WT), ColQ−/− mice treated with water
and ColQ−/− mice treated with salbutamol. The performance of
water treated ColQ−/− mice was significantly worse than WT
littermates at baseline (3weeks old) and at subsequentmeasure-
ments (6 weeks old and 9 weeks old). In comparison, ColQ−/−
mice treated with salbutamol showed a gradual improvement
in grip strength, which became significantly better than water
treated ColQ−/− mice at 9 weeks (after 6 weeks of salbutamol
treatment) (water treated ColQ−/− 41.6±11.7 g vs. salbutamol
treated ColQ−/− 61.9±7.4 g (mean±S.D.)). ColQ−/− mice were
also smaller than WT littermates, having a body weight approx-
imately 50% that of littermates at 3 weeks (Fig. 1B) (34). This low
body weight persisted into adulthood, and was not altered by
salbutamol, with no significant difference in salbutamol treated
ColQ−/− mice body weight during 7 weeks of salbutamol treat-
ment (water treated ColQ−/− 21.3±2.71 g vs. salbutamol treated
ColQ−/− 19.5±2.13 g). In summary, salbutamol led to a gradual
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddz059/5424977 by guest on 19 June 2019
Human Molecular Genetics, 2019, Vol. 00, No. 00 3
Figure 1. Salbutamol treatment improves muscle strength in ColQ−/− mice but does not alter body weight. A. Forelimb grip strength of WT, water treated ColQ−/−
(ColQ−/− WFI) and salbutamol treated ColQ−/− (ColQ−/− SAL) mice measured at 3, 6 and 9 weeks of age. Grip strength is significantly impaired in water treated
ColQ−/− mice compared to WT littermates at baseline, and at subsequent time points. Salbutamol treated ColQ−/− mice showed a tendency towards improved grip
strength after 3 weeks of treatment (6-wks-old) which became statistically significant after 6 weeks of treatment (9-wks-old). n =6 animals per group. Error bars depict
S.D. ∗∗ indicates P< 0.01. B. Growth curve demonstrating changes in body weight over 7 weeks of salbutamol treatment. ColQ−/− mice are significantly smaller than
WT littermates at all time-points and body weight is not affected by salbutamol treatment. n=6 animals per group.
improvement in limb muscle strength but did not affect body
weight in ColQ−/− mice.
Salbutamol treatment improves NMJ structural defects
in ColQ−/− mice
It has previously been shown that the ColQ−/− mouse exhibits
abnormal synaptic structure, including NMJs which appear frag-
mented or immature (34). We studied the pre and postsynaptic
morphology of NMJs from 10 week old ColQ−/− lumbrical mus-
cles and compared these to salbutamol treated ColQ−/− muscles,
using a standardised morphometric analysis platform (‘NMJ-
morph’) (39). ColQ−/− mice did demonstrate presynaptic struc-
tural defects, with small but significant decreases in axon diam-
eter (WT 3.49±0.79 μm vs water treated ColQ−/− 2.90±1.47 μm)
and nerve terminal area (WT 227.16±35.12 μm2 vs water treated
ColQ−/− 166.28±47.16 μm2) (Fig. 2B). These presynaptic defects
were not significantly different in salbutamol treated ColQ−/−
mice (axon diameter and nerve terminal area 2.96±1.43 μm and
159.42±33.89 μm2 respectively).
Postsynaptic morphology was more obviously perturbed in
the ColQ−/− mice (Fig. 2C-E and SupplementaryMaterial, Fig. S1),
with ColQ−/− lumbrical muscles showing significantly reduced
AChR area (WT 332.117±58.55 μm2 vs. water treated ColQ−/−
236.91±63.13 μm2) and reduced NMJ ‘compactness’ (derived
from (AChRArea/Endplate area) x100), ameasure of AChRdisper-
sal (WT 71.77±13.49% vs. water treated ColQ−/− 54.30±19.01%)
(39,40). These postsynaptic defects were significantly improved
in salbutamol treated mice (AChR area 303.52±75.69 μm2 and
compactness 76.23±22.26%).
Furthermore, the area of synaptic contact (the area of
contact between pre and postsynaptic NMJ components) was
significantly reduced in the ColQ−/− mice compared toWT litter-
mates (Fig. 2D) (WT 191.61±46.69 μm2 vs. water treated ColQ−/−
93.8±64.98 μm2), and this was increased by salbutamol treat-
ment (141.63±58.65 μm2). In keeping with previous studies, we
found the number of discrete fragments of AChR richmembrane
was significantly increased in the ColQ−/− mice (WT 2.88±0.93
fragments vs. water treated ColQ−/− 4.10±1.74 fragments). Frag-
mentation was not altered by salbutamol treatment, however
(3.91±1.00 fragments). We also examined these parameters in
soleus muscles (Supplementary Material, Fig. S1). Salbutamol
treatment also improved AChR area, compactness and area of
synaptic contact in soleus muscles, and we found no difference
in the magnitude of the effect of salbutamol in soleus muscle
compared to lumbricals (Supplementary Material, Fig. S1).
These results prompted us to examine whether the fluores-
cence intensity per μm2 of α-BTX, a measure of the local AChR
density, was different in salbutamol treated mice. In lumbricals
fromwater treated ColQ−/− mice,AChR densitywas significantly
reduced compared to WT littermates (mean pixel intensity per
μm2 WT 255.39±149.49 vs.water treated ColQ−/− 119.68±69.49).
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Figure 2. Salbutamol treatment improves postsynaptic NMJ morphology in ColQ−/− mice. A. Representative confocal micrographs of NMJs in the lumbrical muscles
of 10-wk-old WT, water treated ColQ−/− (ColQ−/− WFI) and salbutamol treated ColQ−/− (ColQ−/− SAL) mice, labelled with anti-neurofilament (red) and anti-
synaptophysin (red, both NT) and Alexa fluor 488 α-bungarotoxin (green, AChR).Water treated ColQ−/− mice display variable NMJ morphology with smaller NMJs with
reduced AChR density. Scale bar, 10 μm. B.Quantitative analysis of presynaptic variables from lumbrical muscles. ColQ−/− mice exhibited smaller nerve terminals with
thinner axons, and these variables were unchanged in salbutamol treated mutants. C. Quantitative analysis of postsynaptic variables from lumbrical muscles. Water
treated ColQ−/− mice had reduced AChR area and compactness, which were significantly increased in salbutamol treated ColQ−/− mice compared to water treated
ColQ−/− mice.D.Quantitative analysis of area of synaptic contact. ColQ−/− mice have significantly reduced area of synaptic contact which is increased by salbutamol
treatment but remains smaller than in WT animals. E. Quantitative analysis of fragmentation of NMJs. ColQ−/− NMJs exhibit significantly increased number of AChR
rich fragments per NMJ, and this was not different in salbutamol treated animals. n=180 NMJs analysed per group for B-E. Analysis of NMJ-morph variables from soleus
muscle are provided in Supplementary Material, Figure S2. F. Quantification of α-bungarotoxin fluorescence intensity of individual NMJs measured from projection
of confocal stacks from lumbrical muscles. Fluorescence intensity was significantly decreased in water treated ColQ−/− mice, and was significantly increased in
salbutamol treated ColQ−/− mice compared to water treated ColQ−/− mice. n=120 NMJs analysed per group for F. All error bars depict S.D. Unpaired Student’s t tests.
∗∗∗∗p< 0.0001, ∗∗∗p< 0.001, ∗∗p< 0.01, ∗p<0.05.
In comparison, in salbutamol treated ColQ−/− lumbricals, AChR
density was significantly increased compared to water treated
ColQ−/− mice (mean pixel intensity per μm2 211.89±139.41).
Together, these observations suggest that salbutamol treat-
ment can alter NMJ structural defects in ColQ−/− mice, and in
particular increase AChR area, synaptic area and AChR density.
Salbutamol alters ultrastructural appearances of the
postsynaptic membrane
In mature NMJs, the postsynaptic membrane is invaginated
with extensive folds extending into the postsynapticmembrane,
which amplify the transmitter action of ACh (41). AChRs accu-
mulate at the crests of these postjunctional folds, which can
be visualised at the EM level by electron dense material at the
top of the folds and extending partly down the folds (42). Under
the electron microscope, many NMJs from intercostal muscles
of 10 week old water treated ColQ−/− mice appeared normal, as
has been previously reported in 6 month old ColQ−/− mice (34).
However, in 50% of NMJs the extent of folding appeared clearly
reduced and regions of high electron-density at the crests of
folds were lost (Fig. 3A). We quantified the extent of postjunc-
tional folding using fold index (total surface length of postsynap-
tic membrane measured along the tops of the folds/total length
of postsynaptic membrane including folds) a measure of the
increase in postsynaptic membrane area resulting from folding
(43). This revealed a significant reduction in extent of folding in
ColQ−/− mice compared to WT (mean fold index WT 4.28±1.38
vs. water treated ColQ−/− 2.50±0.72) (Fig. 3B). In addition, in
salbutamol treated ColQ−/− mice, fold index was significantly
increased compared to water treated ColQ−/− mice (3.65±1.03).
Additional features measured from EM images are provided in
Supplementary Material, Table S1.
Immunoreactivity of Agrin, Dystroglycan and MuSK in
ColQ−/− mice
The effects of salbutamol on postsynaptic structural defects
prompted us to explore the effect of salbutamol on MuSK, agrin
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Figure 3. The extent of postjunctional folding is increased in salbutamol treated ColQ−/− mice. A. Representative electron micrographs of sections through single
boutons from intercostal muscles of 10-wk-old WT, water treated ColQ−/− (ColQ−/− WFI) and salbutamol treated ColQ−/− (ColQ−/− SAL) mice. NT: nerve terminal,
PJ: postjunctional folds, SC; Schwann cell. In WT mice, the postsynaptic membrane is extensively infolded and AChRs can be seen as areas of high electron-density at
the crests of the folds (arrows). In ColQ−/− mice, the appearance of increased membrane density at the tops of the folds is lost, the extent of folding is reduced and the
synaptic space appears widened (stars, right panel) although some NMJs appear normal (left panel). Salbutamol treated ColQ−/− NMJs exhibit similar ultrastructural
appearances toWT littermates. Scale bar 0.5 μm. B. Quantitative analysis of changes in the extent of folding with salbutamol treatment. In salbutamol treated ColQ−/−
mice, the extent of postjunctional folding is significantly increased compared to water treated ColQ−/− mice, as measured by fold index (fold length/postsynaptic
length). n≥ 15 boutons from three mice analysed per group. Mann Whitney U test. ∗∗∗∗p<0.0001, ∗∗p<0.01.
and α-dystroglycan. MuSK provides the primary scaffold for
AChR clustering and postsynaptic differentiation (44). The C-
terminus of ColQ binds MuSK and ColQ deficiency leads to
reduced levels of membrane bound MuSK (36,37). The glycopro-
tein agrin is secreted by motor axon terminals to activate the
LRP4/MuSK/Dok7 complex to induce and stabilise AChR clusters
(45). Dystroglycan, a component of the dystrophin associated
glycoprotein complex (DGC), is essential for the assembly of
a synaptic basement membrane, and linking the extracellular
matrix to the cytoskeleton (46). ColQ binds to perlecan which
in turn binds α-dystroglycan, and this interaction is necessary
for the synaptic localisation of AChE (47). In addition, the local-
isation of AChRs at the crests of the folds arises through their
interaction with the DGC (48).
In order to determine membrane bound MuSK protein
levels, we analysed MuSK fluorescence intensities per AChR
cluster in transverse sections of gastrocnemius muscle from
WT, water treated ColQ−/− and salbutamol treated ColQ−/−
mice (Fig. 4A). MuSK fluorescence intensity was significantly
reduced in water treated ColQ−/− mice compared to WT (mean
MuSK-to-α-BTX fluorescence intensity ratio WT 0.76±0.21 vs.
water treated ColQ−/− 0.44±0.06). In salbutamol treated ColQ−/−
muscle, the MuSK-to-α-BTX fluorescence intensity ratio was
increased compared to water treated ColQ−/− mice (Fig. 4B,
mean MuSK-to-α-BTX fluorescence intensity ratio 0.55±0.12
in salbutamol treated ColQ−/− mice). In contrast to MuSK
staining, the fluorescence intensity of agrinwas not significantly
different in either water treated ColQ−/− or salbutamol treated
ColQ−/− mice compared to WT animals (data not shown). In
addition, the distribution and intensity of immunostaining of
α-dystroglycan was qualitatively similar in ColQ−/− and WT
mice, and was not affected by salbutamol treatment (data not
shown).
Salbutamol treatment does not alter muscle fibre area
or fibre type composition in ColQ−/− mice
It has previously been shown that ColQ−/− mice exhibit both
reduced muscle fibre diameter and alteration of fibre type com-
position (35,38). We therefore examined the effect of salbu-
tamol treatment on these parameters. At 10 weeks, muscle
fibre cross sectional area in water treated ColQ−/− mice was
significantly reduced in both gastrocnemius (mean cross sec-
tional area WT 1740±434.73 μm2 vs. water treated ColQ−/−
1342±317.51 μm2) and soleus (WT 1188±105.4 μm2 vs water
treated ColQ−/− 781±185.44 μm2). Muscle fibre area was not
significantly different in salbutamol treated ColQ−/− mice com-
pared to water treated ColQ−/− mice (Fig. 5A and B) (mean cross
sectional area 1308±350.45 μm2 and 802±217.51 μm2 in gas-
trocnemius and soleus muscles respectively). In addition, exam-
ination of fibre type composition in gastrocnemius and soleus
muscles revealed a dramatic reduction inMHC type 1 expressing
fibres in both muscles, as well as an increase in MHC type 2A
fibres in water treated ColQ−/− mice. Again, these changes in
fibre type compositionwere unaffected by salbutamol treatment
(Fig. 5C-F). These data indicate that the effect of salbutamol on
NMJ structure and on grip strength in the ColQ−/− mouse is not
secondary to changes in skeletal muscle trophism.
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Figure 4. Salbutamol treatment alters MuSK immunoreactivity in ColQ−/− mice. A. AChR and MuSK clusters labelled with Alexa 488 α-BTX (green, AChR) and anti-
MuSK antibody (red) respectively on transverse sections of gastrocnemius muscle from 10-wk-old WT, water treated ColQ−/− (ColQ−/− WFI) and salbutamol treated
ColQ−/− (ColQ−/− SAL) mice. Scale bar, 20 μm. B.Quantification of MuSK fluorescence intensities from projection of confocal stacks. MuSK fluorescence intensity per
AChR cluster was decreased in ColQ−/− muscle, and significantly increased in salbutamol treated ColQ−/− mice compared to water treated. n=180 NMJs per group
for B. Unpaired Student’s t tests. ∗∗∗p< 0.001, ∗p< 0.05, n.s. not significant.
Immunoreactivity of β2 adrenoceptors colocalises with
the NMJ in WT and ColQ−/− mice
Salbutamol is a selective ADBR2 agonist, and it has been previ-
ously shown that ADBR2 is the predominant adrenoceptor sub-
type in skeletal muscle (49,50). In order to investigate the distri-
bution of ADBR2 on themusclemembranewe stained transverse
sections of gastrocnemius muscle with ADBR2 antibody and α-
BTX (Fig. 6A). This revealed co-localisation of ADBR2 immunore-
activity at the NMJ. In addition, this pattern of immunostaining
did not appear to be altered in ColQ−/− mice andwas not affected
by 7 weeks of salbutamol treatment (Fig. 6B).
Discussion
Our study provides evidence that treatment of AChE-deficient
ColQ−/− mice with the sympathomimetic salbutamol, over a
period of weeks, partially normalises both their weakness of
grip strength and the structural abnormalities of NMJs that
may help to explain that weakness. It has long been suspected
that activation of adrenergic receptors can alter neuromuscular
transmission. In vitro, ephedrine increases quantal content, and
ephedrine and salbutamol block the AChR channel, although
only when applied at higher concentrations than obtained at
therapeutic doses in humans (51,52). In addition, adrenaline and
noradrenaline can potentiate neuromuscular transmission, and
activation of α1 and β adrenoceptors has been shown to enhance
nerve evoked ACh release (53–55). However, these immediate
effects do not account for the delayed therapeutic action of
salbutamol in patients with CMS, which suggest an additional
longer term modulation of NMJ function. There is, however,
increasing evidence for the role of the sympathetic nervous
system in maintenance of the NMJ. Recent studies demonstrate
that NMJs are intimately linked to a network of sympathetic
neurons within skeletal muscle which increase during postnatal
development, a network which is critical for the morphological
integrity of the NMJ (56,57). We previously showed that salbu-
tamol rescued aberrant NMJ development in zebrafish embryos
lacking Dok7 and MuSK (58). Here, in a setting more closely
resembling human disease and treatment regimens, we show
that long-term administration of salbutamol leads to functional
benefit and improves postsynaptic structural defects in amouse
model of end plate AChE deficiency.
Salbutamol treatment resulted in a significant increase in
grip strength of ColQ−/− mice. This effect was gradual, becoming
significantly better only after 6 weeks of daily administration.
This mirrors the effect in humans with ColQ CMS where, unlike
the rapid clinical benefit seen from AChE inhibitors in other
forms of CMS, the response to sympathomimetics is more grad-
ual with an increasingly positive response over 3–6 months of
treatment (11,59). As previously reported, the phenotype of the
ColQ−/− mouse is not as severe as would be expected from
a complete lack of AChE. Interestingly, in both the salbuta-
mol treated and water treated ColQ−/− mice, grip strength was
improved at 9 weeks compared to 3 weeks. In previous studies
of the ColQ−/− mice, NMJ abnormalities also appeared to lessen
with age, suggesting a compensatory mechanism (34). These
studies suggested that capping of the motor nerve terminal by
the Schwann cell serves to protect the end-plate from lost ACh
clearance (34,60). However, invasion of the synaptic cleft by the
Schwann cell was not a feature in any of the NMJs examined
with EM in this study. The findings may reflect the homeostatic
plasticity of the NMJ, as occurs in response to trauma, toxins
and in autoimmune myasthenia gravis (41,61,62). The precise
processes underlying adaptive plasticity in the ColQ−/− mouse
have not yet been determined.
The effects of β-adrenergic agonists on skeletal muscles are
known to include muscle fibre hypertrophy and alteration of
fibre type composition (63–65). The ColQ−/− mouse exhibits
features of muscle atrophy,with reduction in type I and increase
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Figure 5. Alterations in muscle fibre diameter and type in ColQ−/− mice are not affected by salbutamol treatment. A, B: Frequency distributions of muscle fibre cross
sectional area from 10-wk-old WT, water treated ColQ−/− (ColQ−/− WFI) and salbutamol treated ColQ−/− (ColQ−/− SAL) gastrocnemius (A) and soleus (B) muscles.
Plots represent percentage of fibres in each size bin. Fibres are significantly smaller in ColQ−/− muscles compared with those in WT fibres (Mann-Whitney U test) but
fibre diameter was unaffected by 7 weeks of salbutamol treatment. n=6 muscles per genotype, with ≥500 muscle fibres sampled to generate the size distributions.
∗∗∗p< 0.001, ∗p< 0.05 C—F: Fibre type composition in WT and ColQ−/− muscles. Transverse sections of gastrocnemius (C) and soleus (E) muscles from 10-wk-old WT
and ColQ−/− animals, stained with anti-laminin (green), to delineate the fibre circumference and MHC Type 1 (blue), Type IIa (red) and Type IIb (green). ColQ−/− mice
exhibit significantly fewer Type 1 fibres and increased Type 2A fibres in both gastrocnemius (D) and soleus (F) muscles, which was not affected by 7 weeks of salbutamol
treatment. Scale bar, 50 μm.
in type IIA fibres as well as reduced fibre size (38). It is plausible
therefore, that adrenergic agonists lead to clinical benefit in ColQ
CMS due to promotion of muscle growth. However, our analysis
of fibre type composition and area in both soleus and gastrocne-
mius muscles revealed no detectable effect of salbutamol treat-
ment on anyparametermeasured inColQ−/− mice.This suggests
that the improved grip strength in salbutamol treated ColQ−/−
animals cannot be readily explained by an anabolic effect on
skeletal muscle. This is consistent with the lack of evidence of
clinical benefit of sympathomimetic treatment in myopathies
and muscular dystrophies (20,21,66,67). Since both the structure
and function of the NMJs is abnormal in ColQ−/− mice (34), we
turned our attention to the possibility that salbutamol may act
to enhance muscle activation by action on the NMJs.
In support of this view, we found evidence of a partial nor-
malisation of synaptic area, local AChR density and the extent
of postsynaptic folding in salbutamol treated ColQ−/− mice, all
changes which would be likely to enhance the efficacy of neu-
romuscular transmission. Using standardised analysis of NMJs
(39), we confirmed pronounced defects in the structure of the
NMJs in water treated ColQ−/− mice which are likely to be asso-
ciated with a decreased efficacy of neuromuscular transmission
(34,35). These involved changes to both presynaptic and postsy-
naptic components of the NMJ. On the presynaptic side, there
was a modest reduction in both the terminal axon diameter
and nerve terminal area. There was also a significant reduction
in the area of overlap between the nerve terminal and the
underlying region of high AChR density (‘synaptic area’). There
is an approximately linear relationship between synaptic area
and quantal content, and a pathological reduction in synaptic
area has been demonstrated in patients with ColQ CMS, and
in CMS due to mutations in the postsynaptic adaptor DOK7
(60,68,69). Therefore, any reduction in synaptic area is likely to
be associated with reduced quantal content and the efficacy of
neuromuscular transmission.
On the postsynaptic side, we found that at 10 weeks of age,
the labelling intensity of AChRs was strikingly reduced in water
treated ColQ−/− mice, suggesting a reduced local AChR density at
theNMJs.Any reduction in local AChRdensitywould be expected
to reduce the number of AChRs opened by individual transmitter
quanta and thus impair neuromuscular transmission. However,
previous studies of ColQ−/− mouse showed an increased AChR
density in sternomastoid and soleusmuscles at 7 days of age (36).
These divergent findings may be due to differences in the age of
themice examined, given that at postnatal day 7mouseNMJs are
still undergoing structural and molecular maturation and AChR
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Figure 6. β2 adrenergic receptor immunostaining co-localises with the NMJ.A.Transverse sections of gastrocnemiusmuscle from 10-wk-oldWTmice stainedwith anti-
ADBR2 antibody (red) and Alexa 488 α-BTX (green, AChR). ADBR2 staining is enriched at the NMJ. Scale bar, 20 μm. B. Quantification of ADBR2 fluorescence intensities
per AChR cluster from projection of confocal stacks. ADBR2 fluorescence intensity per AChR cluster was not significantly different betweenWT,water treated ColQ−/−
or salbutamol treated ColQ−/− mice. Unpaired Student’s t tests.
richmembrane is not yet fully restricted to regions ofmotor axon
contact (70). AChR deficiency has also been shown in ColQ CMS
patients (60). In parallel with the reduction of AChR density, we
found a decrease in the area occupied by a high density of AChRs.
This extends previous studies showing reduced AChR area in
adult (diaphragm, levator auris longis) and 7 days old (soleus and
sternomastoid) ColQ−/− mice (35,36).
A likely explanation for reduced AChR density at the NMJ is
the simplification and disorder of the postsynaptic folds asso-
ciated with AChE deficiency (32). Since a substantial fraction
of AChRs are normally present in the membrane of the folds
closest to the nerve, any disruption of membrane folding may
result in reduced numbers of AChRs as detected by fluorescence
microscopy. Consistent with this view, our preliminary analysis
of NMJs from intercostal muscles of ColQ−/− mice confirmed the
significant reduction in the extent and orderliness of postjunc-
tional folds. The high density of voltage-gated sodium channels
in the depths of the folds is believed to facilitate initiation of
the muscle fibre action potential (69,71), suggesting a second
way in which the reduced folding in ColQ−/− mice may impair
neuromuscular transmission.
Treatment of ColQ−/− mice with salbutamol for 7 weeks
resulted in a partial normalisation of a number of the abnor-
malities of NMJ structure which are likely to be associated with
impaired NMJ function, particularly those associated with the
postsynaptic component. These include the area of synaptic
contact, the local AChR density and the extent of folding, with
similar degrees of effect found in lumbrical and soleus muscles.
Whilst electrophysiological studies will be required in order
to confirm that these structural alterations are coupled with
improved NMJ function, the changes are likely to have important
implications for the efficiency of neuromuscular transmission
(41,72–74). Our findings of pronounced postsynaptic structural
effects from salbutamol are in keeping with the fact that it is the
CMS subtypes with predominant postsynaptic alterations which
show greatest clinical benefit from salbutamol and ephedrine
(4,7,11,75).
The differentiation of the postsynaptic region at the NMJ is
strongly influenced by the activity of MuSK (44). ColQ deficiency
has been shown to regulate membrane bound MuSK, and to
subsequently lead to decreased signalling of MuSK as measured
by reduced phosphorylation of the β-AChR subunit (36). This
led us to ask whether salbutamol treatment might enhance
the expression of membrane bound MuSK in ColQ−/− mice.
We observed reducedMuSK immunoreactivity in gastrocnemius
muscle from untreated ColQ−/− mice, and this was significantly
increased by salbutamol treatment. It is not possible to say
whether salbutamol alters the activity of the MuSK signalling
pathway, or whether this finding is secondary to improved post-
synaptic architecture in salbutamol treated muscles. Further
studieswill be required to determinewhether salbutamol affects
MuSK phosphorylation and kinase activity.
The distribution of ADBR2 on skeletal muscle membrane has
not been previously well described. Here we observed ADBR2
immunostaining precisely co-localising with AChRs in gastroc-
nemius muscle from both WT and mutant adult mice, similar to
the patterns previously observed in one study ofmouse extensor
digitorum longus muscle (56). This co-localisation is intriguing
and further suggests that ADBR2 and their signalling compo-
nents have an important contribution to NMJ function.
In some cases of CMS, the clinical benefit from salbutamol
seems to attenuate after years of treatment (unpublished
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observations). This may be due to desensitisation of ADBR2 after
chronic agonist administration, as occurs when β2-adrenergic
agonists are used in the treatment of chronic heart failure and
asthma, although this has not been confirmed in CMS (76,77).
The development ofmore targeted therapies for CMS,potentially
those which act downstream of ADBR2, are therefore essential
to improve quality of care.We previously showed that the effects
of salbutamol at NMJs of zebrafish embryos could be blocked by
a selective ADBR2 antagonist, and could be replicated by directly
increasing cyclic AMP with forskolin (58). Identification of the
cellular processes which are regulated by the cAMP and the
cAMP-dependent protein kinase (PKA) signalling pathway at the
NMJ is required for the identification of possible therapeutic
targets.
Postsynaptic differentiation is controlled by factors released
frommotor nerves, glial cells and by intrinsic muscle signalling.
There are thus a multitude of pathways through which acti-
vation of ADBR2 receptors and the cAMP signalling pathway
could lead to improved postsynaptic NMJ morphology (78,79).
Nonetheless, our observations in the ColQ−/− mouse provide
further evidence for important interplay between the NMJ and
adrenergic signalling pathways. An understanding of the effect
of sympathomimetics at the NMJ will be instrumental in order
to facilitate the development of more targeted therapies, which
benefit NMJ function whilst minimising systemic side-effects.
Materials and Methods
Mice
All procedures were approved by the Home Office and were
carried out in accordance to the Animals Scientific Procedures
Act of 1986 under project licence 70/8538. The generation of
the ColQ−/− mouse was described by Feng et al (34). ColQ+/−
mice were donated by the Krejci laboratory, COGNAC G cognition
action group, Université Paris Descartes. Mice were bred and
housed in the animal facility at the Functional Genomics Unit,
Institute of Genetic Medicine, Newcastle University.
Drug treatment of mice
From post-natal day 21, ColQ−/− mice received daily subcu-
taneous injections for 7 weeks of either Salbutamol (α-[(tert-
Butylamino)methyl]-4-hydroxy-m-xylene-α,α′-diol, Albuterol;
Sigma) diluted in water for injection (n=6 animals) or the
equivalent volume of water alone (n=6 animals). Injections
were delivered into the loose skin over the interscapular area.
Salbutamol was administered at a dose of 5 mg/kg which is
equivalent to doses used in the treatment of CMS patients
(59). Mice were weighed prior to injection daily. Wild type
(WT) littermates were weighed and inspected daily in a similar
manner to injected littermates. Researchers handling the
animals were blinded to the genotype and drug allocation of
each animal. Animals were weighed and inspected daily for
signs of drug toxicity or side effects, and no adverse effects were
observed. All mice were sacrificed within six hours of the last
injection at 10 weeks of age.
Forelimb grip strength test
An electronic grip strength meter (Bioseb) was used to deter-
mine the maximal peak force of the forelimbs (80). Mice were
allowed to grasp the grid and were pulled horizontally by the
tail until the grip was released. The pull force was measured
when the pulling force overcame the mouse’s forelimb grip
strength. Testing was performed in six animals per group at
three time points—3 weeks, 6 weeks and 9 weeks of age. Three
measurements were performed per mouse during each test and
the average of these threemeasurementswas used for statistical
evaluation. These experiments were conducted in a blinded
fashion by the same experimenter, 5 hours after injection.
Whole-mount muscle staining
Whole soleus and hindlimb lumbrical muscles from 10 week old
mice were dissected, washed in phosphate buffered saline (PBS)
for 30 minutes, and then fixed (1% paraformaldehyde in 0.1 M
PBS) for 10minutes before being teased into small bundles. After
teasing, muscles were fixed in 1% PFA overnight at 4 ◦C. Muscles
were permeabilised in ethanol followed by methanol (10 min at
−20 ◦C each), followed by an incubation/permeabilisation step
in 5% horse serum, 5% BSA, 2% Triton X-100 (for 4 hours at room
temperature).Muscleswere incubated overnightwith antibodies
against neurofilament (mouse monoclonal anti-neurofilament,
1:200, Cell Signalling technology), and synaptophysin (rabbit
polyclonal anti-synaptophysin, 1:100, Thermo Fisher Scientific)
or against agrin (mouse polyclonal anti-agrin, 1:250, Abcam) in
PBS containing 5% horse serum, 5% BSA. The next day muscles
were washed in PBS containing 5% horse serum, 5% BSA for four
hours and then incubated in Alexa Fluor® 488 α-bungarotoxin
(α-BTX) (1:250, Thermo Fisher Scientific), Alexa Fluor® 568 goat
anti-mouse (1:250, Thermo Fisher Scientific) and Alexa Fluor®
594 goat anti-rabbit (1:250, Life Technologies) overnight. The
following day muscles were washed in PBS for 4 hours and
then mounted on slides with Vectashield mounting medium for
fluorescence microscopy (Vector Laboratories).
NMJ imaging and analysis
Samples were visualised using a Nikon A1R laser scanning
confocal microscope. Laser power and parameter settings
were kept constant and Z-stack images (1-μm intervals) were
acquired with x63 oil immersion objective and processed
using NIS-elements AR 4.20.02 software. Soleus and lumbrical
muscles from 6 mice per group were imaged; ≥30 NMJs were
analysed per muscle. Variables for NMJ structural analysis
were measured from maximum intensity Z-stack images using
the ‘NMJ-morph’ protocol on ImageJ as described previously
(39). For quantitation of AChR density, confocal micrographs
of control and experimental mice were collected in the same
session permitting comparison of fluorescence intensity. AChR
density was performed only on lumbrical muscles on which
NMJs could be visualised relatively quickly. The perimeters
of clusters were delimited and the area and average pixel
intensity calculated using ImageJ software. The AChR cluster
outline was then placed in an adjacent area without clusters
to record background fluorescence intensity. This reading was
subtracted from the cluster reading, to give a background-
corrected intensity. Lumbrical muscles from six mice per group
were imaged; ≥20 NMJs were analysed per muscle.
Immunostaining on sections
Immunostaining of ADBR2, MuSK and α-dystroglycan was
performed on 10 μm transverse sections of gastrocnemius
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muscle cut using a cryostat (Microm HM 560, Zeiss) in the region
of the motor end-plate. Sections were fixed in acetone at 4 ◦C
for 15 minutes and then permeabilised in 0.1% Triton X-100
for 15 minutes at room temperature. Sections were blocked in
PBS containing 10% goat serum, 1% BSA for 30 minutes and
then incubated with primary antibody (rabbit anti-MuSK 1:500,
Abcam; rabbit anti-ADRB2 1:200; Santa Cruz Biotechnology;
mouse anti-α-dystroglycan 1:100; Santa Cruz Biotechnology) in
blocking buffer for 2 hours at room temperature. Sections were
washed and incubated in Alexa Fluor® 488 α-BTX (1:250), and
secondary antibodies Alexa Fluor® 594 goat anti-rabbit (1:250)
for 1 hour at room temperature. Sections were then washed and
mounted using Vectashield mounting medium.
Quantification of MuSK, agrin and ADBBR2 staining
intensity
Quantification of relative staining intensities was performed as
described previously (36,81). Transverse sections of gastrocne-
mius (MuSK and ADBR2 staining) or whole mounts of lumbrical
muscles (agrin staining) were visualised using a Nikon A1R
laser scanning confocal microscope. Laser power and parameter
settings were kept constant and Z-stack images (1-μm intervals)
were acquired with x63 oil immersion objective and processed
using NIS-elements AR 4.20.02 software. Confocal micrographs
of control and experimentalmicewere collected in the same ses-
sion. Quantification of relative area and fluorescence intensity
of α-BGT to MuSK, agrin or ADBR2 was performed using ImageJ
software.The perimeters of clusterswere delimited on the α-BGT
channel and the area and fluorescence intensity measured. This
selection was restored in the Alexa Fluor® 594 channel and the
area and fluorescence intensity of MuSK, agrin or ADBR2 was
measured. The background intensity in each channel was sub-
tracted from the pixel intensity of the protein of interest, and the
background-corrected intensity for each channel were divided
to give a MuSK/agrin/ADBR2-to-α-BGT fluorescence intensity
ratio. For MuSK and ADBR2 fluorescence intensity, gastrocne-
mius muscles from six mice per group were imaged; ≥40 NMJs
were analysed per muscle. For agrin fluorescence intensity, lum-
brical muscles from six mice per group were imaged and 20
NMJs were analysed per muscle. All imaged AChR clusters were
measured.
Fibre type identification
Transverse 10 μm sections of soleus and gastrocnemiusmuscles
were cut using a cryostat and labelled for Myosin Heavy Chains
(MHC) MHCI, MHCIIa, and MHCIIb and MHCIIx. Sections were
blocked (10% normal goat serum in PBS) for 1 hour at room
temperature and then incubated with primary antibodies: rabbit
polyclonal IgG anti-laminin (Sigma 1:750), MHCI (BA-F8 Mouse
monoclonal IgG2b) 1:25, MHCIIa (Sc71, Mouse monoclonal IgG1),
MHCIIb (BF-F3 Mouse monoclonal IgM) 1:200 and MHCIIx (6H1
Mouse monoclonal IgM) 1:25, all DSHB, for 1 hour at room tem-
perature. Sections were then washed in PBS and incubated in
secondary antibodies for 1 hour, washed and mounted using
Vectashield mounting medium. Images were captured using a
Zeiss Axio Imager fluorescentmicroscopewith Zen software and
analysed using ImageJ software. In each section, every adjacent
field was examined moving from left to right in a systematic
manner until the required number was reached. Cross-sectional
areas and fibre type proportions were measured in 500 fibres
from six non-over-lapping fields at x40 view from six muscles
per group.
Transmission electron microscopy
Fresh tissue samples of intercostal muscles were fixed in 2% glu-
taraldehyde (TAAB Lab), osmicated in 1%osmium tetroxide (Agar
Scientific), dehydrated and embedded in epoxy resin (Epoxy
embedding resin kit, TAAB Lab). Semi-thin survey sections of
0.5 μm were cut and stained with 1% toluidine blue in 1% borax.
Ultrathin sections (70 nm approximately) were then cut and
stainedwith 2% aqueous Uranyl Acetate and Lead Citrate (Leica).
The grids were examined on a Hitachi HT7800 transmission
electron microscope using an Emsis Xarosa camera with Radius
software. Four intercostal muscles from three animals of each
group (salbutamol treated ColQ−/−, water treated ColQ−/− or
WT) were subjected to EM analysis. Quantitative analysis was
done with 15 or more electron micrographs analysed by ImageJ.
At each distinct region of postsynaptic folding the following
features were measured, as described by Slater et al (43): nerve
terminal area (total area of axon terminal); presynaptic length
(total length of the nerve terminal in direct contact with the
muscle fibre); postsynaptic area (total area containing postsy-
naptic folds); postsynaptic length (total surface length of sub-
neural apparatus measured along the tops of the folds); fold
length (total length of postsynaptic membrane including folds);
fold number (the number of distinct postsynaptic folds). These
measurementswere used to calculate the following derived vari-
ables: (i) Occupancy (presynaptic length/postsynaptic length);
(ii) fold index (fold length/postsynaptic length); (iii) fold density
(fold length/postsynaptic area).
Statistical analysis
Data are expressed as means ± S.D. unless otherwise stated.
Statistical analyses were performed using GraphPad Prism Ver-
sion 7 (GraphPad, San Diego, CA, USA) by pair-wise comparisons
between 2 conditions with unpaired Student’s t tests or Mann-
Whitney U tests. We confirmed normal distributions of data
before performing parametric tests using theD’Agostino Pearson
omnibus normality test. P<0.05 denoted significance. Datasets
were tested for outliers using the ROUT method (robust regres-
sion and outlier removal; Q = 1%). None of the outliers affected
statistical significance and all were included in analysis. Images
were analysed in a blinded fashion by the same experimenter.
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Abstract
Background Congenital myasthenic syndrome with episodic apnoea (CMS-EA) is a rare but potentially treatable cause of 
apparent life-threatening events in infancy. The underlying mechanisms for sudden and recurrent episodesof respiratory 
arrest in these patients are unclear. Whilst CMS-EA is most commonly caused by mutations in CHAT, the list of associated 
genotypes is expanding.
Methods We reviewed clinical information from 19 patients with CMS-EA, including patients with mutations in CHAT, 
SLC5A7 and RAPSN, and patients lacking a genetic diagnosis.
Results Lack of genetic diagnosis was more common in CMS-EA than in CMS without EA (56% n = 18, compared to 7% 
n = 97). Most patients manifested intermittent apnoea in the first 4 months of life (74%, n = 14). A degree of clinical improve-
ment with medication was observed in most patients (74%, n = 14), but the majority of cases also showed a tendency towards 
complete remission of apnoeic events with age (mean age of resolution 2 years 5 months). Signs of impaired neuromuscular 
transmission were detected on neurophysiology studies in 79% (n = 15) of cases, but in six cases, this was only apparent 
following specific neurophysiological testing protocols (prolonged high-frequency stimulation).
Conclusions A relatively large proportion of CMS-EA remains genetically undiagnosed, which suggests the existence of 
novel causative CMS genes which remain uncharacterised. In light of the potential for recurrent life-threatening apnoeas 
in early life and the positive response to therapy, early diagnostic consideration of CMS-EA is critical, but without specific 
neurophysiology tests, it may go overlooked.
Keywords Congenital myasthenic syndrome · Neuromuscular disease · Neurophysiology · Neuromuscular junction
Background
Congenital myasthenic syndromes (CMS) are a group 
of disorders caused by mutations in genes encoding pro-
teins responsible for the function and integrity of the 
neuromuscular junction (NMJ), resulting in impairment of 
the safety margin necessary for reliable neuromuscular trans-
mission. The first identified mutations were in genes encod-
ing subunits of the acetylcholine receptors (AChRs), and 
these remain the most common subtypes of CMS worldwide 
today [1]. However, in recent years the discovery of CMS-
related genes has accelerated, and to date over 30 genes have 
been implicated (Fig. 1).
Although the clinical spectrum is increasingly diverse, 
CMS are characterised by fatigable weakness typically of 
early onset, a positive family history, and abnormal neuro-
physiology tests, namely repetitive nerve stimulation (RNS) 
or single-fibre EMG (SFEMG) [1]. In RNS, supramaximal 
electrical stimulation is delivered to a motor nerve via sur-
face electrodes. In normal muscle, the resulting response 
(known as the compound muscle action potential or CMAP) 
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amplitude remains constant over a wide range of frequen-
cies, since the safety margin for neuromuscular transmission 
is large. In patients with abnormalities of neuromuscular 
transmission however, the CMAP amplitude can vary with 
repetitive stimulation. In pre-synaptic disorders involving 
defects of neurotransmitter release, the baseline CMAP 
amplitude is characteristically small, with high-frequency 
nerve stimulation causing an incremental CMAP response 
as a result of calcium build-up in the pre-motor terminal. 
In contrast, in post-synaptic disorders the slight reduction 
in the release of the neurotransmitter acetylcholine (ACh) 
caused by low-frequency stimulation can cause the end-plate 
potential to fall below the threshold required to generate a 
muscle action potential in a proportion of the muscle fibres. 
This results in decrement of the CMAP amplitude. However, 
in many cases, whether the disorder is pre- or post-synaptic 
cannot be effectively differentiated using neurophysiological 
testing alone.
In CMS due to mutations in the gene encoding the pre-
synaptic choline acetyltransferase (CHAT), the deficit is not 
in calcium-triggered ACh release, but in re-synthesis of ACh 
following re-uptake by the nerve terminal [2, 3]. Since the 
terminal contains a large reserve pool of ACh vesicles, a 
decremental response on RNS is only apparent once this 
pool has been exhausted. Hence, low-frequency stimulation 
typically produces no decrement, with the abnormality only 
becoming apparent following prolonged high-frequency 
nerve stimulation (e.g. 10 Hz for 5 min).
SFEMG determines the variability in the latency of 
neuromuscular transmission for individual muscle fibres 
within the same motor unit, or “jitter”. Increased jitter is 
more sensitive for detecting impaired neuromuscular trans-
mission than RNS, but is less specific since the findings are 
essentially identical for both pre- and post-synaptic disorders 
and hence must be interpreted along with clinical symptoms 
and signs.
CMS may be particularly difficult to diagnose in neo-
nates, in whom non-specific features such as generalised 
hypotonia, arthrogryposis and poor suck or cry may be 
the only clinical signs. In this age group, certain subsets 
of CMS may be associated with life-threatening episodic 
apnoea (CMS-EA); a rare, but potentially treatable cause 
of apparent life-threatening events (ALTEs). Whilst CMS-
EA was initially described in association with mutations 
in CHAT [2], the genetic basis has expanded, and several 
more recently described CMS genes have been shown to be 
associated with EA (Table 1). Genetic diagnosis for these 
conditions is all the more imperative given that effective 
treatments may prevent these life-threatening crises, but 
treatment response varies depending on the genetic subtype. 
The underlying mechanism of EA in disorders of neuro-
muscular transmission is unknown. We reviewed the clinical 
course of 19 patients with CMS-EA, to demonstrate poten-
tial diagnostic pitfalls and to assess long-term prognosis.
Methods
Clinical information was reviewed from 34 patients who 
currently attend the CMS clinic at the John Walton Mus-
cular Dystrophy Research Centre, Newcastle Upon Tyne, 
United Kingdom, and 929 patients from around the world 
who were referred to our laboratory for genetic testing 
between 1997 and 2011 in the context of a clinical suspi-
cion of CMS following review by experienced neuromus-
cular clinicians [4]. Patients had convincing evidence of 
CMS on the basis of clinical features, neurophysiological 
studies, laboratory investigations (including measurement 
of AChR antibodies and serum creatine kinase) and, in 
many cases, a prior muscle biopsy. EA was noted as being 
present where the clinician had recorded recurrent periods 
of respiratory arrest during the disease course; patients 
described as having respiratory insufficiency (causing 
inadequate oxygenation) but lacking clear description of 
recurrent apnoeic events (with cessation of respiration) 
were not included. CMS-EA was clearly described in 
32 patients; however, detailed clinical information and 
follow-up were available for 19 CMS-EA patients. For 
these cases, clinical, genetic and neurophysiological data 
were retrospectively reviewed. Genomic DNA samples or 
EDTA blood were provided to our laboratory from neuro-
muscular and neurology centres worldwide. Sanger-based 
mutation screening was carried out on a gene-after-gene 
basis according to phenotype. In one case, which has been 
previously described, the causative gene (MYO9A) was 
identified following whole exome analysis [5]. Informed 
Fig. 1  Heterogeneity of genetic defects in CMS: Mutations are 
described in genes encoding pre-synaptic, synaptic and post-syn-
aptic proteins, proteins of the extracellular matrix and dystrophin-
associated glycoprotein complex and in ubiquitously expressed pro-
teins involved in glycosylation (GFPT1, DPAGT1, ALG2, ALG14, 
GHMPPB) and mitochondrial function (SLC25A1) which may act 
at multiple sites. Genes in which mutations have been previously 
described in patients with EA are highlighted in red
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consent was obtained from all participants by local 
institutions. All genetically undiagnosed patients had 
been screened for mutations in CHAT, RAPSN, CHRNE, 
COLQ, DOK7, CHRNA1, CHRND, CHRNB1, SLC5A7 and 
SLC18A3. Neurophysiological assessment was performed 
at local institutions according to protocols described pre-
viously [6, 7]. Decrement was defined as a decrease in 
CMAP amplitude of 10% or more between the first and 
fourth CMAPs.
Results
Episodic apnoea was described in 3% (n = 32/963) of CMS 
cases. Of the CMS-EA cases, 44% (n = 14/32) were geneti-
cally diagnosed, compared with 93% (n = 866/963) of all 
CMS cases. The most common causative mutations were in 
the CHAT gene (16% of CMS-EA cases), with mutations in 
COLQ (9%), RAPSN (6%), SLC5A7 (6%), MYO9A (3%) and 
CHRNE (3%) being causative for the remainder of the cases 
with genetic diagnoses (Fig. 2).
In 13 cases, there was insufficient information on 
long-term follow-up and these were excluded from fur-
ther analysis. Clinical features, neurophysiology and man-
agement are described, therefore, for the remaining 19 
cases (Table 2).
Clinical features
All cases were proband, apart from cases 14 and 15 who 
are siblings. There was no family history of a neuromuscu-
lar disorder in any case, and consanguinity was reported in 
only two families. The disease manifested at birth in 84% 
(n = 16) of cases, with the remaining three cases present-
ing within the first 2 months of life. Signs present at birth 
were hypotonia (16 cases) and arthrogryposis (4 cases). 
Table 1  CMS genes associated with EA
Gene Protein and function Clinical features
CHAT Choline acetyltransferase (ChAT); re-synthesis of acetylcholine 
(ACh) from choline and acetyl-CoA in pre-synaptic nerve 
terminal [2]
Can exhibit striking clinical variability both between and within 
families. Positive response to AChEIs is seen in almost all 
cases [3, 22]
RAPSN Rapsyn; post-synaptic scaffolding protein, interacts with AChRs 
to induce clustering [23]
Two main phenotypes: late-onset with fatigable limb weakness, 
early onset characterised by arthrogryposis, high-arched pal-
ate, and facial, cervical and bulbar weakness [24–26]
CHRNE 
(fast 
channel)
Epsilon subunit of AChR, altered kinetic properties following 
binding of ACh to receptor [27, 28]
Severe weakness with crises [29]
SLC5A7 High-affinity choline transporter 1, resynthesises ACh in the pre-
synaptic nerve terminal [30]
Phenotypes range from severe form with arthrogryposis, hypoto-
nia and early lethality, to neonatal onset CMS with prominent 
EA [20]
SLC18A3 Vesicular acetylcholine transporter (VAChT), uptake of ACh 
into pre-synaptic vesicles [20]
Ptosis, ophthalmoplegia and fatigability. Deterioration of symp-
toms in cold temperature described in one case [20]
COLQ ColQ, collagenic tail of AChE which anchors AChE in the post-
synaptic membrane [31, 32]
Broad phenotype, from adult onset limb girdle CMS to early 
onset severe and progressive forms. Slowing of the pupillary 
light reflex (25% of cases). Worsening with AChEI therapy 
[31, 33]
CHRND Delta subunit of AChR Phenotype overlapping with rapsyn-CMS [34–36]
SCN4A Voltage gated sodium channel (Nav1.4), influx of sodium ions 
into post-synaptic membrane and generation of muscle action 
potential [37, 38]
Relatively severe limb weakness, ophthalmoplegia and ptosis. 
Apnoeic attacks which persisted from infancy into early adult-
hood are described [38]
MYO9A Unconventional myosin Myo9A, presumed pre-synaptic function 
[5]
Identified in two families, neonatal onset EA which responded 
dramatically to pyridostigmine and 3,4-DAP is described [5]
Fig. 2  Proportion of CMS-EA subtypes in our patient cohort (n=32)
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Antenatal complications were recognised in 42% (n = 8) 
of patients, and included reduced foetal movements and/or 
polyhydramnios.
Age of onset of EA was variable. Most patients had 
their first apnoea in the hours following birth (n = 5, 26%) 
or in the first 4 weeks of life (n = 5, 26%). For four cases 
(21%), the first apnoeic event occurred between the age of 
1–4 months, and four cases developed EA between 4 and 
12 months of age. In one case, EA did not occur until the 
age of 18 months.
Cognitive development was abnormal in nine cases 
(47%); in three cases, this was severe and considered to be 
secondary to hypoxic brain damage. Brain MRI was avail-
able for ten patients, and described as normal in seven, with 
two cases showing features in-keeping with hypoxic ischae-
mic encephalopathy, and one case (with CHAT-CMS) show-
ing hypoplasia of the cerebellar vermis.
Median diagnostic delay from first symptoms to the 
clinical diagnosis of CMS (prior to genetic confirmation) 
was 8 months (range 1–96 months). Differential diagno-
ses included laryngomalacia, epilepsy, cardiac conduction 
defects, congenital hypothyroidism, Prader–Willi syndrome 
and spinal muscular atrophy.
Apnoeic events and respiratory function
Infections, including respiratory tract infections, were the 
most common precipitating factor for apnoeas, reported 
in 74% (n = 14) of patients (Table 3). Apnoeas were also 
reported during feeding, stress, crying, increased activ-
ity and increased environmental temperature. Frequency 
of apnoeas varied significantly, independent of genotype, 
from approximately one episode per month, to very fre-
quent episodes occurring up to 40 times per day.
During apnoeic episodes, myasthenic features typically 
worsened, with worsening of hypotonia, bulbar weakness 
and ptosis reported in 14, 6 and 4 cases, respectively. 
Approximate duration of events ranged from 30 s to over 
30 min (persisting until the patient was intubated and 
ventilated, and resulting in permanent brain damage), but 
mean duration of a typical event was 2 min.
There was significant morbidity and mortality in the 
cohort, with two patients having died following pro-
longed apnoeas, aged 11 months (genetically undiag-
nosed) and 3 years (with RAPSN mutations), respectively, 
and a further case with severe hypoxic brain injury being 
permanently ventilated (SLC5A7 mutations). However, 
overall progressive improvement and tendency towards 
resolution of apnoeic episodes was reported in the major-
ity of cases (Fig. 3). For 11 cases there was complete 
remission of apnoeas (mean age of resolution 2 and 
5 months). A further five cases showed tendency towards 
remission but still experienced apnoeas during infections. Ta
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There was no genotype–phenotype correlation between 
cases who had remission of EA and those who still expe-
rienced apnoeas.
Neurophysiology
All patients had neurophysiological assessment; 4 cases 
had RNS and SFEMG, and 15 cases had been investigated 
using RNS alone. Abnormal RNS was seen in 15/19 cases 
(79%); in four cases, in whom only RNS was performed, no 
decrement was detected. In 5 of the 15 cases with abnormal 
RNS, stimulation at 3 Hz was borderline or negative, but 
prolonged high-frequency RNS (10 Hz for 5 min) revealed 
marked decrement. In a further patient (genetically undiag-
nosed) increment was detected on prolonged stimulation. 
All cases who had SFEMG in addition to RNS demonstrated 
increased jitter.
Management
18 cases had been treated with acetylcholinesterase inhibi-
tors (AChEIs) at some point. Of these, 67% (n = 12) had a 
sustained clinical improvement, which included all patients 
with mutations in RAPSN and CHAT, one patient with 
SLC5A7 mutations and seven patients who were genetically 
undiagnosed. Transient improvement but subsequent dete-
rioration following commencement of AChEIs was seen in 
two patients (both genetically undiagnosed). AChEIs had 
no effect in four cases (three genetically undiagnosed, and 
one SLC5A7-CMS). The β2-agonist salbutamol resulted in 
clinical improvement in three cases (genetically undiag-
nosed, fast channel syndrome and CHAT-CMS), transient 
improvement in one case (undiagnosed) and no response 
in the remaining three cases (one undiagnosed, and two 
with SLC5A7-CMS). 3,4-Diaminopyridine (3,4-DAP) was 
used as an adjunctive therapy in two cases, resulting in 
improvement in one (with CHAT-CMS) and no response 
in the other (genetically undiagnosed). All six cases in 
whom abnormal RNS had only been detected following 
prolonged high-frequency stimulation had clinical benefit 
from AChEI therapy.
Most patients (n = 14, 74%) had normal respiratory func-
tion between apnoeic events. Three cases required noctur-
nal non-invasive ventilation (one with CHAT-CMS and two 
genetically undiagnosed cases), and one was permanently 
ventilated via tracheostomy. Hospital attendances were com-
mon, with 41% (n = 8) of cases requiring frequent (> 1 per 
year) admissions. Fourteen patients had required ventilation 
during periods of respiratory crisis (11 invasive and 3 non-
invasive ventilation).
Table 3  Apnoeic events and respiratory function in our patient cohort
LRTI lower respiratory tract infection
Precipitating events Associated symptoms during apnoea Recurrent LRTI Respiratory function 
between episodes
Case 1 Feeding, infection, stress Hypotonia, bulbar weakness, ptosis Yes Normal
Case 2 Feeding, infection, stress Hypotonia Previously, now resolved Normal
Case 3 Infection Hypotonia Previously, now resolved Normal
Case 4 Infection, feeding Hypotonia Yes Normal
Case 5 Infection, during sleep Hypotonia, bulbar weakness Yes Normal
Case 6 Stress, infection, higher temperature Ptosis, bulbar weakness, hypotonia Previously, now resolved Normal
Case 7 Crying Hypotonia No Normal
Case 8 Infection None noted Previously, now resolved Normal
Case 9 Feeding, infection Ptosis, bulbar weakness, hypotonia No Normal
Case 10 Infection Hypotonia Yes Permanently ventilated
Case 11 Infection, feeding, crying None noted Yes Normal
Case 12 Feeding, infection Hypotonia, facial weakness Yes Impaired
Case 13 Feeding No Yes Normal
Case 14 Feeding Hypotonia, ptosis, cyanosis Yes Not assessed
Case 15 Infection, increased activity, sleep Hypotonia Yes Normal
Case 16 Infection, increased activity, sleep Hypotonia, bulbar weakness Yes Normal
Case 17 Feeding Hypotonia No Normal
Case 18 Feeding, infection, during sleep Hypotonia, cyanosis Yes Impaired
Case 19 Infection, feeding Hypotonia, cyanosis Yes Impaired
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Discussion
Apparent life-threatening events (ALTEs), defined as epi-
sodes characterised by some combination of apnoea, skin 
colour change, change in muscle tone and choking or gag-
ging [8], have an extremely broad differential diagnosis. 
Causes include epilepsy, cardiac arrhythmia or structural 
cardiac defects, gastro-oesophageal reflux disease, respira-
tory tract infections and upper airway obstruction [9–12]. 
ALTEs are most common in the first 10 weeks of life, with 
cyanosis and apnoea often being the most prominent or 
only symptoms [11]. CMS is rarely considered as a pos-
sible differential diagnosis for ALTEs, thus many patients 
undergo extensive investigation before the possibility is con-
sidered. In our cohort, average diagnostic delay was sub-
stantial at 8 months. Worsening of myasthenic symptoms 
during apnoeas was frequently observed, and these features 
may provide a diagnostic clue. In practice, however, many 
patients may be admitted directly to intensive care units and 
may not be examined by a paediatric neurologist or neuro-
muscular specialist during these crises.
In early infancy, abnormal neurophysiology tests may 
be the only indication of a NMJ disorder. However, we 
observed in this cohort that without specific neurophysi-
ological assessment, a pre-synaptic abnormality may go 
overlooked. In 32% (n = 6) of cases, no abnormality was 
observed at low-frequency RNS, with decrement or incre-
ment only becoming apparent following prolonged high-
frequency stimulation. In two of these cases, the genetic 
diagnosis was of ChAT deficiency, in which re-synthesis of 
ACh is known to be impaired. In the other four cases, the 
genetic diagnosis was unknown, but it may be that these also 
affect proteins involved in this pathway. Failure to perform 
this additional test could result in the diagnosis of CMS-EA 
being discounted. Furthermore, all of these cases showed a 
positive response to AChEI therapy. Such prolonged studies 
can be uncomfortable for the patient, and may require seda-
tion. Nevertheless, given the risk of fatal apnoeas if the diag-
nosis is missed, and the potential for clinical improvement 
with AChEIs, these prolonged studies should be performed 
if deficiency of ACh re-synthesis is suspected.
The underlying mechanism(s) giving rise to these sudden 
and recurrent apnoeas is yet to be characterised. Respira-
tory control mechanisms respond to input from neural and 
chemical receptors, which are integrated by the respiratory 
centres in the medulla and pons. These subsequently provide 
neuronal drive to respiratory muscles, maintaining upper air-
way patency and determining the level of ventilation. Recur-
rent apnoea could be due to an abnormality at any point 
along this axis. The majority of mutations causing CMS-
EA lead to pre-synaptic defects (Fig. 1), which have impor-
tant functions for both central and neuromuscular synaptic 
function. This, along with the tendency for patients to have 
normal respiratory function between apnoeas, could point 
to a centrally mediated mechanism. In addition, the pro-
portion of patients with impaired cognitive function in our 
cohort (47%) was higher than expected and is not something 
that has been previously well-characterised in disorders of 
the NMJ. Any impairment of higher function in CMS-EA 
patients is often explained by hypoxic brain damage due 
to repeated respiratory failure, although the possibility of 
impaired CNS maturation due to reduced neurotransmitter 
in central cholinergic neurons has not been fully explored. 
The most common CMS-EA gene, CHAT, has important 
functions in both central and peripheral synapses, and defi-
ciency of ChAT has been reported in Alzheimer’s disease, 
idiopathic Parkinson’s disease, Huntington’s disease and 
schizophrenia [13–16]. Furthermore, in cases of sudden 
infant death syndrome, decreased activity of ChAT has been 
demonstrated in the CNS [17, 18]. Cognitive and behav-
ioural have also been described in the recently identified 
CMS subtype due to mutations in SLC5A7, which encodes 
the high-affinity choline transporter 1, necessary for uptake 
of choline from the synaptic space for the synthesis of ACh 
at central and peripheral cholinergic synapses [19]. A further 
CMS-EA gene involved in ACh release, SLC18A3, encodes 
the vesicular acetylcholine transporter (VAChT), which 
mediates the vesicular storage of ACh in the central and 
peripheral nervous system. SLC18A3 mutations are associ-
ated with a severe CMS phenotype and learning difficulties 
are also described [20, 21]. The CMS-EA genes SNAP25B, 
VAMP1 and MUNC13 encode proteins of the SNARE com-
plex. These are essential for calcium-triggered exocytosis at 
central and neuromuscular synapses; therefore, it is unsur-
prising that CMS due to mutations in these genes may be 
associated with epilepsy and impaired brain development 
[22, 23]. Abnormalities of the CNS have also been reported 
in CMS due to mutations in the unconventional myosin gene 
Fig. 3  Resolution of apnoeic events over time: For the majority of 
cases, the period of recurrent EAs (orange) during a patient’s life 
span (gray) began in the first months of life and resolved in early 
childhood. Cases marked * are deceased
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MYO9A. MYO9A also appears to have pre-synaptic function 
and localization at the NMJ, although the mechanism for 
NMJ dysfunction in these patients is yet to be determined 
[5].
Administration of one or more drugs is indicated once 
the diagnosis of CMS-EA is established. Several drugs 
have shown convincingly positive effects in reducing the 
frequency of apnoeas, including AChEIs, 3,4-DAP and sym-
pathomimetics (ephedrine or salbutamol). Because of the 
sudden nature of these attacks, parents should be provided 
with an inflatable rescue bag and fitted mask, trained in CPR 
and may be provided with a home apnoea monitor. Parents 
may also be instructed to give additional AChEI doses dur-
ing infection or other potential precipitating events.
We recognise that this study has several limitations. We 
include a small number of patients, contributed to by the 
rarity of the condition. Data were collected retrospectively 
and over a long period of time (1997–2011) during which 
the awareness of CMS and availability for genetic testing 
has increased. However, even in this patient cohort, who 
continues to be tested for new causative CMS genes as they 
are discovered, a relatively large proportion (56%) of cases 
remain genetically undiagnosed. CMS-EA is a challenging 
diagnosis, with several mimics, and this proportion could 
suggest an alternative diagnosis other than a neuromuscular 
transmission defect in these patients. However, it may also 
reflect further CMS causing genes which have not yet been 
discovered.
Given the likelihood of recurring episodes, the poten-
tial for psychomotor impairment due to secondary hypoxic 
brain damage, and the positive effect of available treatments, 
CMS-EA is an important diagnosis not to miss. Prompt diag-
nosis and initiation of treatment and ventilatory support is 
imperative in early life, when EA may be frequent, but the 
majority of cases will exhibit a tendency towards remission. 
Improved understanding of the mechanism of this condition 
may provide insights into further causative genes for geneti-
cally undiagnosed patients, and lead to improved diagnostic 
and treatment strategies.
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The neuromuscular junction (NMJ) is one of the best-studied cholinergic synapses. Inherited defects of peripheral neurotransmission
result in congenital myasthenic syndromes (CMSs), a clinically and genetically heterogeneous group of rare diseases with fluctuating
fatigable muscle weakness as the clinical hallmark. Whole-exome sequencing and Sanger sequencing in six unrelated families identified
compound heterozygous and homozygous mutations in SLC5A7 encoding the presynaptic sodium-dependent high-affinity choline
transporter 1 (CHT), which is known to be mutated in one dominant form of distal motor neuronopathy (DHMN7A). We identified
11 recessive mutations in SLC5A7 that were associated with a spectrum of severe muscle weakness ranging from a lethal antenatal
form of arthrogryposis and severe hypotonia to a neonatal form of CMS with episodic apnea and a favorable prognosis when well
managed at the clinical level. As expected given the critical role of CHT for multisystemic cholinergic neurotransmission, autonomic
dysfunctions were reported in the antenatal form and cognitive impairment was noticed in half of the persons with the neonatal
form. The missense mutations induced a near complete loss of function of CHT activity in cell models. At the human NMJ, a delay
in synaptic maturation and an altered maintenance were observed in the antenatal and neonatal forms, respectively. Increased synaptic
expression of butyrylcholinesterase was also observed, exposing the dysfunction of cholinergic metabolism when CHT is deficient
in vivo. This work broadens the clinical spectrum of human diseases resulting from reduced CHTactivity and highlights the complexity
of cholinergic metabolism at the synapse.
The synapse is a highly specialized structure that is funda-
mental for the function of the neuron by mediating effi-
cient chemical transmission to its postsynaptic cell. One
of the best-studied synapses used as a model is the cholin-
ergic neuromuscular junction (NMJ). Cholinergic trans-
mission is unique among the neurotransmitter systems
in that it is rapidly stopped not only by clearance but
also by enzymatic cleavage of the neurotransmitter in the
synaptic space by cholinesterases to ensure quick succes-
sive postsynaptic responses.1 Toward this aim, the nerve
terminal takes up choline from the synaptic space through
the presynaptic sodium-dependent high-affinity choline
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Table 1. Clinical Features of the Subjects with a Neonatal Form of CMS-EA due to SLC5A7 Mutations
Individual 1
(France)
Individual 4
(Algeria)
Individual 5
(Italy)
Individual 6
(Italy)
Individual 7
(Romania)
Sex; age at onset male; birth male; 2 months female; birth male; birth male; birth
Mutations c.194G>A
(p.Gly65Glu),
c.313C>T
(p.Pro105Ser)
c.143A>G
(p.Asp48Gly),
c.143A>G
(p.Asp48Gly)
c.524A>G
(p.Tyr175Cys),
c.1030G>C
(p.Val344Leu)
c.331T>C
(p.Tyr111His),
c.1252T>G
(p.Phe418Val)
c.872T>C
(p.Ile291Thr),
c.1336A>G
(p.Arg446Gly)
Pregnancy uneventful uneventful uneventful uneventful uneventful
First symptoms (age) sudden apneas (b),
hypotonia (b)
long meals
(2 months), brief
bradypneas
(5 months)
respiratory distress (b),
sudden apneas (b)
sudden apneas (b),
weak cry (b)
sudden apneas (b),
hypotonia, cyanosis
(b), sucking
difficulties (b)
Neonatal period sudden apneas
misdiagnosed as
seizures; ventilation
till 6 weeks; sucking,
swallowing, and
chewing difficulties;
axial hypotonia
slow feeding; few
minutes bradypneas;
stridor; swallowing
difficulties
frequent apneas
requiring ventilation
support
frequent apneas;
dysphagia; acute
ptosis
sudden apneas with
cyanosis when crying
misdiagnosed as
breath holding
Motor delay yes (walk 22 months) yes (sit 9months, walk
20 months)
yes (walking never
gained)
yes (walk 17 months) yes (sit 7months, walk
18 months)
Symptoms during Course
FUD 16 years 4 years 5 years 11 years 3 years and 9 months
EA yes, until starting
AChEI at 18 months
2 episodes yes, till now no yes, until starting
AChEI at 4 months
CH yes no yes no ND
Ventilation;
tracheostomy
yes (5 months); yes
(from 6 months to
5 years)
no; no yes; no no; no no; no
Bulbar weakness;
facial weakness
sucking, swallowing,
chewing till
10 months; facial
weakness from
18 months till now
(mild chewing,
articulation)
intermittent stridor,
no dysphagia;
hypomimia
yes (tube feeding due
to swallowing and
chewing difficulties);
constant facial
weakness
yes (nasal voice,
occasional
dysphagia); no
dysphonia and
dysphagia until
2 years; ND
Ptosis; OPH yes; yes yes (from 4 months);
yes
yes; yes yes; yes yes; yes
Limb fatigability;
weakness
yes; yes (Gowers till
28 months, run at
6 years), waddling gait
yes; no yes; severe proximal yes; yes (lower limb
girdle)
yes; fatigability
Axial weakness yes (neck and spine),
improved by AChEI
yes (neck
intermittently)
yes yes (neck, flexion and
extension)
yes (normal walk but
climbs stairs with one
foot at time)
Scoliosis; cont. mild; no no; no no; no kyphosis; no no; no
Amyotrophy no no yes no no
DMN signs no no no pes planus no
CD; behavior no; normal no; normal yes; abnormal yes; normal yes; ND
Course Characteristics
Evolution marked improvement
since AChEI
administration at
18 months
improvement since
AChEI administration
at 18 months
stable with episodic
crises, muscle
weakness without
progression
spontaneous recovery
of respiratory crises
improved after
increasing AChEI
Fluctuationsa yes (few days) yes (one day) no yes (diurnal) yes (respiratory
intercurrence)
Exacerb.; MC no; no no; no no; no yes; no yes; ND
(Continued on next page)
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transporter 1 (CHT) to resynthesize ACh by the action
of choline acetyltransferase (ChAT). The high-affinity
choline uptake from the synaptic space by this hemicholi-
nium-3 (HC-3)-sensitive transporter CHT represents the
limiting step for sustained ACh synthesis and is tightly
regulated with ChAT activity.2
The NMJ achieves action potential transmission from
themotoneuron nerve terminal to the skeletal muscle fiber
to control muscle contraction. Defective neurotransmis-
sion at the NMJ results in myasthenia, i.e., fluctuating
fatigable muscle weakness.3 The inherited types of myas-
thenia form the group of congenital myasthenic syn-
dromes (CMSs) characterized by an early age of onset, dis-
ease progression, no ACh receptor (AChR) antibodies, and
responsiveness to treatments, especially acetylcholines-
terase (AChE) inhibitors. Mutations in 23 genes are known
to cause CMS. Among them is found CHAT (MIM: 118490)
that is mutated in a recessive form of CMS with sudden
episodes of apnea (CMS-EA [MIM: 254210]).4,5 On the
other hand, one dominant-negative truncating mutation
in SLC5A7 (MIM: 608761) encoding CHT causes a distal
hereditary motor neuronopathy, type VIIa (DHMN7A
[MIM: 158580]) with progressive distal muscle wasting
and vocal cord paresis, questioning the relationship of
CHT with CMS.6 Worldwide, there are still many individ-
uals with a clinical diagnosis of CMS who remain geneti-
cally undiagnosed. In this paper, we report loss-of-function
mutations of SLC5A7 in six unrelated families as the
underlying cause of a recessive form of CMS that clini-
cally ranges from muscle hypotonia with early neonatal
lethality to a neonatal form sharing striking similarities
to CMS-EA resulting from CHAT mutations.
The six families were part of two distinct European
CMS cohorts. Participants gave informed consent through
a prospective donor scheme approved by national ethic
committees (DC-2012-1535 and AC-2012-1536), and
genomic DNA was isolated from blood samples. Medical
histories were taken from all participants by neurologists.
All parents displayed no peculiar medical history and
were healthy at clinical examination. Electroneuromyog-
raphy (ENMG) and repetitive nerve stimulation (RNS)
were carried out under standardized protocols.7 A detailed
clinical description of the two unrelated individuals (1 and
2) who underwent whole-exome sequencing is found in
the Supplemental Note, and Table 1 summarizes the clin-
ical features of the five isolated individuals (1, 4–7) with
a neonatal form close to CMS-EA.5 To summarize, brief
and recurrent EA occurred neonatally as the inaugural
symptom in all subjects with the neonatal form. Other
symptoms of CMS were present such as hypotonia, weak-
ness and fatigability, hypomimia, and oculo-bulbar symp-
toms. A significant decrement in the EMG with RNS was
observed in four individuals (1, 4, 5, 7). AChE inhibitors
were highly efficient for three subjects (1, 4, and 7) with
cessation of the EA and improvement of all myasthenic
symptoms. Although individual 6 had no decrement
in EMG with RNS, he had mild ptosis worsening at the
end of the day, ophtalmoparesis (impaired abduction of
left eye and impaired adduction of right eye) with variable
strabismus, and striking limb fatigability, all features
Table 1. Continued
Individual 1
(France)
Individual 4
(Algeria)
Individual 5
(Italy)
Individual 6
(Italy)
Individual 7
(Romania)
Last Examination
Age 16 years 4 years 5 years 11 years 3 years and 9 months
PV/NIV; T no; no no; no PV; yes no; no no; no
Bulbar; facial no; yes (minimal) yes (mild stridor); yes
(intermittently)
yes; yes yes (nasal voice); yes yes (nasal voice); yes
Ptosis; OPH yes; yes (fluctuant in
severity)
yes; yes (persistent) yes; yes (persistent) yes; yes (permanent) yes; yes (permanent)
Limb weakness;
fatigability
no; yes (moderate,
lower limbs)
no; yes generalized and
constant severe
weakness; no
yes (distal upper and
proximal lower); no
yes; yes
Axial weakness no yes (neck,
intermittent)
yes yes (neck) no
EMG (age) 18 months 16 months 14 months 3 years 4 months
Decrement 3 Hz 66% no, but yes after a
pulse of 10 s at 20 Hz
70% no (no challenging
conditions done)
10%–20%
Therapy and effect AChEI, þþþ AChEI, þþþ AChEI, þ AChEI,;
salbutamol, b
AChEI, þþ
Abbreviations are as follows: b, birth; FUD, follow-up duration; EA, episodic apnea; AChEI, acetylcholinesterase inhibitors; OPH, ophthalmoparesis; CH, chronic
hypoventilation; ND, not determined; cont., contractures; DMN, distal motor neuropathy; CD, cognitive deficit; MC, myasthenic crisis; Exacerb., exacerbation;
PV, permanent ventilation; NIV, nasal intermittent ventilation; T, tracheostomy.
aExcept sudden apneas.
bAdequate dose and duration of treatment were not optimal.
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consistent with a diagnosis of CMS. The two sibs of family
2 displayed a more severe antenatal phenotype with hy-
dramnios and arthrogryposis of fingers with knees and
malformative features in individual 2 (see Supplemental
Note). Death occurred at the age of 10 (individual 3) and
15 (individual 2) days.
After exclusion ofCHATmutations by Sanger sequencing,
whole-exome sequencing was performed in family 1 on
blood genomic DNA though enrichment capture using
the SureSelect Human All Exon v5 kit (Agilent Technolo-
gies) and paired-end massive parallel sequencing in a
HiSeq 2000 machine (Illumina) with an average coverage
of 603. Whole-exome sequencing and variant analyses
were performed for individual 2 (family 2) as previously
described.8 Two heteroallelic candidate variants in SLC5A7
were found to be linked with the disease when searching
for rare variations (less than 1% of frequency in control
databases) with a recessive model of inheritance in the two
families (Figure S1). In family 1, two missense variations
(c.194G>A [p.Gly65Glu] and c.313C>T [p.Pro105Ser];
GenBank: NM_021815) segregated with the disease. In
family2, the twodeceased infantswerecompoundheterozy-
gous for one missense (c.1082G>A [p.Arg361Gln]) and one
nonsense (c.123_126del [p.Ile42*]) variation inherited from
their parents. No other candidate gene was retained in the
two families when recessive inheritance and single-nucleo-
tide variations not reported in polymorphic database were
used as filtering parameters.
We then searched for SCL5A7 mutations by Sanger
sequencing of its 10 exons in 95 unrecognized individuals
with CMS-EA who did not have mutations in CHAT.
Four isolated subjects were found to harbor two distinct
Figure 1. Schematic Representation of
CHT and Position of the Variants Linked
to the Antenatal Form with Arthrogrypo-
sis and to the Neonatal Form of CMS
(A) The substitutions affecting an amino
acid residue already described as critical
for CHT activity are in red. All amino
acid changes result from mutations that
were in the heterozygous state except
c.143A>G (p.Asp48Gly), which was
homozygous (circle). The variants studied
at the functional level are underlined.
The changes resulting in DHMN7A
(p.Lys499Asnfs*13) and linked to ADHD
(p.Ile89Val) are also indicated.
(B) The alignment of human CHT with the
sequences of five model species (rat,
mouse, zebrafish, Torpedo mamorata, and
Caenorhabditis elegans with the percent
of amino acid identities in brackets) dem-
onstrates the high conservation of the
substituted residues.
SLC5A7 compound heterozygous
candidate mutations with a recessive
inheritance pattern (individuals 4–7,
Table 1). All mutations were in-
herited except c.331T>C encoding
the p.Tyr111His substitution (individual 6), with a
maternal mutant allele arising de novo. None of the candi-
date mutations were reported in control databases (in-
house, dbSNP, 1000 Genomes, ExAC), except c.1082G>A
(p.Arg361Gln, family 2) and c.872T>C (p.Ile291Thr,
individual 7) that were reported in 2 and 7 of 121,350
alleles in the heterozygous state (ExAC), respectively. All
missense substitutions were reported as pathogenic by
SIFT, PolyPhen-2, and MutationTaster.
The 10 missense mutations were located all along the
580 amino acid residues composing CHT that consists of
13 transmembrane segments (Figure 1A).9 All substituted
for an amino acid residue that is highly conserved during
evolution (Figure 1B). Four variations affected amino acids
that have been demonstrated to be critical for choline
uptake activity (Asp48, Tyr111, Arg361, and Arg446).2,10
We investigated the pathogenicity of five of these
ten missense substitutions that were distributed all along
the transporter (c.143A>G [p.Asp48Gly], c.194G>A
[p.Gly65Glu], c.313C>T [p.Pro105Ser], c.1082G>A
[p.Arg361Gln], and c.1336A>G [p.Arg446Gly]) on CHT
activity in vitro to determine their functional effect.
We introduced the single-nucleotide changes into the
human cDNA encoding CHT (OriGene Technologies) by
site-directed mutagenesis (GenScript). The WT and
mutant cDNA constructs were transiently transfected
into HEK293T cells using Fugene6 reagent (Promega),
and membrane expression as well as choline uptake
were evaluated. Figure 2A shows typical immunostaining
patterns (ApoTome 2 acquisition, Carl Zeiss) obtained
on permeabilized cells stained with a monoclonal
antibody directed against human CHT (clone 62-2E8,
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Sigma-Aldrich). We observed CHT membrane immuno-
labeling for the five investigated missense mutations, sug-
gesting conserved cell trafficking of the mutated CHT
compared to control.
We then determined whether the choline uptake by
CHT was altered by the amino acid substitutions. HC-3-
sensitive choline transport by transfected cells was
evaluated on a period of 6 min using 1 mM 14C-choline
(PerkinElmer) subtracting the uptake observed with 1 mM
HC-3 (Sigma-Aldrich), since choline uptake bymock-trans-
fected HEK293 cells was not sensitive to this HC-3 concen-
tration.10 Whole-cell lysates were assayed for accumulated
radioactivity by liquid scintillation spectrometry (Packard
Tri-carb Liquid Scintillation Counter). Specific CHT-medi-
ated choline uptake was severely impaired for all mutants
tested, with residual activity varying between 0% and
10% of control levels (Figure 2B). Although total choline
uptake by mock-transfected cells was not saturated in
the low micromolar range of choline concentrations, the
wild-type CHT-mediated component of choline transport
was characterized by a Km of 2.5 mM and a Vmax of
75 pmol/well (0.5 nmol/mg protein) over 6 min. When
choline uptake by the p.Asp48Gly and p.Pro105Ser iso-
forms of CHTwas analyzed at this range of concentrations,
the low level of uptake did not allow convergence
(p.Asp48Gly) or gave a much lower estimate of Vmax at
5 pmol/well, with a Km of 0.8 mM (p.Pro105Ser, data not
shown). The other variants were not tested because their
residual activity was even less than that of p.Asp48Gly.
Western blot analyses of total cell extracts using an affinity
purified polyclonal anti-CHT antibody (Abcam) confirmed
that the amino acid substitutions did not affect the size of
CHTand that the drastic reduction of choline transport ac-
tivity of mutated CHTwas not due to reduced protein level
compared to the wild-type CHT (Figure 2C). The size and
pattern of the detected bands closely resembled those
observed previously for homo-oligomers.10 CHT functions
as a homo-oligomer, and two amino acid substitutions
(c.265A>G [p.Ile89Val] and c.1497delG [p.Lys499Asnfs*
13]) observed in humans have been reported to exert
Figure 2. Heterologous Expression and
Transporter Activity of CHT in Transfected
HEK293T Cells
(A) Immunostaining of heterologous CHT
using anti-SLC5A7 antibodies showed a
membranous staining of the wild-type
(WT) and the five variant CHT investigated
in HEK293T cells transiently transfected
with hSLC5A7 cDNA constructs (c.143A>G
[p.Asp48Gly], c.194G>A [p.Gly65Glu],
c.313C>T [p.Pro105Ser], c.1082G>A
[p.Arg361Gln], and c.1336A>G [p.Arg446
Gly]). Nuclei are stained with DAPI (blue).
Scale bars represent 10 mm.
(B) Evaluation of the choline transporter
activity sensitive to HC-3, corresponding
to the heterologous expression of CHT ac-
tivity in transiently transfected HEK293T
cells. The y axis bar is interrupted for a
better visualization of the residual trans-
porter activity of the variant proteins.
(C) Western blot analysis of heterologous
CHT in total cell extracts of HEK293 cells
transiently transfected with the wild-type
or mutant hSLC5A7 constructs performed
in denaturating conditions. Three main
bands (95 kDa) were observed using a
polyclonal antibody directed against hu-
man CHT. Anti-GAPDH antibody was
used as loading control. No band specific
to CHT was observed in extracts from cells
transfected with eGFP alone (eGFP), con-
firming the specificity of the antibody.
The size and amount of the bands specific
to heterologous CHT were similar between
the wild-type (lines WT1 and 2) and the
five variants.
(D) Evaluation of HC-3-sensitive choline
transport when coexpressing the wild-
type and the c.313C>T (p.Pro105Ser) and c.194G>A (p.Gly65Glu) mutant constructs in transiently transfected HEK293T cells. The
activities recorded in cells coexpressing the indicated combinations of cDNA are compared to the summation of the individual activities
obtained when the cells were transfected with the wild-type or the mutant constructs.
The results are expressed as mean5 SEM. Statistical significance was calculated by Student’s t test with a level of statistical significance
set at p < 0.05 (***p < 0.001).
The American Journal of Human Genetics 99, 753–761, September 1, 2016 757
a dominant-negative effect on the wild-type CHT.6,11
We therefore coexpressed the cDNAs containing the
c.194G>A (p.Gly65Glu) and the c.313C>T (p.Pro105Ser)
mutations—the two compound heterozygous mutations
identified in individual 1—with the wild-type cDNA or
with each other. The CHT activity of co-transfected cells
was less than that calculated from the addition of CHT ac-
tivities obtained when the cDNA were transfected individ-
ually (Figure 2D). However, the impact of the variants on
the WT transporter activity was low, concordant with the
recessive nature of the tested mutations.
Cholinergic metabolism is critical for NMJ formation,
and knock-out Slc5a7 mice lacking CHT display defective
innervation patterns at the NMJ.12 To determine whether
the NMJ structure was impacted when CHT activity is
deficient in human, we investigated the NMJs in muscle
biopsy samples available for the 16-year-old individual 1
(deltoid muscle) and for the deceased newborn 2 (autopsy
material) via standard protocols.13 CHT was immuno-
stained at the NMJ in the muscle biopsies of the two indi-
viduals at a level similar to the control muscle biopsy using
a polyclonal antibody (Abcam) as expected from the
in vitro analyses of CHT protein levels (Figure 3A). Dener-
vation-reinnervation processes at the NMJs were evident in
the muscle sample of individual 1 (Figure 3B and Table S1).
Electron microscopy further confirmed the occurrence of a
partial denervation-reinnervation process with small nerve
terminals and empty synaptic gutters (n ¼ 5; Figure S2A).
When present, nerve terminals contained synaptic vesicles
that appeared normal in quantity (Figure S2B). Well-
defined secondary synaptic folds were observed, suggest-
ing normal formation of the post-synaptic element. Cyto-
plasmic immunostaining of terminal Schwann cells using
S100 antibodies did not detect major abnormalities except
for a less well-defined staining pattern compared to control
(Figure S3A), which was confirmed at the ultrastructural
level (Figure S2A). Autopsy material of newborn 2 showed
immature NMJs with thin and unbranched terminal axons
contacting undefined subneural folds that sometimes ap-
peared to be polyneuronally innervated (Figure 3C). This
is consistent with delayed NMJ development in this
newborn, since elimination of polyneuronal innervation
should be completed during the 25th week in utero.14
To determine whether critical synaptic actors of cholin-
ergic metabolism were impacted by defective CHT activity,
we investigated their localization by immunostaining.
ChAT (polyclonal antibody, Abcam) and the vesicular
acetylcholine transporter VAChT (monoclonal antibody,
clone S6-38, Abcam)—which allows the storage of ACh
into synaptic vesicles1—were present in levels that look
similar to controls (Figure S3B). Enzymatic (Koelle-Frieden-
wald) and fluorescent staining of AChE using fasciculin-2
also appeared similar between case and control subjects
(Figure S4A and data not shown). By contrast, the
immunostaining of butyrylcholinesterase (BChE, 11D8
clone)15—the cholinesterase bound to perisynaptic
Schwann cells in mature NMJs16—was abnormally strong
in the NMJs of both subjects compared to control samples
(Figure S4B). These data indicate synaptic remodeling
when CHT activity is impaired at the human peripheral
cholinergic synapse.
Figure 3. Immunostaining Analyses of NMJs in Muscle Samples
from Individuals 1 and 2
(A) CHT immunostaining (green) and post-synaptic nAChR fluo-
rescent staining (red in b, d, f) on transversal muscle sections
showed the presence of CHT at NMJs in individuals 1 (c, d) and
2 (e, f) with a staining intensity similar to the adult control (a, b).
(B andC) Representative pictures of muscle biopsies stained for the
motor axons with an anti-neurofilament (in green) and for post-
synaptic nAChR with a-bungarotoxin (in red).
(B) The staining pattern of the two synaptic elements in the
young adult individual 1 led us to classify the NMJs in three cate-
gories depending upon the innervation status of each NMJ: dener-
vated (b), remodeled (c), or neoformed (d, d0, d0 0; d is themerged rep-
resentation of d0 and d0 0). One NMJ from the adult control (a) with
well-defined synaptic gutters responsible for the well-circumscribed
post-synaptic nAChR fluorescent staining is shown for comparison.
(C) Three representative images of immature NMJs observed in the
autopsy material of the deceased newborn (individual 2) with no
well-differentiated pattern for the postsynaptic apparatus (a, b,
c), evidence for accumulation of neurofilament staining in nerve
terminal (arrow in b and c), and polyinnervation (arrowhead in c).
Scale bars represent 10 mm.
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Our data bring the total number of presynaptic forms of
CMSs to five and demonstrate that SLC5A7 is the second
most frequent mutated gene linked to a presynaptic form
after CHAT. The phenotype of the five children presenting
with the neonatal form who are reported in this paper is
fully reminiscent of recessive CMS-EA due to ChAT defi-
ciency.5,17 CHAT mutations lead to impaired synthesis of
ACh by reduced ChAT protein level or kinetic defects de-
pending upon the mutation.18 The similarity of CMS-EA
resulting from SLC5A7 or CHAT loss-of-function muta-
tions is to be expected because both diminish the synthesis
of ACh in the nerve terminal, thereby limiting the ability
of the cholinergic synapse to continue functioning when
the demand of ACh release is high.2 The association of a
lethal antenatal form could be expected because CHT is
detected at high levels in E14 rodent spinal cord when
NMJ begins to form.19
One interesting observation was the strong immuno-
staining of synaptic BChE observed in the two analyzed
muscle biopsy samples. BChE has not been well investi-
gated as an actor in ACh metabolism at the NMJ. This
cholinesterase is bound to perisynaptic Schwann cells,
and its absence does not cause disease in mice or
humans.16,20–22 The upregulation of BChE does not
seem to be a secondary consequence of NMJ remodeling
with denervation-reinnervation events because these are
frequently observed when analyzing NMJs of individuals
with CMS. Conceivably, BChE finely tunes neuromuscular
transmission, probably by regulating the binding of ACh
to a7 nAChR located on the terminal Schwann cells.16
Interestingly, the sole inherited human disease resulting
from one nucleotide deletion (c.1497delG [p.Lys499Asnfs*
13]) in SLC5A7 already reported in the literature is
DHMN7A with no signs of myasthenia.6,23,24 The individ-
uals reported here did not present any features of neurop-
athy at last examination, but we cannot exclude the devel-
opment of neuropathic signs with age. The residual CHT
activity in DHMN7A was estimated to be 25% in vitro,
which is higher than that observed for the CMS-EA-associ-
ated mutations.6 This may point to a relationship between
the residual CHT activity and the associated phenotype
that deserves further investigations.
CMS-EA is one of the most lethal CMS types due to the
sudden episodes of apnea in neonates. The most frequent
cause of obstructive apneas in newborns is a passive
pharyngeal collapse during inspiration due to low muscle
tone, which is probably favored by the congenital muscle
weakness. Sudden apneic episodes have been sometimes
reported in fast-channel syndrome and forms of CMS re-
sulting from mutations in the genes encoding the skeletal
muscle sodium channel and rapsyn.25–28 However, sudden
EA as a constant feature is specific to forms of CMS
resulting from ChAT and CHT deficiency, highlighting a
relationship between congenital dysfunction of choline
homeostasis and EA. ACh deficit also has probable dysau-
tonomic effects in line with the established importance
of cholinergic pathways in the autonomic nervous system.
This is supported by the tachycardia and hypertension in
mice heterozygous for a null allele of Slc5a7.29,30 In vivo
administration of HC-3—the specific inhibitor of CHT—
leads to respiratory paralysis from central dysfunction,
and cholinergic agonists as well as AChE inhibitors exert
significant effects on respiratory rhythm.31,32 The strong
link observed between CHT deficiency and the occurrence
of sudden EA therefore underlines the still not well-charac-
terized role of central cholinergic transmission in the fine
control of respiratory function.33
CHT is present in central cholinergic neurons and cholin-
ergic neurotransmission is important for cognitive and
behavioral functions.19 One hypomorphic polymorphism
in SLC5A7 (rs1013940 corresponding to the c.265A>G
[p.Ile89Val] variation) is associated with pediatric attention
deficit-hyperactivity disorder (ADHD [MIM: 143465]).34
Among the individuals with CMS-EA due to recessive
SLC5A7mutations reported here, three (5, 6, and 7) present
cognitive deficits. If the multifactorial etiology of cognition
must be considered before evoking any strong risk of cogni-
tive or behavioral deficits in subjects with impaired CHT,
our observation leads to the recommendation of carefully
following up the subjects to detect and adequately manage
any central phenotype due to CHT deficiency.
To summarize, our present work demonstrates the exis-
tence of a clinical spectrum resulting from CHT dysfunc-
tion that highlights the complexity of synaptic cholinergic
metabolism and its genetics in human diseases with
possible multisystem involvement that deserves further
investigation.
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